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ABSTRACT 
 Elyse C. Dankoski: Dynamic Modulation of In Vivo Serotonin Signaling  
 (Under the direction of Prof. R. Mark Wightman) 
 
  Serotonin signaling influences many neural processes and is highly implicated in the 
etiology and treatment of depression. Understanding how in vivo elements regulate serotonin 
signaling may provide insight into serotonergic function in the depressed brain. This work 
presents a modification to fast-scan cyclic voltammetric methods that enables rapid, spatially 
resolved, and chemically selective measurement of in vivo serotonin signaling in the substantia 
nigra pars reticulata. We used this modified technique to investigate the dynamics of serotonin 
neurotransmission. Initial investigations found that serotonin release can be evoked by electrical 
stimulations in vivo, but it is greatly attenuated in comparison to serotonin evoked in brain slices. 
We hypothesized that feedback from intact inhibitory circuitry restricted serotonin signaling in 
vivo. A comparison of in vivo dopamine and serotonin release revealed a critical role for the 
serotonin transporter (SERT) in limiting serotonin signaling. This process is likely involved in 
the therapeutic effects of selective serotonin reuptake inhibitors (SSRIs), which are common 
pharmacotherapies for depression. Further studies found that acute SSRI treatment uniquely 
enhances serotonin signaling by disrupting inhibitory feedback to the dorsal raphe nucleus. We 
hypothesized that this action plays an important role in the 3-6 week lapse between SSRI 
treatment onset and clinical efficacy. Indeed, in a study of chronic SSRI treatment, we found that 
long-term reductions in SERT function result in enduring enhancement of serotonin signaling. In 
a healthy brain, this signaling is the product of dynamic, multi-systemic modulation, and SERT 
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activity likely drives both ambient and transient serotonin concentrations in a coordinated, 
equilibrated manner. Our finding that the introduction of mild stress can significantly impact the 
effects of SSRIs implicates a more complex network of elements in the modulation of serotonin 
signaling. Future work will address how stress interacts with serotonergic function. 
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CHAPTER 1: MONITORING SEROTONIN SIGNALING WITH FSCV 
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Introduction 
The neurotransmitter serotonin (also called 5-hydroxytryptamine or 5-HT) can be 
found in nearly every region of the central nervous system. Its functions are as diverse as the 
areas it innervates, and it is a complex component of many psychiatric disorders. This 
pervasive involvement in brain-wide neurocircuitry is supported by an exceptionally large 
family of receptors whose collective functional scope enables the multifarious actions of 
serotonin throughout the brain (Barnes & Sharp, 1999). Much of our knowledge about 
serotonin comes from studies investigating its actions via these receptors, which remain the 
target of many pharmacotherapies involving serotonergic signaling. However, the release and 
uptake dynamics of serotonin precipitate its downstream effects, and exploring how these 
dynamics are modulated has provided key insights to the serotonin system and its therapeutic 
potential. 
A number of techniques have been used to characterize serotonin signaling in the 
brain. In vivo microdialysis has provided key insights into natural and pharmacologically-
induced fluctuations in ambient extracellular levels of serotonin. However, even recent 
advancements in microdialysis sampling rates provide markedly lower temporal resolution 
than required to examine individual release and uptake events (Schultz & Kennedy, 2008). 
                                                          
1
 This chapter previously appeared as an article in Frontiers in Integrative Neuroscience. The original citation is 
as follows: Dankoski EC and Wightman RM. “Monitoring serotonin signaling on a sub-second time scale.” 
Front. Integr. Neurosci. 7, 44 (Jun 2013). 
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Electrophysiological measurements can infer some properties of neurotransmitter release by 
measuring postsynaptic response, and this method works well for neurotransmitters like 
glutamate and GABA, whose ligands effect instantaneous changes in ionic current or 
membrane potential. However, most serotonin receptors in the brain are G-protein coupled 
and activate intracellular cascades over time periods of 400 ms or more, resulting in 
postsynaptic effects that are too slow or heterogeneous to reveal information about small, fast 
changes in concentration. Rigorous characterization of serotonin signaling requires a 
technique that operates on the same temporal and spatial scales as its release and uptake 
processes. 
Electroanalytical techniques, which combine chemical selectivity with high temporal 
resolution, are often used in brain tissue to monitor small, fast changes in neurotransmitter 
concentrations concurrent with release and uptake. Serotonin signaling has been studied 
using several electroanalytical techniques, including differential pulse voltammetry and 
chronoamperometry (for a review, see (Stamford, 1985)). Among these techniques, fast-scan 
cyclic voltammetry (FSCV) is the best combination of temporal and chemical sensitivity for 
measuring endogenous changes in serotonin concentration in brain tissue. This article will 
review the findings of voltammetric studies and discuss their contribution to current 
understanding of the mechanisms modulating serotonin release and uptake. 
1. Fast-scan cyclic voltammetry of serotonin 
FSCV is an electrochemical technique that detects changes in endogenous 
neurotransmitter levels rapidly enough to distinguish release and uptake events in brain 
tissue. The monoamine neurotransmitters dopamine, norepinephrine, and serotonin are well-
suited to voltammetric detection because they oxidize predictably and at low potentials. To 
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evaluate changes in neurotransmitter concentration, FSCV measures the current generated by 
the oxidation of a neurotransmitter. Oxidation is driven by a potential waveform applied to a 
carbon-fiber sensor. The current generated is proportional to the concentration of analyte at 
the carbon surface, so the current-to-concentration relationship can be quantified by 
calibrating microelectrodes in authentic standards before or after experimental use. Chemical 
selectivity, or the ability to identify the neurotransmitter being measured, is facilitated by 
analyzing the plot of generated current vs. applied potential. This current-voltage curve is 
termed the cyclic voltammogram. Monoamines oxidize and reduce at predictable potentials, 
and their cyclic voltammograms have a characteristic shape that is easy to recognize. An 
example of a voltage waveform, cyclic voltammograms, and in vitro calibration is shown in 
Figure 1.1. The “fast-scan” in the technique’s name refers to the potential waveform, which 
is applied rapidly and repeatedly, producing up to 10 cyclic voltammograms per second. The 
carbon-fiber microelectrode sensors used in FSCV have small dimensions (5 x 100 m), and 
this small size enables sampling from as few as 100 synapses at a time, with the electrode 
targeted to a discrete brain region. Thus, FSCV is a technique for which temporal and spatial 
scales of data collection are compatible with monitoring neurotransmission. 
1.1. Brain regions with measurable serotonin release 
In brain slices, changes in serotonin concentration can be evoked using local 
electrical stimulation in brain regions containing serotonergic neurons or their axonal 
projections. The dorsal raphe nucleus (DRN), a tiny hub in the core of the medulla, contains 
the majority of serotonin-producing neurons that send ascending projections into the brain.   
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Voltammetric measurements detect serotonin efflux from both axonal and 
somatodendritic sites in this region because a subset of serotonergic neurons synapse locally. 
Although axonal serotonin release is prevalent throughout the central nervous system, 
experiments employing FSCV are typically constrained to brain regions dense with 
serotonergic terminals and limited interference from other neurotransmitters and metabolites. 
These studies predominantly take place in the substantia nigra, a midbrain region composed 
of the pars compacta, packed with dopamine-synthesizing neurons, and the pars reticulata 
(SNpr), a networked relay region that includes the densest serotonergic projections from the 
DRN to any forebrain region (9 x 10
6
 sites per mm
3
) (Moukhles et al., 1997). In the SNpr, 
serotonin is the predominant electroactive neurotransmitter evoked by electrical stimulations, 
frequently  observed in the absence of somatodendritic dopamine release (Cragg, Hawkey, & 
Greenfield, 1997). However, Moukhles et al. (1997) reported that serotonergic processes 
form synaptic junctions at a high rate in the SNpr than any other brain region. It should be 
considered, therefore, that serotonin dynamics described in this region may be dissimilar to 
the dynamics in other brain regions, including the cerebral cortex, neostriatum, and 
hippocampus, where a majority of serotonin terminals form non-junctional synapses 
(Descarries et al., 1990). Serotonin efflux has also been described using FSCV in brain slices 
containing the suprachiasmatic nucleus (SCN) and ventral lateral geniculate nucleus (vLGN), 
hypothalamic and thalamic areas with similarly robust serotonergic innervation. 
Serotonin measurements in in vivo FSCV experiments have taken place exclusively in 
the SNpr. Thick vasculature and meninges above the DRN make targeting this region in the 
intact brain with a fragile carbon-fiber microelectrode difficult. Other serotonergic regions of 
interest, such as the hippocampus and prefrontal cortex, have not been explored due to 
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significant chemical interference from other monoamines. However, recent advancements in 
neuronal stimulation technology may help circumvent this problem, and these potential 
future directions will be discussed in more detail in the conclusion of this article. 
1.2. Electrochemical identification 
Electrochemical methods, including FSCV, lack absolute chemical specificity. Some 
chemical species, particularly those with similar structure, can interfere with detection of the 
desired substance by oxidizing at similar or identical potentials. Therefore, voltammetric 
measurements rely on five criteria for identification of endogenously released substances: 
First, cyclic voltammograms obtained under experimental conditions must have high 
correlation with cyclic voltammograms of the authentic compound. Second, presence of the 
neurotransmitter must be validated by independent chemical identification, such as 
microdialysis, tissue content analysis, or radioligand binding in the targeted brain region. The 
third criterion requires precise anatomical positioning of the sensor into the brain region of 
interest. Fourth, observed release should follow known physiological properties for the 
neurotransmitter and target brain region. Finally, identification of the released substance is 
dependent on pharmacological validation. 
O’Connor and Kruk (1991a) systematically addressed the criteria for electrochemical 
validation in the first published report of endogenous serotonin measured in rat brain slices 
using FSCV (O'Connor & Kruk, 1991a). The cyclic voltammogram obtained from 
electrically-evoked serotonin is highly correlated to the one obtained after adding known 
concentrations of serotonin to the bath solution. Stimulation trains (500 ms in duration) 
elicited transient flux in serotonin levels in the DRN, where serotonin-synthesizing neurons 
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are located, and SCN, a region dense in serotonin projections from the DRN (Fuxe, 1965). 
The evoked concentrations measured in both brain regions was completely and reversibly 
abolished by removal of calcium from the buffer solution or addition of sodium-channel 
blocker tetrodotoxin, complying with known physiological properties of exocytotic release. 
RO 4-1284, an irreversible vesicular monoamine transporter 2 (VMAT2) inhibitor, 
attenuated release, confirming that observed release was vesicular in nature. Inhibition of 
monoamine oxidase had no effect on stimulated efflux, ruling out interference from 
serotonin’s metabolite, 5-HIAA. Finally, the clearance rate of serotonin in the DRN and SCN 
could be decreased after application of citalopram, a selective serotonin uptake inhibitor, but 
not by benztropine, a norepinephrine uptake inhibitor, to bath solution. Similar procedures 
validate the identity of serotonin detected in subsequent experiments by this and other 
groups. 
Bunin and Wightman (1998) later investigated an aspect of serotonin’s physiological 
release properties that had not been addressed by initial voltammetric characterizations. The 
dimensions of carbon-fiber microelectrodes are considerably larger than the synaptic cleft 
into which neurotransmitters are released (Figure 1.2). Consequently, FSCV detects 
extracellular, not intrasynaptic, changes in concentration, and its measurements are limited to 
the neurotransmitter concentration that diffuses into the extrasynaptic space following 
release. A number of neuromodulators diffuse beyond the synaptic space to reach their 
receptors and transporters in a process called volume transmission (Fuxe et al., 2010), and 
prior evidence from non-voltammetric techniques implicated serotonin as a volume 
neurotransmitter. Ultrastructural studies of serotonergic terminals throughout the brain 
suggest that they form predominantly non-junctional synapses (Chazal & Ralston, 1987).   
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This terminal architecture, together with reports that expression of serotonin transporters and 
receptors occurs primarily on extrasynaptic regions of neuronal processes (Kia, Brisorgueil, 
Hamon, Calas, & Verge, 1996; Zhou, Tao-Cheng, Segu, Patel, & Wang, 1998), is indicative 
of volume transmission. In light of this information, Bunin and Wightman (1998) 
hypothesized that electrically-evoked serotonin should reach the extracellular space via 
diffusion, without buffering from uptake and receptor binding sites. This was found to be the 
case for both somatodendritic and terminal release, where the concentration of serotonin 
evoked per stimulation pulse during 20-pulse trains was equivalent to the concentration 
evoked by a single pulse (Bunin & Wightman, 1998). Therefore, the authors concluded that 
serotonin concentrations measured by voltammetry reflect physiological volume transmission 
from the synapse to its extrasynaptic targets. 
1.3. Technical considerations 
Since O’Connor and Kruk’s first report of voltammetric detection of serotonin, 
several modifications have been implemented to adapt and improve the use of FSCV for 
novel applications. The voltage potential waveform (-1 to +1.4 to -1) used by the Stamford 
and Kruk labs, as well as others, in serotonin studies cited throughout this review was 
adjusted by Jackson and Wightman (1995) to improve temporal resolution. This modification 
to an N-shaped waveform, which scans from +0.2 to +1.0 to -0.1 back to +0.2 (Figure 1.1A), 
was designed to reduce serotonin adsorption to the electrode surface, as this slows electrode 
response times. It also avoids fouling reactions of serotonin’s oxidative and reductive 
byproducts, improving electrode sensitivity and stability over time (Jackson, Dietz, & 
Wightman, 1995). The modified waveform’s improvement enhanced electrode response 
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times and enabled more accurate measurements of release and uptake rates, facilitating closer 
examination of the kinetic parameters of serotonin release. 
Improvement of carbon-fiber microelectrode sensors has been another ongoing 
adaptation to voltammetric measurements of serotonin. Brazell and Adams (1987) first 
reported that dip-coating a carbon-fiber microelectrode in Nafion, a cation-selective polymer, 
improves serotonin and dopamine detection (Brazell et al., 1987; Jackson et al., 1995). 
Nafion enhances serotonin detection in two ways: first, by directly increasing the electrode’s 
sensitivity to (positively-charged) serotonin, and second, by reducing its sensitivity to 
interfering anionic species such as uric acid and serotonin’s metabolites. Years later, the 
success of the first in vivo voltammetric measurements of endogenous serotonin 
concentrations in a rat owe their success to the enhanced sensitivity and temporal resolution 
facilitated by Nafion-coated sensors and the modified voltage potential waveform (Hashemi, 
Dankoski, Petrovic, Keithley, & Wightman, 2009). 
It is important to note that many labs continued their investigations of serotonin 
release without adopting either modification. Because each study reports on electrically-
evoked changes in serotonin concentration, which are derived from in vitro calibrations, 
comparing findings between labs is not considered an issue within this review. It is important 
to note that these calibrations do not take into account the deleterious effects of electrode 
fouling that may be appreciably different over the course an experiment depending on the 
waveform used. Regardless of waveform choice, however, demonstration of a linear 
relationship between concentration applied and the current evoked establish the suitability of 
a waveform for stable detection of serotonin. 
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2. Electrical stimulation 
Many of the optimal electrical stimulation parameters for evoking somatodendritic 
and terminal serotonin in brain slices are consistent with previously established physiological 
principles. Serotonergic fibers are not myelinated and, like other unmyelinated fibers, are 
maximally excited by wider stimulation pulse widths, up to 2 ms in length (Anden, Fuxe, & 
Ungerstedt, 1967; Bunin, Prioleau, Mailman, & Wightman, 1998; Merrill, Wall, & Yaksh, 
1978; Millar, Stamford, Kruk, & Wightman, 1985). The amplitude of evoked serotonin 
concentration is also strongly dependent on increases in stimulation intensity (up to 380 A) 
and number of pulses in a stimulation train. Maximal release amplitudes are also positively 
correlated with increasing frequency, up to 100 Hz (Bunin & Wightman, 1998; Iravani & 
Kruk, 1997; O'Connor & Kruk, 1991b), although a detailed investigation by John, et al. 
(2006) found that electrically-evoked concentrations were less sensitive to stimulation 
frequencies above 30 Hz (John, Budygin, Mateo, & Jones, 2006). These constrained ranges 
of frequency dependence could reflect limitations in vesicular availability, but Aghajanian et 
al. (1990) has posited that processes in terminal regions store enough serotonin to sustain 
long, high frequency release (Aghajanian, Sprouse, Sheldon, & Rasmussen, 1990). Although 
serotonergic neurons are typically thought to fire at a rate of 0.5-5 Hz, burst-firing in the 
DRN has been measured at a rate of 100 Hz (Aghajanian, Wang, & Baraban, 1978; Hajos, 
Gartside, Villa, & Sharp, 1995; Vandermaelen & Aghajanian, 1983). Differences in the range 
of frequency sensitivity between studies may therefore reflect dynamic, physiological 
fluctuations and could point to yet another regulatory component within the serotonin 
system. Future investigation of the mechanisms influencing frequency dependence would be 
an interesting addition to our understanding of serotonin signaling.  
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Although voltammetric studies of serotonin have used a wide array of stimulation 
parameters, one type has been used repeatedly in the studies reviewed in this article. Pseudo-
one-pulse (El Yacoubi et al.) stimulations consist of 5-10 pulses applied at 100-200 Hz and 
are shorter than 100 ms in duration. They are designed to approximate a single electrical 
impulse but evoke more consistent efflux. In brain slice experiments, POP stimulations are 
often used to avoid creating an endogenous “tone” at receptors, which facilitates more direct 
investigation of selective agonists and antagonists effects on autoreceptor-mediated 
modulation of release (Limberger, Trout, Kruk, & Starke, 1991; Thienprasert & Singer, 
1993). 
Endogenous serotonin concentrations have been evoked in vivo using electrical 
stimulation of the DRN as well as the medial forebrain bundle (MFB). A subset of 
serotonergic neurons that project to the SNr also send axon collaterals to forebrain structures 
via the MFB (van der Kooy & Hattori, 1980). Electrical stimulation of these collaterals 
excites SNr-projecting neurons in a retrograde direction, eliciting serotonin in the desired 
region (Hashemi, Dankoski, Wood, Ambrose, & Wightman, 2011). While targeting a 
stimulation electrode to the MFB is less challenging than targeting the DRN, this stimulation 
site can also be used to evoke neurotransmitter release in many brain regions. This may have 
indirect effects on serotonin signaling, complicating interpretation of data. Many optimal 
stimulation parameters are consistent between in vitro and in vivo measurements, including 
pulse width, stimulation intensity, and stimulation length. However, the concentration of 
serotonin evoked in the SNr is remarkably lower than predicted by brain slice measurements, 
prompting curiosity about the potential for serotonergic regulatory mechanisms that require 
intact brain tissue. 
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3. Release 
Local electrical stimulations of serotonin terminals in brain slices typically evoke 
concentration changes in the 100 nM range. In vivo, however, serotonin concentrations 
evoked in the SNpr rarely reach 100 nM, even after pharmacological manipulations 
(Hashemi et al., 2012). In vivo serotonin release, measured in an intact brain, is presumably 
limited by negative feedback from somatodendritic and terminal autoreceptors as well as 
inhibitory neurotransmitters that are released concurrently, which may account for some of 
the disparity in release amplitudes. In brain slices, concentration flux coincides with onset of 
the stimulation pulse train and this rising phase reaches its maximum within milliseconds of 
the stimulation’s end. Serotonin evoked in vivo tends to overshoot the duration of 
stimulation. The overshoot is partially an effect of the broader area of release sites activated 
by a remote stimulation location, but is also due to limited diffusion rates through a Nafion 
polymer coating that is applied to enhance sensitivity in vivo (Hashemi et al., 2009). 
As mentioned in a previous section, electrically-evoked serotonin concentrations 
measured in brain slices are sensitive to stimulation frequency. A proposal by Wightman et 
al. (1988) explains this observation: more uptake occurs in the time between stimulation 
pulses during low frequency stimulations, which limits the summation of extracellular 
neurotransmitter concentration (R. M. Wightman et al., 1988). Jennings et al. (2010) 
hypothesized that shifts in uptake rate associated with differential serotonin transporter 
expression would predictably alter this frequency dependence. Mice with either gain or loss 
of SERT expression both displayed significantly lower sensitivity to stimulation frequency 
than their wild-type littermates. Furthermore, in wild-type mice, a selective serotonin 
transporter inhibitor reduced sensitivity to stimulation frequency (Jennings, Lesch, Sharp, & 
12 
 
Cragg, 2010). These findings underscore the importance of SERT in establishing a 
functional, dynamic equilibrium between release and uptake that enables coherent serotonin 
signaling. 
Time-resolved measurements with FSCV also enable examination and comparison of 
the kinetic parameters of serotonin transmission. Neurotransmitter uptake is assumed to 
follow Michaelis-Menten dynamics, and uptake as well as concentration evoked per stimulus 
pulse can be calculated using a modified model of enzyme kinetics. Figure 1.3 shows the 
equations used to model (i) uptake and (ii) release and representative signals predicted for 
stimulations of varying frequency. In brain slice preparations, the concentration evoked per 
stimulation pulse ([5-HT]pulse) was found to be 100 ± 20 nM in DRN, and significantly lower 
in the SNpr, at 55 ± 7 nM. Differences in [5-HT]pulse are proportional to differences in tissue 
content between the two brain regions, indicating that local stores of serotonin may influence 
the concentration that can be evoked by electrical stimulation (Bunin et al., 1998). In vivo [5-
HT]pulse in the SNpr is much lower, comparatively: 1.5 nM per pulse using DRN stimulation, 
and 1.1 nM per pulse from the MFB. Figure 1.4 shows an averaged recording of in vivo 
serotonin signals in the SNr; note that the concentration evoked is strikingly lower than 
predicted by the model in Figure 1.3. Given that both Bunin et al. (1998) and Hashemi et al. 
(2011) conducted experiments in the SNpr, the nearly 50-fold difference cannot be attributed 
to differences in tissue content. Instead, this discrepancy between brain slice and in vivo 
preparations suggests powerful regulatory mechanisms acting on serotonin release in vivo 
which may depend on intact circuitry. 
Hashemi et al. (2012) investigated mechanisms that may limit in vivo 
neurotransmission by using a common MFB stimulation to compare serotonin and dopamine 
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efflux in the SNpr and nucleus accumbens, respectively. The dopamine system serves as a 
good basis for comparison with the serotonin system because the two monoamines share 
parallel features in the mechanisms controlling their synthesis, release, modulation, uptake, 
and metabolic degradation. Inhibition of the monoamine synthesis enzyme aromatic amino 
acid decarboxylase and VMAT2 considerably decreased the concentration of evoked 
dopamine to 18% and 6% of control amplitudes, respectively, but affected serotonin to a 
much lesser extent (48% and 72%, respectively). Serotonin efflux was also resistant to short 
term depression after repeated stimulation pulse trains, while dopamine efflux was attenuated 
by 38% after 20 stimulations. This suggests that a relatively small proportion of the available 
vesicular serotonin is mobilized for release by each electrical stimulation train, a finding 
which may partially explain the low concentrations observed in vivo. 
3.1. Modulation by autoreceptors 
Three subtypes of serotonin receptors, all 5-HT1-type, are expressed on serotonergic 
axons, soma, and dendrites and function as autoreceptors that provide inhibitory feedback. 5-
HT1-type receptors are found throughout the brain as autoreceptors, expressed on pre-
synaptic serotonin terminals, and also as heteroreceptors, expressed on post-synaptic targets. 
The most well-studied autoreceptors, 5-HT1A, 1B, and 1D are seven transmembrane, G-
protein coupled receptors (GPCRs). 5-HT1B and 1D autoreceptors negatively couple to 
adenylyl cyclase (Yocca & Maayani, 1990). 5-HT1A heteroreceptors throughout the brain 
also inhibit adenylyl cyclase activity, but autoreceptors in the DRN apparently function 
through a different Gi-coupled mechanism (Clarke, Yocca, & Maayani, 1996). In vivo studies 
of these autoreceptors are challenging because even highly-selective drugs inadvertently 
target pharmacologically-identical heterosynaptic receptors, which are often expressed at 
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high levels in the same brain region as the autoreceptor. Intact circuitry thus makes it difficult 
to extricate direct effects of autoreceptor activity from indirect regulation by heteroreceptors. 
Voltammetric measurements in brain slices avoid some of the problems associated 
with 5-HT1-type receptor pharmacology. In slices, the absence of spontaneous activity in 
serotonergic cells , due either to separation from cell bodiesin a terminal slice or to 
elimination of noradrenergic inputs in a DRN slice, results in loss of endogenous serotonin 
tone (Judge & Gartside, 2006). Therefore, these experiments avoid tonic activation of 
autoreceptors and can also avoid transient autoreceptor activity, when appropriate, using POP 
stimulations. This provides an opportunity to study the timing and function of these receptors 
in relative isolation. O’Connor and Kruk (1991b) showed that the non-selective autoreceptor 
antagonist methiothepin did not affect the concentration of serotonin evoked by POP 
stimulations, but increased serotonin elicited by longer stimulations. Further exploration with 
stimulations of varying frequency and duration determined that activation of autoreceptors 
requires a stimulation period of at least 400 ms (O'Connor & Kruk, 1991b). This time frame 
is comparable to the activation window for dopamine autoreceptors in striatal and limbic 
regions. Phillips et al. (2002) found that the activation delay observed for dopamine 
autoreceptors reflects timing of intracellular cascades added to the rate of neurotransmitter 
diffusion in a given brain area (P. E. Phillips, Hancock, & Stamford, 2002). 
5-HT1A, 1B, and 1D receptors are expressed at high levels in the DRN, where they 
negatively influence neuronal firing rate and extracellular levels of serotonin (Adell, Celada, 
& Artigas, 2001; Moret & Briley, 1997; Pineyro, Castanon, Hen, & Blier, 1995; Sprouse & 
Aghajanian, 1987). Voltammetric studies corroborate the inhibitory functions of all three 
receptors in this region by demonstrating that their selective agonists can reduce the 
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amplitude of electrically-evoked serotonin release (Davidson & Stamford, 1995b; Hopwood 
& Stamford, 2001). Although its heteroreceptor analogues are prominently expressed in 
limbic regions, 5-HT1A autoreceptors are only expressed in the DRN and median raphe 
nucleus (Verge et al., 1985). Serotonin levels in forebrain terminal regions are affected by 5-
HT1A-mediated changes in DRN unit activity (Casanovas, Lesourd, & Artigas, 1997; Kreiss 
& Lucki, 1994), but only 5-HT1B and 1D autoreceptors are expressed locally to functionally 
inhibit release in these regions. Voltammetric measurements in the SCN and vLGN confirm 
absence of 5-HT1A autoreceptor function in these terminal regions. 5-HT1B and 1D 
receptors, and not 5-HT1A receptors, negatively influence serotonin efflux in vLGN brain 
slices (Davidson & Stamford, 1996; O'Connor & Kruk, 1992). 
The 5-HT1A receptor may be the trump card in this family of autoreceptors: 5-HT1A 
receptor mRNA is expressed in nearly 100% of serotonergic cells and up to 15% of 
GABAergic interneurons in the DRN (H. E. Day et al., 2004). This receptor robustly 
regulates both neuronal firing rates and extracellular serotonin levels in the DRN (Hjorth & 
Sharp, 1991; Sprouse & Aghajanian, 1987). Voltammetric measurements find that 
antagonists for 5-HT1A and 1B have a supra-additive effect when administered together: 
increase in serotonin efflux is greater when both receptors are blocked than would be 
expected given the effect of each antagonist alone (Roberts & Price, 2001). In addition, the 
effects of 5-HT1B receptor antagonists on serotonin efflux are overpowered by 5-HT1A 
receptors unless they are also blocked, suggesting that these receptors compensate for 
reductions of 5-HT1B activity. Given these results, it is suggested that 5-HT1A and 1B 
receptors exhibit a functional interaction that is facilitated by proximal expression sites on 
serotonin neurons. Interest in 5-HT1A receptors has increased in the last decade, as they may 
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play a role in depression and anxiety-related disorders (Ohno, 2010). Use of FSCV in future 
studies could meaningfully contribute to our understanding of how 5-HT1A receptor-
mediated modulation of serotonin release plays a role in the etiology and treatment of these 
disorders. 
Much speculation has occurred regarding the explanation for seemingly parallel 
functions of 5-HT1B and 1D autoreceptors. Both receptors are expressed in most 
serotonergic brain regions and have superficially redundant effects. One theory posits that 
these autoreceptors differ in their affinity for serotonin: one high affinity and the other low 
affinity. However, it has since been demonstrated that their affinities are nearly identical 
(Boess & Martin, 1994). More likely, the two receptors are expressed in different anatomical 
locations, and thus provide site-specific regulation of serotonin release, e.g. dendritic vs. 
axonal localizations in the DRN. Stamford et al. (2000) have reviewed the evidence 
supporting this hypothesis (Stamford, Davidson, McLaughlin, & Hopwood, 2000). 
The SNr expresses the highest concentration of 5-HT1B autoreceptors and 
heteroreceptors in the murine brain (Pazos & Palacios, 1985). 5,7-HT-induced lesions of 
serotonin neurons reduced 5-HT1B expression level by 37%, presumably due to degradation 
of serotonin terminals (Verge et al., 1986); this suggests that over 1/3 of 5-HT1B receptors 
expressed in the SNr could function as autoreceptors. Heterosynaptic function of 5-HT1B 
receptors on presynaptic sites in the SNr has been well-documented and may yield important 
therapeutic findings (Sari, 2004), but its functionality as an autoreceptor in the SNr remains 
controversial. Iravani and Kruk (1997) found no effects of 5-HT1B receptor antagonists on 
electrically-evoked serotonin concentrations in SNr slice preparations (Iravani & Kruk, 
1997). However, Threlfell and Cragg (2010) report that these autoreceptors influence short-
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term depression of serotonin efflux. In paired stimulation trains, the concentration of 
serotonin evoked by the second stimulation (S2) reached 30% of that evoked by the first 
stimulation (S1) when there was a 1 second delay between S1 and S2. Antagonists of 5-
HT1B receptors relieved this depression by up to 20% (Threlfell, Greenfield, & Cragg, 
2010). 5-HT1B autoreceptors are thus apparently functional in the SNpr, although their 
modulatory effects may be less robust than in other brain regions. 
It is possible that the role of autoreceptors could be better elucidated by in vivo 
voltammetric studies, where endogenous serotonin tone is undisturbed and autoreceptor 
function is closer to normal physiological levels.  However, a limited number of studies 
currently address the effects of serotonin’s autoreceptors in vivo. In practice, it is difficult to 
selectively target 5-HT1-type receptors on serotonin terminals when pharmacologically 
indistinct 5-HT1-type heteroreceptors are expressed throughout the brain. As with in vivo 
microdialysis, the direct roles of the autoreceptor would be difficult to extricate from indirect 
modulation by in situ circuitry. Recent technological advancements in iontophoresis enable 
spatially-resolved, quantitative drug delivery at the site of voltammetric measurements (Herr 
& Wightman, 2013). Future studies using FSCV combined with this drug-delivery method 
have great potential to answer important questions about serotonin’s autoreceptors. 
4. Uptake 
Serotonin clearance is achieved primarily via active transport. Its transporter, SERT, 
is a member of the Na
+
/Cl
-
 transporter family, which includes dopamine, norepinephrine, 
GABA, and glutamate transporters (Bennett, Logan, & Snyder, 1973; Iversen, 1974). SERT 
displays high affinity for serotonin in the nanomolar concentration range (Blakely et al., 
1991). Inhibitors of SERT, or selective serotonin reuptake inhibitors (SSRIs), have been a 
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significant target of research efforts for decades, owing to their widespread use as 
antidepressant medications. Given acutely, SSRIs exert striking effects on the serotonin 
system: they elevate extracellular serotonin levels in the DRN (Bel & Artigas, 1992), which 
in turn decreases rate of cell firing due to activation of 5-HT1A autoreceptors (Chaput, de 
Montigny, & Blier, 1986; Gartside, Umbers, Hajos, & Sharp, 1995). However, in therapeutic 
practice, SSRIs relieve depressive symptoms only after a chronic period of 3-6 weeks. It is 
during this period that the effects of transport inhibition on serotonin transmission become 
less clear. FSCV provides an ideal method for deciphering the effects of SSRIs because it can 
distinguish between changes in released serotonin and changes in rate of uptake. 
Electrically-evoked changes in serotonin concentration are cleared from the 
extrasynaptic space within seconds of stimulation termination. The term t½ is often used to 
compare rates of clearance; t½ is the time elapsed between peak concentration of 
neurotransmitter and its decay to half this amplitude. Across brain regions, brain slice and in 
vivo voltammetric measurements report similar values of t1/2 ranging from approximately 1 to 
3 s (Davidson & Stamford, 2000; Hashemi et al., 2012; Iravani, Muscat, & Kruk, 1999; 
O'Connor & Kruk, 1994). Rates of neurotransmitter clearance may positively correlate with 
the density of transporter sites in a given brain region: Bunin et al. (1998) report clearance 
rates of 1,300 ± 20 nM/s in the DRN and 570 ± 70 nM/s in the SNr, and quantitative 
autoradiographic studies report two to four-fold greater SERT binding levels in the DRN 
(Kovacevic, Skelin, & Diksic, 2010; Kovachich, Aronson, Brunswick, & Frazer, 1988). 
However, some comparisons of SERT density across brain regions do not support this 
conclusion, particularly in species other than rat, so more thorough investigation of the 
relationship between transporter expression and SERT density is needed. In addition to 
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influencing uptake rate, brain slice studies in mice that either lack or overexpress SERT have 
demonstrated a negative correlation between transporter expression level and concentration 
of serotonin evoked by electrical stimulation (Jennings et al., 2010; John et al., 2006). The 
disparity observed between clearance rates in the DRN and SNpr is conspicuously 
proportional to differences Bunin et al. (1998) reported in release rates. This suggests a 
consistent relationship between transporter expression levels, uptake rates, and release rate. 
Modeling serotonin signaling kinetics in more brain regions could confirm whether this 
relationship holds true throughout the brain. 
SSRIs decrease rate of neurotransmitter clearance while increasing the maximum 
amplitude of electrically-evoked serotonin concentrations. In brain slices, SERT inhibition 
slows clearance (measured as an increase in t½) by 150-700%. This wide spread of responses 
may be attributable to experimental variability between studies, particularly differences in 
stimulation parameters. Indeed, in vivo studies of SSRI effects in the SNr using identical 
stimulation parameters report comparable changes in t½ using MFB and DRN stimulation 
sites (increasing by 324% and 306%, respectively)(Hashemi et al., 2012; Hashemi et al., 
2009). SSRIs also increase evoked serotonin concentrations by 200%-450% in SNr brain 
slices, and up to 410% in vivo (Hashemi et al., 2012; Iravani et al., 1999; John et al., 2006). 
In this case, the intensity of the SSRI’s effect is associated with different stimulation 
frequencies or pulse number. Structure and selectivity differences between SERT inhibitors 
may also contribute to variable responses between voltammetric studies; however, 
differences between SSRIs have not been specifically investigated using FSCV. Serotonin 
efflux in SNr brain slices has been modeled to describe the effects of an SSRI, fluoxetine, on 
apparent KM, the Michaelis-Menten constant (John et al., 2006). Quantifying changes to KM, 
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Vmax and [5-HT]p may be a more effective way to contrast the effects of various SERT 
inhibitors on serotonin signaling in future studies in brain slices and in vivo. Thorough 
comparison of these effects could inform clinical usage of these pharmacotherapies. 
4.1. Autoreceptors mediate some effects of acute uptake inhibition 
In addition to their inhibitory influence on release, serotonin’s autoreceptors appear to 
modulate response to SERT inhibition. A number of studies report that autoreceptor 
antagonists can potentiate the rise in extracellular serotonin levels elicited by SSRIs (Artigas, 
Perez, & Alvarez, 1994; Hjorth, 1993), and 5-HT1A autoreceptors also mediate reduction of 
firing rate by SSRIs in the DRN (Gartside et al., 1995). The concentration change evoked by 
POP stimulations, deliberately rapid enough to avoid creating an endogenous tone, typically 
does not activate autoreceptors and is thus not affected by their antagonists. However, in 
brain slices of the DRN, paroxetine-induced increases in serotonin efflux were potentiated by 
5-HT1A and 1B/D receptor antagonists (Davidson & Stamford, 1995a). Therefore, it is 
hypothesized that SERT inhibition causes an increase in extracellular serotonin levels 
sufficient to activate autoreceptors, even in brain slices. This produces an inhibitory tone, 
such that autoreceptor antagonists can further unmask SSRI-induced increases in release. 5-
HT1B and 1D autoreceptors appear to similarly potentiate the effects of SSRIs in distal brain 
regions, as the Stamford lab also reports increases in paroxetine’s effects in the vLGN when 
co-administered with 5-HT1B and 1D receptor antagonists (Davidson & Stamford, 1997b). 
The interaction between regulation of release and uptake functions may also be an important 
detail in understanding how chronic uptake inhibition functions in treating depressive 
disorders. 
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4.2. Chronic uptake inhibition 
The gap between onset of acute physiological effects and the therapeutic efficacy 
achieved in a chronic treatment period implies that SSRI-induced increases in serotonin 
levels are not directly producing antidepressant effects. Instead, elevated serotonin levels 
may influence long-term changes in serotonin signaling and its downstream targets to relieve 
symptoms of depression (Blier, de Montigny, & Chaput, 1987). The effects of long-term 
SERT inhibition are conflicting: some find increases in extracellular serotonin levels, and 
some find no changes. Associated with these outcomes are variable reports of autoreceptor 
desensitization or hypersensitization of 5-HT1A and 1B autoreceptors (Bosker, 
Klompmakers, & Westenberg, 1995; Bosker, van Esseveldt, Klompmakers, & Westenberg, 
1995; Chaput, de Montigny, et al., 1986; R. Invernizzi, Belli, & Samanin, 1992; R. 
Invernizzi, Bramante, & Samanin, 1995; Moret & Briley, 1996). Studies examining the 
effects of chronic SSRI treatment using FSCV have produced more consistent findings. 
FSCV measurements of serotonin signaling after 21 days of SSRI exposure reveal 
that rate of clearance, measured by t½ , is unchanged by this treatment. This lack of change is 
intriguing because radioligand binding studies report brain-wide reductions in SERT density 
after chronic inhibition (Kovacevic et al., 2010). It may reflect compensation by other 
clearance mechanisms, such as low affinity serotonin transporters. High and low affinity 
transport systems have been described for other monoamine neurotransmitters (Hagan, 
Schenk, & Neumaier; Iversen, 1974; Stamford, Kruk, & Millar, 1990; Stamford, Kruk, 
Millar, & Wightman, 1984). Although studies suggest that these transporters may play an 
important role in serotonin signaling (Daws, 2009), there are presently no FSCV studies 
describing their role in modulating release and uptake. The role of non-selective uptake 
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transporters in modulating serotonin signaling, particularly following chronic SSRI 
treatment, would be interesting to investigate using FSCV. 
Long-term SSRI treatment increases stimulation-evoked serotonin concentrations in 
the DRN and other brain regions by 20-100%, depending on the experiment and brain region 
studied (Davidson & Stamford, 1998, 2000; O'Connor & Kruk, 1994).These findings concur 
with the results of Schoups and De Potter (1986), who found that electrically-evoked release 
of tritiated serotonin (
3
[H]5-HT) in the hypothalamus increased after 21 days of SSRI 
treatment (Schoups et al., 1986). Although increases in serotonin efflux are observed after 
acute SERT inhibition, these can be explained by changes in rate of uptake. However, t½ was 
not altered in any voltammetric investigation of long-term SSRI treatment. Therefore, 
increases in evoked concentrations induced by chronic treatment must rely on another 
mechanism. Changes in other aspects of release may contribute to this effect, for example: 
the quantity or composition of serotonin stored in vesicles, regulation of intracellular 
calcium, or excitability of the synaptic membrane. In-depth exploration of these mechanisms 
has not yet been explored using voltammetric methods. 
Alterations in 5-HT1A autoreceptors contribute to the effects of chronic SSRIs on 
serotonin signaling. Under normal conditions, activated 5-HT1A receptors inhibit serotonin 
release and neuronal firing rates, and chronic SSRI treatment may modify this activity. 
Selective suppression of 5-HT1A autoreceptors can produce antidepressant behavioral effects 
in the absence of SSRIs (Bortolozzi et al., 2012). Many investigations have described 
functional desensitization of 5-HT1A receptors after chronic SERT inhibition, but to varying 
degrees across brain regions (Bosker et al., 2001; Cremers et al., 2000; Kreiss & Lucki, 1994, 
1997; Rossi, Burke, McCasland, & Hensler, 2008). Davidson and Stamford (1998) compared 
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serotonin release and uptake and neuronal firing rates in the DRN of rats treated with water 
or paroxetine for 21 days. Paroxetine-treated rats had significantly higher serotonin release 
rates but exhibited no differences in firing rate. Interestingly, application of a 5-HT1A 
receptor agonist revealed that firing rate was less sensitive, and release amplitude more 
sensitive, to this manipulation. Contradictory findings of 5-HT1A receptor sensitivity was 
not a total surprise: prior studies found similar desensitization of 5-HT1A receptors in the 
control of firing rate after chronic paroxetine treatment (Blier, de Montigny, & Chaput, 1988, 
1990; Chaput, de Montigny, et al., 1986), and O’Connor and Kruk (1994) had previously 
reported sensitization of 5-HT1A receptors controlling release amplitude. The dichotomous 
effect of chronic SSRIs on 5-HT1A receptor sensitization indicates a functional distinction 
between the receptors mediating neuronal firing and those controlling release. Given the 
complex effects of chronic SSRIs on 5-HT1A autoreceptors in the DRN, it would be 
interesting to see how these changes translate to serotonin release in an intact brain. 
Currently, however, no studies employing FSCV have examined the effects chronic SERT 
inhibition in vivo. 
5-HT1B and 1D receptors also desensitize after chronic SERT inhibition, although 
the extent to which this occurs appears to vary between brain regions. O’Connor and Kruk 
(1994) reported desensitization of 5-HT1B receptors in SCN after chronic treatment with 
fluoxetine. In contrast, the Stamford lab found no changes in the sensitivity of 5-HT1B 
receptors in the vLGN, instead finding desensitization of 5-HT1D receptors after chronic 
paroxetine. This inconsistency may reflect differences in autoreceptor expression in the SCN 
and vLGN, or result from difficulty in selectively targeting the 5-HT1B receptor 
pharmacologically (O’Connor and Kruk do not address the effects of 5-HT1D receptors in 
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their study). Additionally, while O’Connor and Kruk (1994) found no desensitization of 5-
HT1B receptors in the DRN, Davidson and Stamford (2000) later demonstrated that 5-HT1B 
receptor desensitization was apparent only when the 5-HT1A autoreceptor is antagonized 
(Davidson & Stamford, 2000). This adds further weight to the conjecture that 5-HT1A and 
1B receptors functionally interact in the DRN. 
4.3. Monoamine oxidase 
Metabolic degradation of serotonin by the enzyme monoamine oxidase (MAO) also 
contributes to serotonin clearance, especially in the developing brain (Cases et al., 1998; 
Cases et al., 1995). However, MAO inhibition in brain slices has no reported effect on 
release amplitudes or uptake (O'Connor & Kruk, 1991a), a finding used to confirm absence 
of serotonin’s metabolites from the voltammetric signal. Owesson and Stamford (2002) 
showed a greater role of MAO in regulating serotonin efflux using transgenic mice lacking 
MAO-A expression. MAO-A is the isoenzyme that preferentially degrades norepinephrine, 
epinephrine, dopamine, and serotonin, and mice lacking this enzyme have decreased 
neuronal firing rates in the DRN and increased extracellular serotonin levels (Evrard et al., 
2002). In brain slices of the DRN, MAO-A-deficient mice displayed significantly greater 
serotonin efflux and reduced clearance rates compared to wild-type controls. Additionally, 
the effects of citalopram were smaller and radioligand binding showed significantly lower 
expression of SERT in these mice (Owesson et al., 2002). This suggests that serotonin 
signaling is subject to regulation by MAO under the right experimental conditions. In vivo 
work supports this idea, as a recent study has shown that MAO inhibitors dramatically 
increase serotonin efflux in the SNpr (Hashemi et al., 2012). MAO inhibition also has a much 
greater effect on serotonin than dopamine efflux when compared in vivo, suggesting a unique 
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role for metabolic degradation in the regulation of serotonin transmission compared to other 
monoaminergic systems. 
5. Future Directions 
Most of the studies reviewed in this article focused on describing the role of 
autoreceptors and transporters in modulating serotonin signaling throughout the brain. 
However, signaling is also considerably influenced by many other neurotransmitter systems, 
including norepinephrine, glutamate, GABA, and a number of neuroendocrine modulators. 
These external influences are highly implicated in serotonin’s involvement in a number of 
psychiatric disorders and, while they have been investigated by other techniques, their 
functions have not been fully described using subsecond voltammetric measurements. 
Evaluating the effects of external modulatory mechanisms on the subsecond dynamics of 
serotonin signaling could provide important clues about their role in neurological disorders. 
Ongoing methodological developments continue to progress voltammetric 
measurements beyond the current experimental limits.  While electrochemical techniques 
have been optimized for serotonin detection (Lama, Charlson, Anantharam, & Hashemi, 
2012), multi-electrode arrays are being developed which would enable measurements of 
multiple neurotransmitters in multiple locations simultaneously. Additionally, iontophoretic 
methods adapted for FSCV now enable localized, quantitative drug delivery, enabling 
investigation of recording-site specific effects in vivo. FSCV can also be paired with 
concurrent electrophysiological measurements to couple information about neurotransmitter 
release to single-unit responses of post-synaptic neurons. Iontophoretic and 
electrophysiological methods have already been applied to voltammetric studies of dopamine 
release in anaesthetized and freely-moving animals (Takmakov, McKinney, Carelli, & 
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Wightman, 2011), and the Wightman group is currently working to adapt these methods for 
serotonin detection. 
It has previously been challenging to selectively study serotonin’s autoreceptors in 
vivo because homologous receptors are expressed throughout the brain. However, many 
novel drug-delivery and transgenic methods have been developed to avoid this type of 
complication. DREADDs, designer receptors with exogenous ligands, have been used to 
target specific G-protein-activated cascades in serotonergic neurons (Dong, Allen, Farrell, & 
Roth, 2010). A light-activated 5-HT1A receptor has been generated that can be expressed 
only on serotonergic neurons (Oh, Maejima, Liu, Deneris, & Herlitze, 2010). Furthermore, 
transgenic mice and rats offer many opportunities to study signaling in models of 
neurological disorders and targeted deletions. The effects of SERT deletion or 
overexpression on serotonin signaling have been investigated in brain slices of the SNr but 
not in an in vivo preparation. Many conditional knockout mouse models, which avoid 
confounding developmental effects, are now available for serotonin’s transporter and 
receptors. These techniques could lead to more selective targeting and better characterization 
of serotonin’s receptors and their downstream effectors in combination with voltammetric 
measurements. 
Voltammetric measurements have, until recently, been limited to brain regions with 
high levels of the neurotransmitter of interest and limited presence of other electroactive 
compounds. This is because electrical stimulations indiscriminately excite all proximal nerve 
terminals. Use of optogenetic stimulation circumvents this barrier by enabling selective 
excitation of a specific population of neurons. Channelrhodopsin-2-mediated serotonin efflux 
has been measured in fly larvae using FSCV in a technique developed by the Venton group. 
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The light-evoked efflux is vesicular and subject to regulation by synthesis and uptake 
transport in a manner that is similar to mammalian serotonin release (Borue, Condron, & 
Venton, 2010; Borue, Cooper, Hirsh, Condron, & Venton, 2009). Selective stimulation of 
serotonergic neurons in a mammalian model would permit measurements in brain regions 
with significant interference from other electroactive neurotransmitters, such as the 
hippocampus. 
Finally, while voltammetric measurements of serotonin have presently only occurred 
in brain slices and anaesthetized animals, an exciting future direction for research will be 
monitoring serotonin signaling in an awake, freely moving animal. FSCV has been used to 
measure endogenous dopamine and norepinephrine release in freely moving animals, and this 
research has led to groundbreaking information coupling real-time neurotransmission to 
specific facets of behaviors. Many questions remain about serotonin’s role in both basic and 
complex nervous system processes, and coupling FSCV to relevant behavioral paradigms 
may yield important clues about its function. 
Conclusion 
Serotonin signaling is an important component in the etiology and treatment of many 
neurological disorders. By combining sub-second temporal resolution with nanomolar 
sensitivity to concentration changes, FSCV has revealed a great deal about dynamic 
serotonin transmission. These findings are summarized by the illustration in Figure 1.5. 
Studies using voltammetric methods have emphasized the importance of autoreceptor-
mediated inhibitory feedback mechanisms in normal signaling as well as response to SSRIs. 
Further, recent in vivo measurements suggest that intact brain circuitry supports the 
involvement of multiple modulatory mechanisms in the control of serotonin signaling.  
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The work presented in this dissertation describes some of the mechanisms that control 
serotonin release and uptake in an in vivo preparation. In chapter 2, we present modifications 
to existing voltammetric methods which enable detection of endogenous serotonin release in 
an intact brain for the first time. In chapter 3, we model this release, finding that it is 
significantly smaller than concentrations evoked in brain slices. Chapter 4 describes how the 
similar biochemical components of dopaminergic and serotonergic systems differentially 
modulate release of the two neurotransmitters, and the work suggests that SERT plays a 
significant role in regulating both release and uptake. In chapter 5, we further elucidate this 
role, showing how SERT inhibitors can potentiate serotonin release by dysregulating the 
control over serotonin signaling that occurs at a neuronal level. Finally, in chapter 6, we 
show how long-term SERT inhibition, modeled after chronic antidepressant therapies, causes 
enduring plasticity in the regulation of serotonin signaling. Importantly, this effect can be 
attenuated by ongoing stress throughout SSRI treatment. Taken together, chapters 5 and 6 
suggest that acute responses to SERT inhibition may predicate the therapeutic effects of 
long-term treatment. Non-serotonergic neurochemical responses to stress may modify 
serotonin signaling following acute and chronic SSRIs in a way that influences chronic 
therapeutic outcomes. Future work will focus on how environmental stress is transduced by 
the serotonergic system into adaptive behavioral responses. 
Support 
 The authors wish to thank the Electronics Facility at University of North Carolina for 
their contribution to selected studies cited in this review. Our work was funded by the 
National Institute of Health (R01 NS38879 to RMW). 
  
29 
 
Figure 1Figure 1.1 In vitro calibration of microelectrodes 
 
Figure 1.1 In vitro calibration of microelectrodes. (A) Voltage potential waveform, described 
by Jackson, et al. (1995), for detection of serotonin. (B) Cyclic voltammograms (current-
voltage curves) obtained for known concentrations of serotonin injected into a flow cell 
apparatus. The concentration (right) and its corresponding oxidation current amplitude (left 
axis) are noted by dashed lines. (C) Maximal oxidation current vs. concentration of serotonin. 
The data is fit to a linear regression (black line), the slope of which gives a calibration factor 
for serotonin measured at these electrodes. 
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Figure 2Figure 1.2 Illustration of a carbon-fiber microelectrode in SNr 
 
Figure 1.2 Illustration of a carbon-fiber microelectrode in SNr. Scaling of the microelectrode 
to in situ serotonergic fibers (gray) and uptake sites (yellow) is a representation based on 
Moukhles, et al. (1997).  
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Figure 3Figure 1.3 A model predicts serotonin release and uptake at different frequencies. 
 
Figure 1.3 A model predicts serotonin release and uptake at different frequencies. Top panel: 
Equation (i) describes rate of uptake (v) as a function of maximal uptake rate (Vmax), the 
Michaelis constant for SERT (KM), and concentration of released serotonin ([5-HT]). 
Equation (ii) describes the expected concentration of released serotonin given a stimulation 
with number of pulses (p) and frequency (f), less the uptake that occurs over this time period. 
Lower panel: Concentration evoked by 50 pulse stimulation trains at 100, 20, and 10 Hz, as 
predicted by the model. Traces are representations of data based on Bunin et al. (1998). 
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Figure 4Figure 1.4 Sample trace of in vivo serotonin release and uptake. 
 
 
 
 
 
Figure 1.4 Sample trace of in vivo serotonin release and uptake.  Release was elicited using 
60 pulses, 60 Hz, 325 uA stimulation of the DRN and recorded in mouse SNr. Average of 
signals from 7 subjects.  
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Figure 5Figure 1.5 A synopsis of the findings presented in this article. 
 
 
 
 
Figure 1.5 A synopsis of the findings presented in this article. Serotonin (5-HT) is 
synthesized from tryptophan in a two-step process requiring tryptophan hydroxylase and 
aromatic amino acid decarboxylase. Serotonin is packaged into vesicles by vesicular 
monoamine transporter 2 (VMAT2) and is released via calcium-dependent exocytosis. 
Released serotonin diffuses to extrasynaptic receptors and transporters via volume 
transmission. Its autoreceptors (5-HT1A, 1B, and 1D) are inhibitory and coupled to Gi 
proteins. The serotonin transporter (SERT) has high affinity and selectivity for uptake of 
extracellular serotonin. Inside the terminal, serotonin is primarily metabolized by monoamine 
oxidase (MAO). 
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CHAPTER 2: VOLTAMMETRIC DETECTION OF 5-HYDROXYTRYPTAMINE 
RELEASE IN THE RAT BRAIN 
2
 
Introduction 
5-Hydroxytryptamine (5-HT), or serotonin, is an electroactive indole that acts as an 
important neurotransmitter in the brain. It has been the focus of considerable research efforts 
over the last 30 years. Despite its implication in several neurological disorders such as 
depression and anxiety (Aghajanian & Wang, 1978), for which serotonin-altering 
medications are widely prescribed, little is known about its dynamics in the brain. 
Limitations in analytical techniques for in vivo 5-HT detection come from a combination of 
low endogenous levels and rapid uptake of 5-HT from the extracellular space. 
We have previously reported on the use of fast-scan cyclic voltammetry for in vivo 
dopamine monitoring (May, Kuhr, & Wightman, 1988; Stamford et al., 1984). Both 
dopamine and 5-HT undergo reversible 2-electron oxidations that yield characteristic and 
distinguishable cyclic voltammograms. However, unlike dopamine, the oxidative 
electrochemistry of 5-HT is complex, yielding many oxidation side-products which adsorb to 
the carbon surface on the conventional positive sweeping scan (Wrona & Dryhurst, 1990; 
Wrona, Lemordant, Lin, Blank, & Dryhurst, 1986). Even at the high scan rates (400 Vs
-1
) 
used to detect dopamine with fast scan cyclic voltammetry, these oxidation side-products still 
                                                          
2
 This chapter previously appeared as an article in Analytical Chemistry. The original citation is as follows: 
Hashemi P, Dankoski EC, Petrovic J, Keithley RB, and Wightman RM. “Voltammetric detection of 5-
Hydroxytryptamine release in the rat brain.” Anal. Chem. 81:22 (Nov 2009) pp. 9462-71. 
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polymerize and produce films that quickly and irreversibly foul the carbon surface. This 
fouling has been reported to be minimized on diamond microelectrode surfaces since the 
diamond surface expresses significantly less oxygen groups when compared to the carbon 
surface.6 These microelectrodes have been used to provide real-time monitoring of 5-HT in 
guinea ileum where the endogenous 5-HT levels are relatively high (10-20 μM) (Bertrand, 
Hu, Mach, & Bertrand, 2008; Patel, Bian, Quaiserova-Mocko, Galligan, & Swain, 2007). 
Neurochemical measurements with diamond microelectrodes however, remain a challenge in 
part due to the relatively large size of the microelectrodes (~76 μm diameter) (Park et al., 
2008). 76 μm is larger than inter-capillary distance in the rat brain (~30 μm); in brain tissue, 
such devices with dimensions larger than inter-capillary distance have been shown to cause 
tissue damage (Silvani et al., 2004). Even modest tissue damage caused by these 
microelectrodes may impede the measurements of synaptic 5-HT overflow that carbon fiber 
microelectrodes (~5 μm) are able to detect. 
In previous work, we modified the electrochemical waveform that is routinely used 
for dopamine monitoring with carbon fiber microelectrodes to minimize the majority of side 
reactions using Nafion-modified carbon-fiber disc microelectrodes (Jackson et al., 1995). We 
showed the feasibility of this modification for in vivo use via a model described by Stamford 
et al. (1990), where striatal dopaminergic cells are forced to release high levels of 5-HT by 
arresting dopamine production and pre-loading dopamine neurons with a 5-HT precursor (5-
HTP) (Bull et al., 1990). Although this was not a physiological situation, it demonstrated that 
fast-scan cyclic voltammetry can be applied to 5-HT measurements. This modified waveform 
also enables stable detection of 5-HT in tissue slice preparations in experiments that last up 
to 8 hours and in D. melanogaster (Borue et al., 2009; Bunin & Wightman, 1998; John & 
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Jones, 2007a). However, despite these studies, there remain no in vivo reports of the use of 
this approach for endogenous 5-HT detection. 
A major physiological difference between tissue slice preparations and the intact 
brain is the concentration of extracellular metabolites such as 5-hydoxyindole acetic acid (5-
HIAA). This metabolite is present at 200-1000 times the basal concentration of 5-HT in 
serotonin containing regions in the intact brain whereas in tissue slices, extracellular species 
such as ascorbic acid, and by the same reasoning 5-HIAA, wash out (Bell, McIlwain, & 
Thomas, 1956; Rice, 1999; Ross & Stenfors, 1997; Schenk, Miller, Gaddis, & Adams, 1982). 
5-HIAA is an indole with electrochemical oxidation properties similar to 5-HT. Given the 
high and persistent baseline extracellular concentrations of 5-HIAA, we hypothesize that in 
vivo microelectrode implantation in a 5-HT rich brain region, even in the absence of 5-HT 
release, will lead to a quick and profound deterioration of the microelectrode due to electrode 
fouling by 5-HIAA. 
Because 5-HIAA is negatively-charged in solution, cation exchange polymers such as 
Nafion can be deposited onto the microelectrode surface to limit its access. Carbon-fiber 
microelectrode discs can be dip-coated with Nafion in a straightforward process due to 
electrostatic properties of silica groups on the surface of the glass capillary (Baur, Kristensen, 
May, Wiedemann, & Wightman, 1988; Jackson et al., 1995). However, the small surface area 
of the discs makes them unsuitable for in vivo use: the microelectrode must have a larger 
surface area to sample enough release sites to record a substantial signal since these sites are 
not uniformly distributed throughout the tissue. Cylindrical carbon-fiber microelectrodes 
provide a large enough surface area to address this problem but uniform deposition of Nafion 
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onto cylindrical carbon-fiber microelectrodes is more challenging because the carbon fibers 
are inherently hydrophobic, and thus repel the negatively-charged polymer. 
In this paper, we modify a technique described by Rice et al. to electrochemically 
deposit a thin, uniform layer of Nafion onto a cylindrical carbon-fiber microelectrode (Rice 
& Nicholson, 1989). Environmental scanning electron microscopy (ESEM) imaging displays 
the Nafion film on the carbon fiber surface and in vitro analyses confirm an attenuation of 
diffusible 5-HIAA to the microelectrode surface. Furthermore, the Nafion coating increases 
the sensitivity of the microelectrode to 5-HT. The cyclic voltammogram can easily be 
distinguished from other electroactive brain species, and common anionic species such as 
ascorbic acid are repelled. In previous work, we showed that microelectrodes with Nafion 
films of 340 nm still allowed rapid enough time responses to observe in vivo chemical 
dynamics (Kawagoe & Wightman, 1994). In this work, we modify the experimental 
deposition parameters to obtain a similar thickness. Using an in vitro dopamine step response 
and the diffusion coefficient of dopamine through Nafion, we calculate the thickness of the 
elecrodeposited Nafion film. Further, we back-calculate a diffusion coefficient for 5-HT 
through Nafion. 
To validate this modified technique in vivo, we apply the microelectrodes to a rat 
model of 5-HT release in which we electrically stimulate 5-HT cell bodies in the dorsal raphe 
nucleus (DRN) and measure their terminal output in the substantia nigra reticulata (SNpr). 
The efficacy of the technique is verified by addressing previously described criteria for 
validation of microsensor selectivity in vivo (P. E. M. Phillips & Wightman, 2003). These 
include voltammetric identity, anatomical and physiological verification, chemical validation 
of 5-HT presence in release sites and pharmacological validation. 
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Experimental Methods 
Carbon-fiber Microelectrodes 
Carbon-fiber microelectrodes were constructed as described previously (Cahill et al., 
1996). Cylindrical microelectrodes were made by vacuum aspiration of single a 2.5-μm-
radius T-650 carbon fiber (Thornel, Amoco Co.) into a glass capillary of 0.6 mm external 
diameter and 0.4mm internal diameter (A-M Systems, Inc., Sequim, WA). A micropipette 
puller (Narashige, Tokyo, Japan) was used to taper the glass and form a carbon-glass seal. 
The exposed length of the carbon fiber was cut to approximately 100 μm. 
Nafion Electrodeposition 
The exposed length of carbon fiber from the glass tip of the microelectrode was 
soaked for 30 minutes in isopropyl alcohol (IPA) to clean the surface (Ranganathan, Kuo, & 
McCreery, 1999). The procedure for electrodeposition of Nafion was modified from work by 
Rice et al.(1989).  The tip of microelectrode was lowered in Nafion solution (5 wt% 1100 
EW NAFION ® in methanol, ION POWER, DE) and a constant potential of + 1.0 V vs. 
Ag/Ag Cl was applied to the microelectrode surface for 30 seconds. The microelectrode was 
dried in air for 10 seconds and then at 70º C for 10 minutes. The microelectrodes were stored 
dry prior to use. 
Environmental Scanning Electron Microscopy 
ESEM allows for imaging of low conductance or entirely non-conductive samples 
while eliminating the need for sputter coating. Control and Nafion-modified microelectrodes 
were imaged in low-vacuum (0.65 Torr) on a FEI Quanta 200 ESEM equipped with Schottky 
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field emission gun (accelerating voltage used in the studies was 10 kV); secondary electron 
images were obtained with a large field secondary electron detector. 
Data Acquisition 
In most experiments, a 5-HT specific waveform was used as described elsewhere 
(Jackson et al., 1995). Briefly, this waveform was applied with a scan rate of 1000 V s
−1
 with 
a resting potential of 0.2 V versus Ag/AgCl. The potential is ramped up to 1.0 V, then down 
to -0.1 V and back to resting potential of 0.2 V. In one experiment, the conventional 
dopamine waveform was used as described by Heien et al. (Heien, Phillips, Stuber, Seipel, & 
Wightman, 2003).  In brief, this triangular waveform was applied at 400 V s
-1
 with a resting 
potential of -0.4V. The potential is then ramped up to 1.3V and back to the resting potential 
of -0.4 V. In both cases, scans were repeated every 100 ms. A customized version of TH-1 
software (ESA, Chelmsford, MA) written in LABVIEW (National Instruments, Austin, TX) 
was used for waveform output and data acquisition. The software allowed output of 
waveforms with a DAC/ADC card (NI 6251 M). The second card (NI 6711) was used for 
triggering the DACs and ADCs as well as for synchronization of the electrochemical 
experiment with flow injection of the analytes. A custom-built instrument for potential 
application to the electrochemical cell and current transduction (University of North Carolina 
at Chapel Hill, Department of Chemistry Electronics Facility) was employed. Signal 
processing (background subtraction, signal averaging, and digital filtering (4-pole Bessel 
Filter, 5 kHz)) was software-controlled. 
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Chemicals 
5-HT, 5-HIAA, dopamine, norepinephrine, epinephrine, DOPAC (3,4-dihydroxyphenylacetic 
acid), ascorbic acid, citalopram and GBR 12909 were purchased and used as received from 
Sigma−Aldrich. A physiological buffer solution (15 mM Tris, 126 mM NaCl, 2.5 mM KCl, 
25 mM NaHCO3, 2.4 mM CaCl2, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 2.0 mM Na2SO4) at 
pH 7.4 was used in all flow injection analysis experiments. All aqueous solutions were made 
using doubly distilled deionized water (Megapure System, Corning model D2). 
Flow Injection Apparatus 
The flow injection analysis apparatus has been described elsewhere (E. W. 
Kristensen, Wilson, & Wightman, 1986a). Briefly, the carbon-fiber microelectrode was 
affixed in the output of a flow-injection apparatus that consisted of a six-port HPLC loop 
injector mounted on a two-position actuator (Rheodyne model 7010 valve and 5701 actuator) 
that was operated with a 12 V DC solenoid valve kit (Rheodyne, Rohnert Park, CA). The 
apparatus allowed for the introduction of a rectangular pulse of analyte to the microelectrode 
surface by a syringe infusion pump (Harvard Apparatus model 940, Hollison, MA) at a flow 
rate of 2 mL min
-1
. 
Modeling of Film Thickness and Diffusion Coefficients 
A procedure from Kawagoe and Wightman was modified in order to determine both 
the thickness of the Nafion film, lp, and the diffusion coefficient of 5-HT inside the Nafion 
film, D5-HT (Kawagoe & Wightman, 1994). The response to a step concentration of 
dopamine (10 μM) was measured on a Nafion-coated carbon-fiber microelectrode using the 
modified 5-HT waveform in the flow injection system. The process was repeated with the 
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same microelectrode for a step concentration of 5-HT (1 μM). Each peak current vs. time 
trace was extracted, corrected to zero background, and normalized to a maximum of 1. The 
normalized dopamine trace was fit to the equation:  
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 (Eq. 1) 
where C(t) is the concentration at the microelectrode surface, C0 is the concentration in bulk 
solution outside the Nafion film, D is the diffusion coefficient of the analyte inside of the 
Nafion film, and t is the time from the initial exposure to the concentration bolus. lp was 
allowed to vary between 1 and 1000 nm in 1 nm increments. A value of 1 x 10-9 cm
2
s
-1
 
(from previous work) was used for the diffusion coefficient for dopamine inside the Nafion 
film, DDA, this value closely resembles the reported values through thick Nafion films 
(Kawagoe & Wightman, 1994; Rocha & Carapuca, 2006). The value of lp that gave the best 
least-squares fit between the model and the step concentration of dopamine was used as an 
initial estimate for the thickness of the Nafion film. This thickness was used in Equation 1 to 
fit the normalized response to the 5-HT concentration step where D5-HT was allowed to vary 
between 0.1 x 10-10 cm
2
s
-1
 and 1.0 x 10-8 cm
2
s
-1
 in 0.1 x 10-10 cm
2
s
-1
 steps. The value of 
D5-HT that gave the best least-squares fit between the model and the step concentration of 5-
HT was used to generate an improved estimate for lp which was then used to obtain an 
improved estimate for D5-HT and the process was repeated iteratively until the solutions for 
lp and D5-HT converged. 
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Surgery 
Male Sprague-Dawley rats weighing between 350-425 grams were anaesthetized with 
urethane (1.5 g/kg rat weight) and positioned into a stereotaxic frame. Holes were drilled in 
the skull according to stereotaxic coordinates referenced to bregma and taken from a 
stereotaxic atlas (Paxinos & Watson, 2007). Placement of the carbon-fiber microelectrode 
was in the SNpr (stereotaxic coordinates AP, -5.2; ML, +2.0; DV, −8.5 mm) and the bipolar 
stimulating electrode in the DRN (AP −8.0; ML, 0.0; DV, −6.0 mm). The Ag/AgCl wire that 
served as the reference electrode was implanted into the contralateral hemisphere. Biphasic 
stimulating pulses, 2 ms each phase, 300 μA each phase, were applied at 60 Hz for two 
seconds to evoke 5-HT release. Stimulation-evoked release was recorded during and after the 
stimulation, and selectivity for 5-HT was verified pharmacologically. Clearance of 5-HT 
from the extra-cellular fluid depends largely upon selective re-uptake through serotonin 
uptake transporters (SERTs), and these transporters can be blocked by selective serotonin 
reuptake inhibitors (SSRIs) (Hyttel, 1982). To pharmacologically verify our signal, we 
administered the SSRI citalopram (10 mg kg
-1
) (Hyttel, 1982). Similarly, clearance of 
dopamine can be selectively blocked by administration of a dopamine transporter (DAT) 
inhibitor, GBR 12909 (Andersen, 1989); we administered GBR 12909 (15 mg kg
-1
) to 
ascertain contribution of dopamine to the signal (May et al., 1988).  
Results and Discussion 
Characterization of Cylindrical Microelectrodes with the 5-HT Modified Waveform 
We have characterized 5-HT detection with the waveform employed by Jackson et al. 
(1995) but with cylindrical carbon-fiber microelectrodes without Nafion coatings. Figure 2.1 
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shows in vitro comparisons between a single injection of either dopamine (1 and 2) or 5-HT 
(3 and 4) onto clean microelectrodes with (A) the conventional waveform used for detection 
of dopamine at 400 Vs
-1
 and (B) the modified Jackson waveform at 1000 Vs
-1
. The color 
plots are a 2-dimensional representation of the cyclic voltammograms with current changes 
detected upon injection of the sample shown in false color (D. J. Michael, Joseph, Kilpatrick, 
Travis, & Wightman, 1999). Individual cyclic voltammograms recorded at three time points 
during the injection (1, 3 and 5 s) are displayed under each color plot. With the conventional 
waveform (A), a typical dopamine response (1) shows the cyclic voltammograms are stable 
throughout the injection. In contrast, a 5-HT injection using this waveform (Chazal & 
Ralston) yields a cyclic voltammogram that changes at each time point, gaining extra peaks 
both on the forward and backward parts of the scan. This is indicative of the adsorption of 
products formed during the electrooxidation. This problem does not occur with the modified 
waveform for 5-HT (4), in which the cyclic voltammograms retain their shape throughout the 
injection as previously reported.11 This is predominantly due to two characteristics of the 
modified waveform. First, when scanning at 1000 Vs
-1
 compared to 400 Vs
-1
, more of the 
side reactions are outrun. Second, by holding the rest potential of the microelectrode at 0.2 V, 
the major adsorbed product is oxidized and its contribution to the current during the scan is 
minimized. A further point of interest is that the modified waveform does not show as good 
sensitivity towards dopamine (2), yielding approximately 8 nA for a 10 μM dopamine 
injection compared to 20 nA for a 1 μM 5-HT injection. Further, the cyclic voltammogram 
for dopamine can be easily distinguished from 5-HT by its reduction peak, which occurs on 
the positive scanning part of the wave (shown in red arrows). Dopamine reduction ordinarily 
occurs at -0.2V, which is beyond the negative sweep of the modified waveform. The 
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reduction peak on the forward part of the negative scan is most likely due to the reduction of 
the quinone group on dopamine-o-quinone, a reaction that at 1000 Vs
-1
 is kinetically 
sluggish. 
Microelectrode Fouling by 5-HIAA 
Despite the fact that the modified 5-HT waveform has previously been implemented 
for recordings in D. melanogaster (Borue et al., 2009), tissue slice preparations (Bunin & 
Wightman, 1998; John & Jones, 2007a), and in vivo models with preloaded dopaminergic 
cells (Jackson et al., 1995), we found that the electrochemical signal deteriorated during in 
vivo endogenous 5-HT monitoring. In preliminary in vivo investigations with the 5-HT 
waveform, we stimulated 5-HT release by DRN stimulation and measured in the SNpr. In 
contrast to the Jackson study where 5-HT release was evoked artificially in a brain region 
that is physiologically dopaminergic, the SNpr has high 5-HT content. In the SNpr, the 
electrochemical responses were very low in amplitude and the cyclic voltammograms were 
irreproducible. The oxidation and reduction peaks observed on an in vivo cyclic 
voltammogram show little similarity to the in vitro chemical signature for 5-HT shown in 
Figure 2.1-4. In vivo, a small oxidation peak is recorded on the initial positive scan, but a 
larger peak occurs on the subsequent negative scan. Additionally, the in vitro signal has a 
reduction peak at 0 V on the negative scan, whereas the in vivo cyclic voltammogram has this 
peak on the forward part of the negative scan (Figure 2.2A). The appearance of peaks on the 
reverse scans of in vivo signals indicates filming at the carbon fiber surface, which slows 
oxidative and reductive processes. 
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The results shown in Figure 2.1-4 indicate that the filming is not due to 5-HT 
oxidation, since it does not occur with 5-HT alone in solution. The major metabolite of 5-HT 
in the brain, 5-HIAA, may contribute to this filming. It is present in the extracellular fluid in 
concentrations that are approximately 200-1000 times that of 5-HT (Ross & Stenfors, 1997). 
These two indoles are very similar in structure and may consequently have similar filming 
electrochemistry. Therefore, we added 5-HIAA (10 μM) to the flow injection buffer and the 
solutions of 5-HT. In this experiment, the microelectrode was cycled in the 5-HIAA 
containing buffer for two hours before injection. Cyclic voltammograms of 5-HT obtained 
under these conditions resemble those obtained in vivo (Figure 2B). Note that this fouling has 
not been observed in rat brain slices, wherein reproducible cyclic voltammograms can be 
obtained for up to 8 hours (Bunin & Wightman, 1998; John & Jones, 2007a). However, in 
slices, the tissue is continually perfused, allowing for washout of extracellular substances. 
For example ascorbate is rapidly lost from the perfused slices for this reason, and the same 
appears true for 5-HIAA (Bell et al., 1956; Rice & Nicholson, 1989; Schenk et al., 1982). 
This filming was not an issue in the Jackson et al. study, in which we recorded super-
physiological concentrations of 5-HT release with a Nafion-modified microelectrode disc 
(Jackson et al., 1995). Interestingly, monoamine oxidase (MAO), the enzyme responsible for 
5-HIAA formation is profoundly less active in D. melanogaster than in mammalian nervous 
tissue, which minimizes the problem of 5-HIAA fouling in the fruit fly model (Dewhurst, 
Croker, Ikeda, & McCaman, 1972). We conclude that it is not feasible to obtain in vivo cyclic 
voltammograms that have the shape found in vitro in brain regions with high levels of 5-HT 
because of fouling of the microelectrode by 5-HIAA. 
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Exclusion of 5-HIAA from the Microelectrode Surface 
5-HIAA is an anion at physiological pH. To exclude anions from carbon 
microelectrodes a cation exchange polymer is a popular choice (Baur et al., 1988; Brazell et 
al., 1987; G. A. Gerhardt, A. F. Oke, G. Nagy, B. Moghaddam, & R. N. Adams, 1984). Our 
own work has employed carbon-fiber microelectrode discs that can be coated with a thin 
layer (~300 nm) of Nafion by a dip-coating procedure (Cahill et al., 1996; Jackson et al., 
1995; Kawagoe & Wightman, 1994; May et al., 1988; Wiedemann, Basse-Tomusk, Wilson, 
Rebec, & Wightman, 1990). Nafion adsorbs readily to the silica groups of the glass barrel in 
which the microelectrode is housed. However, with a cylindrical microelectrode, the 
hydrophobic carbon fiber extends 75 – 100 μm beyond the glass barrel and is thus not 
proximate to these silica groups. Further, the dip-coating procedure does not uniformly coat 
the surface of the microelectrode. Because of its negative charge, Nafion® can be 
electrostatically deposited onto cylinders (Brazell et al., 1987; Rice & Nicholson, 1989). We 
applied +1.0 V vs. Ag/Ag Cl to the cylindrical microelectrode while immersed in a 5% 
Nafion solution in methanol. These parameters were chosen to provide protection against 5-
HIAA while still maintaining a film sufficiently thin that the response time is not greatly 
increased. Figure 2.3i shows ESEM images comparing (A) a bare cylinder to (B) a Nafion-
modified cylinder. The resolution of the instrument allows us to observe individual striations 
on the surface of the bare carbon-fiber microelectrode; however, because of electroformation 
of a film, these striations are indistinguishable on the Nafion-modified carbon fiber. Also 
apparent is the excess extension of this film beyond the tip of the carbon fiber on the Nafion-
modified microelectrode. 
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Figure 2.3ii shows a comparison between (A) a bare microelectrode to (B) a Nafion-
modified microelectrode in their responses to 1 μm 5-HT (dashed line) and 10 μM 5-HIAA 
(solid line). Both microelectrodes measured approximately 100 μm in length. Before Nafion 
coating, the sensitivity to 5-HT is about 30 times greater than for 5-HIAA. This is a result of 
the greater adsorption of 5-HT. Nafion deposition reduces the 5-HIAA response at the 
microelectrode surface: in the displayed example, a bare microelectrode yields 10.7 nA in 
response to a 10 μM 5-HIAA injection, whereas a Nafion-modified microelectrode yields a 
3.3 nA response. Moreover, in this example, the Nafion-modified microelectrode displays 
increased sensitivity to a 1 μM 5-HT injection, yielding 36.5 nA compared to the bare 
microelectrode response, 26.5 nA. On average, Nafion-modified microelectrodes yield 49.5 ± 
10.24 nA to a 1 μM 5-HT injection compared with 20.8 ± 1.84 nA for a bare electrode (n=4 ± 
SEM) (Table 2.1). 
Exclusion of Electronegative Species and Survey of Other Endogenous Electroactive 
Neurotransmitters 
Averaged responses (n=4) to common anionic and cationic species on a bare 
microelectrode compared to a Nafion electrodeposited microelectrode are presented in Table 
2.1. We observe enhanced sensitivity to 5-HT and dopamine, sensitivity to norepinephrine 
and epinephrine remained approximately unchanged, and decreased sensitivity to the anions 
ascorbic acid, DOPAC, and 5-HIAA. These differences arise from the partition of the species 
between the Nafion film and the solution. Importantly, the 5-HT molecule pre-concentrates 
in the Nafion membrane and results in the observed sensitivity enhancement, a phenomenon 
that has previously been reported to be advantageous for chemical sensors. The increased 
sensitivity of Nafion-modified microelectrodes is also evident in the averaged 5-HT 
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calibrations for these two microelectrodes in a flow-through buffer that contains 
physiological levels of 5-HIAA (Figure 2.3iii), where the fouling species are repelled. After 
Nafion electrodeposition, the microelectrode is almost 200 times more sensitive to 5-HT than 
to 5-HIAA. 
To confirm exclusion of other electroactive anions, we compared responses of bare 
and Nafion-modified microelectrodes to other endogenous species. Figure 2.4 compares the 
responses of bare (grey) to Nafion-modified (black) microelectrodes to (i) ascorbic acid (400 
μM), (ii) DOPAC (20 μM), and (iii) 5-HIAA (10 μM). A shows the averaged responses to 
these species (n=4 ± SEM) while B shows a single example of the corresponding cyclic 
voltammograms for bare (grey, dashed) and Nafion-modified (black, solid). The 
concentration ratios chosen are in the physiological range (Miele & Fillenz, 1996; Smith, 
Olson, & Justice, 1992). It is evident that Nafion-modified microelectrodes exclude the 
negatively-charged specie compared to bare microelectrodes. The ascorbic acid response is 
reduced from 50.6 ± 15.6 nA to 20.0 ± 4.7 nA. The DOPAC response is reduced from 4.9 ± 
1.2 nA to 1.6 ± 0.2 nA. Finally, the 5-HIAA response is reduced from 13.8 ± 1.6 nA to 2.9 ± 
0.9 nA. Thus, Nafion electrodeposition enhances specificity for 5-HT by excluding anions. 
Diffusion of 5-HT through a thin Nafion Film 
In previous work, we modeled a dopamine step concentration response and calculated 
the thickness of a Nafion dip-coated microelectrode disc to be 340 nm (Kawagoe & 
Wightman, 1994). This thickness, despite slowing response time, still allows for observations 
of dynamic chemical changes associated with release and uptake of dopamine. We chose our 
electrodeposition parameters to attain this magnitude of thickness on our electrodeposited 
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microelectrodes. Figure 2.5 shows a representative example application of Equation 1 in 
modeling step concentrations of dopamine and 5-HT in a flow injection system to determine 
lp and D5-HT. A shows simulations for various values of lp to a normalized step 
concentration of dopamine, assuming a value of 1.0 x 10-9 cm
2
s
-1
 for DDA (from previous 
work), which is very close to the value reported for thick films (1.5 x 10-9 cm
2
s
-1
) (Kawagoe 
& Wightman, 1994; Rocha & Carapuca, 2006). For the microelectrode shown in Figure 2.5, 
lp is approximately 300 nm. Figure 2.5B shows simulations for various values of D5-HT to a 
normalized step concentration of 5-HT, using lp from the best fit model to the step in 
dopamine concentration. A value for D5-HT of approximately 5.0 x 10-10 cm
2 
s
-1
 best fits 
the experimental step in 5-HT concentration for this microelectrode. The value of D5-HT 
was used to improve the solution for lp, which was used to improve the solution to D5-HT 
and the process was repeated until values for lp and D5-HT converged. Values for lp and D5-
HT were determined to be 340 + 8 nm and 7.6 + 0.8 x 10
-10
 cm
2
s
-1
, respectively (average + 
SEM, n=5). The value of lp is consistent with values obtained by dip coating carbon-fiber 
microelectrode discs (Kawagoe & Wightman, 1994). As expected, D5-HT and DDA are both 
several orders of magnitude smaller than conventional values for diffusion coefficients in 
bulk solution because these molecules are diffusing through a denser polymer network. In 
addition, D5-HT is smaller than that of DDA, which is consistent with values obtained 
previously in bulk solution (Gerhardt & Adams, 1982). 
In Vivo Electrochemical Identification 
To validate the in vivo signal, we address previously described criteria for 
characterization of a novel electrochemical signal (P. E. M. Phillips & Wightman, 2003). 
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Figure 2.6i compares the normalized cyclic voltammograms of 50 nM 5-HT in vitro 
to that obtained in SNR in vivo. Close similarity between the shapes of the cyclic 
voltammograms confirms identification of 5-HT in vivo (r
2
 = 0.94). Figure 2.6ii is the 
corresponding color plot from which this cyclic voltammogram is taken at the time indicated 
by the dashed white line. 
In vivo microdialysis coupled to HPLC in the SNpr confirms the release of 5-HT in 
the SNpr brain region (Bergquist, Shahabi, & Nissbrandt, 2003; Hewton, Salem, & Irvine, 
2007; Thorre, Sarre, Ebinger, & Michotte, 1997). Tissue content analysis in the SNpr 
confirms the presence of endogenous 5-HT at high levels (Palkovits, Brownstein, & 
Saavedra, 1974; Reubi & Emson, 1978). 
In vivo investigations of DRN electrical stimulation have shown that stimulations 
even lower than 60 Hz are sufficient for evoking serotonin release (Hajos-Korcsok & Sharp, 
2002). Autoradiographic tracing studies report on the existence of a serotonergic pathway 
from the DRN to the SNpr (Azmitia & Segal, 1978; Halaris, Jones, & Moore, 1976; Moore, 
Halaris, & Jones, 1978a; Wirtshafter, Stratford, & Asin, 1987). While there are no reports of 
a dopaminergic projection from the DRN to the SNpr (Stratford & Wirtshafter, 1990), the 
target location of the microelectrode is proximal to dopamine terminals in a region just above 
the SNpr, the substantia nigra pars compacta (SNpc), which could theoretically contribute 
erroneously to the signal. Figure 2.6ii demonstrates stimulation-evoked 5-HT release in the 
target area (8.5 mm ventral to the top of the skull) of the SNpr. Figure 6iii demonstrates that 
little release is measured 1.5 mm above the SNpr (7 mm ventral to the top of the skull), 
confirming specificity of the anatomical placement of the microelectrode. 
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Lastly, although we have shown that the modified microelectrode displays almost 50 
times more sensitivity to 5-HT than to dopamine in vitro, we verify pharmacologically that 
dopamine does not contribute to the in vivo signal. We administered GBR 12909 (15 mg kg
-
1
) and citalopram, (10 mg kg
-1
) pharmaceutical agents that respectively inhibit re-uptake of 
dopamine by DAT or 5-HT by SERT (Andersen, 1989; Hyttel, 1982). If the transporter 
specific to the analyte is blocked, clearance time of the released specie will increase. Figure 
2.7 shows stimulated release of 5-HT upon (A) control, (B) GBR 12909, and (C) citalopram 
treatments in the same anaesthetized rat displayed as current in 2-dimensional false color (i) 
and concentration vs. time traces (ii). GBR 12909 has no significant effect on analyte 
amplitude or clearance, whereas citalopram significantly increases release amplitude and 
more importantly, clearance time, providing pharmacological identification of the released 
specie as 5-HT. 
As we have confirmed the identity of the released analyte according to the criteria of 
Phillips and Wightman (2003), we report that the presented technique enables the first 
quantitative, in vivo sub-second recording of 5-HT release and uptake. 
Conclusion 
FSCV of in vivo 5-HT is challenging due to the electrochemically fouling side-
products produced when 5-HT is oxidized. The electrochemical modifications that allow 5-
HT to be monitored in tissue slice preparations and in D. melanogaster are not sufficient for 
in vivo monitoring where there are persistent and high levels of fouling 5-HT metabolites 
such as 5-HIAA. By electrodepositing Nafion onto cylindrical carbon-fiber microelectrodes, 
we have shown that 5-HIAA can be excluded from the microelectrode surface; moreover, 
due to pre-concentration of the positively-charged 5-HT ions in solution, the microelectrodes 
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are 50 – 100% more sensitive to 5-HT. Having reproduced the dip-coated thickness of the 
Nafion film (~300 nm) described by our own previous work (Kawagoe & Wightman, 1994), 
we back-calculated a diffusion coefficient for 5-HT through a Nafion film on a cylindrical 
carbon-fiber microelectrode. The Nafion-modified cylinders significantly exclude 
contributions from common brain anions. Validation of the in vivo signal meets previously 
established criteria for identification of a novel analyte with a microsensor: we have 
demonstrated electrochemical validation, established independent chemical analyses, verified 
anatomical and physiological feasibility as well as pharmacological characterization of the 
signal. 
We have used this technology to present the first measurement of 5-HT release and uptake in 
vivo. We plan to apply this method to answer long-anticipated questions regarding the 
dynamics, characteristics, and pharmaceutical effects of 5-HT in vivo. 
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Figure 6Figure 2.1 Comparison of waveforms for detection of dopamine and serotonin 
 
Figure 2.1 Comparison of waveforms for detection of dopamine and serotonin. Signals 
shown were obtained following introduction of dopamine (1 and 10 μM) (top) and 5-HT (1 
μM) (bottom) into a flow injection system. employing both the traditional (A) and modified 
(B) waveforms. The current response is represented in false color. Representative cyclic 
voltammograms (vs. Ag/Ag Cl) at time points (i), (ii) and (iii) are single scans recorded at 1, 
3, and 5 s post sample injection, respectively. 
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Figure 7Figure 2.2 Comparison of cyclic voltammograms obtained in vivo vs. in vitro 
 
 
 
 
 
Figure 2.2 Comparison of cyclic voltammograms obtained in vivo vs. in vitro. Cyclic 
voltammograms (vs. Ag/Ag Cl) for (A) the signal obtained in vivo with DRN stimulation and 
SNpr measurement and (B) in vitro signal obtained via 1 μM 5-HT injection onto the 
microelectrode after it had cycled for 2 hours in a buffer containing physiological levels of 5-
HIAA (10 μm). 
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Figure 8Figure 2.3 Nafion-modified microelectrodes are more sensitive to 5-HT. 
 
Figure 2.3 Nafion-modified microelectrodes are more sensitive to 5-HT. Top panel (i) shows 
ESEM images for (A) bare microelectrode and (B) Nafion-modified microelectrode. Panel 
(ii) shows cyclic voltammograms (vs. Ag/Ag Cl) for (A) a bare microelectrode compared to a 
(B) Nafion-modified microelectrode and their responses to 10 μM 5-HIAA (black line) and 1 
μM 5-HT (grey dashed line). Bottom panel (ii) shows the respective concentration vs. current 
calibrations of (A) a bare microelectrode and (B) a Nafion-modified microelectrode in a 
buffer containing physiological levels of 5-HIAA (10 μM). The values are averages (n=4) ± 
SEM. The data is plotted with a polynomial line of best fit. 
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igure 9Table 2.1 Comparison of Responses of Bare vs. Nafion-Modified  
Microelectrodes to Common Brain Species 
 
Species 
Average Response 
 
Bare Electrode 
(nA ± SEM) 
Nafion Electrode 
(nA ± SEM) 
Nafion / Bare 
5-HT (1 μM) 20.8 ± 1.83 49.50 ± 10.24 2.38 
Dopamine (10 μM) 8.50 ± 1.33 12.07 ± 2.61 1.42 
Norepinephrine (10 μM) 8.30 ± 3.50 7.45 ± 1.42 0.90 
Epinephrine (10 μM) 6.63 ± 3.80 6.32 ± 0.70 0.95 
Ascorbic Acid (400 μM) 50.62 ± 15.63 20.02 ± 4.73 0.40 
DOPAC (20 μM) 4.90 ± 1.17 1.55 ± 0.24 0.32 
5-HIAA (10 μM) 13.78 ± 1.63 2.85 ± 0.90 0.21 
 
Table 2.1 Comparison of Responses of Bare vs. Nafion-Modified Microelectrodes to 
Common Brain Species. Averaged in vitro responses obtained from four electrodes for 
common electroactive brain species on bare and Nafion®-modified microelectrodes. The 
values are an average (n=4 ± SEM). 
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Figure 10Figure 2.4 Response of bare and Nafion-modified electrodes to common electronegative species 
 
Figure 2.4 Response of bare and Nafion-modified electrodes to common electronegative 
species. Comparison of the responses of bare (grey) and Nafion-modified (black) 
microelectrodes to electronegative species (i) ascorbic acid, (ii) DOPAC and (iii) 5-HIAA in 
vitro. The values are averages (n=4) ± SEM. (B) shows single examples of the cyclic 
voltammograms (vs. Ag/Ag Cl) for bare (dashed grey line) and Nafion®-modified (black 
solid line) for (i) ascorbic acid, (ii) DOPAC and (iii) 5-HIAA.   
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Figure 11Figure 2.5 Determination of lp and D5-HT for a Nafion-coated carbon-fiber microelectrode using flow 
injection analysis 
 
 
 
Figure 2.5 Determination of lp and D5-HT for a Nafion-coated carbon-fiber microelectrode 
using flow injection analysis. Panel A shows a normalized peak current response (grey 
dashed) towards a step concentration in dopamine (10 μM) fitted with equation 1 using 
various example values of lp, assuming a value of DDA of 1 x 10-9 cm2s-1 (solid black 
lines). Panel B shows a normalized peak current response towards a step concentration of 5-
HT (1 μM) fitted with equation 1 using various example values of D5-HT and a value of lp 
obtained from the best fit to the dopamine step concentration. 
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Figure 2.6 Electrochemical and anatomical validation of 5-HT detection. Panel (i) shows a 
normalized comparison of an in vivo signal (black solid) to an in vitro 5-HT (100 nM) 
measurement. Panel (ii) is the corresponding in vivo color plot with potential on y-axis 
plotted against time on the x-axis at 8.5 mm ventral to the surface of the skull, the white dash 
line signifies the time section at which the cyclic voltammogram is taken. The current 
response is represented in false color, the black line horizontal to the x-axis is the duration of 
the stimulation. Panel (iii) is the in vivo color plot with potential on y-axis plotted against 
time on the x-axis at 7 mm ventral to the surface of the skull.  
Figure 12Figure 2.6 Electrochemical and anatomical validation of 5-HT detection. 
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Figure 2.7 Pharmacological validation of 5-HT signal with GBR 12909 and citalopram. The 
top panel shows the potential on y-axis plotted against time on the x-axis, the current 
response is represented in false color. The black blocks horizontal to the x-axis are the 
durations of the stimulations. The bottom traces show concentration vs. time. These 
responses are for (A) stimulation-evoked control response, (B) 40 minutes after systemic 
administration of GBR 12909 (15 mg kg
-1
) and (C) 40 minutes after systemic administration 
of citalopram (10 mg kg
-1
). 
 
 
 
 
 
 
 
 
Figure 13Figure 2.7 Pharmacological validation of 5-HT signal with GBR 12909 and citalopram 
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CHAPTER 3: SIMULTANEOUS SEROTONIN AND HISTAMINE RELEASE 
FOLLOWING MEDIAL FOREBRAIN BUNDLE STIMULATION 
3
 
Introduction 
5-HT is an important neuromodulator and dysfunctions of the 5-HT system are 
particularly well-documented in neurological disorders such as anxiety and depression (Petty, 
Davis, Kabel, & Kramer, 1996). In vivo neurochemical measurements of 5-HT are necessary 
for furthering our understanding of the mechanisms that govern these disorders, and will 
improve their diagnosis and treatment. Microdialysis studies have correlated in vivo basal 
level 5-HT changes to behavioral and pharmacological manipulations (Barnes & Sharp, 
1999; Rueter, Fornal, & Jacobs, 1997). Basal 5-HT levels are determined by numerous 
individual neurotransmission events that are averaged in one microdialysis reading 
(Robinson & Wightman, 2007) and to fully understand the mechanisms that underlie these 
slow changes requires quantitative, sub-second endogenous 5-HT detection. This has 
traditionally been accomplished with fast-scan cyclic voltammetry (FSCV) in tissue slice 
preparations (Bunin & Wightman, 1998; John et al., 2006; O'Connor & Kruk, 1991a; Rice et 
al., 1994). These studies have provided a solid understanding of 5-HT release and uptake 
kinetics (Bunin et al., 1998), 5-HT receptor pharmacology (Davidson & Stamford, 1996; 
Threlfell et al., 2010), and 5-HT metabolism by monoamine oxidase (John & Jones, 2007b). 
Recently, FSCV has been used to perform similar characterizations in D. melanogaster 
                                                          
3
 This chapter previously appeared as an article in Journal of Neurochemistry. The original citation is as 
follows: Hashemi P, Dankoski EC, Wood KM, Ambrose RE, and Wightman RM. “In vivo electrochemical 
evidence for simultaneous 5-HT and histamine release in the rat substantia nigra pars reticulata following 
medial forebrain bundle stimulation.” J. Neurochem. 118, 5 (Sep 2011) pp. 749-59. 
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(Borue et al., 2010; Borue et al., 2009). While these types of studies are essential to describe 
basic 5-HT mechanisms, in vivo measurements in a mammalian brain are necessary to 
understand how 5-HT dynamics are modulated in the complex entity of the intact nervous 
system. Recently we described a FSCV technique in which carbon-fiber microelectrodes 
were coated with Nafion to monitor 5-HT in vivo (Hashemi et al., 2009). The Nafion 
modification reduces electrode fouling while increasing its sensitivity to 5-HT. This is the 
first technique capable of monitoring endogenous, in vivo 5-HT release and uptake on a sub-
second time scale. In this previous work, we established a physiological model where we 
evoked 5-HT release with a bipolar stimulating electrode in the dorsal raphe nucleus (DRN), 
the location of 5-HT cell bodies, and recorded terminal 5-HT release and uptake in the 
substantia nigra pars reticulata (SNpr) (Hashemi et al., 2009).   
In this paper, we explore an alternative method of evoking 5-HT release in the SNpr. 
Using the well-documented efferent circuitry of the DRN (Azmitia & Segal, 1978; Imai, 
Steindler, & Kitai, 1986; Moore, Halaris, & Jones, 1978b; Parent, Descarries, & Beaudet, 
1981), we exploit a branched 5-HT projection to both the SNpr and the striatum (Imai et al., 
1986; van der Kooy & Hattori, 1980) that is located in the medial forebrain bundle (MFB). 
We previously showed that electrical stimulation of the MFB released an unidentified 
substance in the red nucleus of the rat, that we suspected was 5-HT (Kita, Kile, Parker, & 
Wightman, 2009). This suggested that MFB stimulation could evoke 5-HT release in targets 
posterior to the stimulating electrode. Here, we confirm this expectation by demonstrating 
that branched 5-HT fibers can be retrogradely activated, allowing the experimenter to avoid 
targeting the DRN, an anatomically challenging surgical technique. However, we find that 
MFB stimulation elicits release of an additional species in the SNpr. With electrochemical 
63 
 
and pharmacological data, in addition to literature well documenting histamine’s 
physiological, anatomical and independent chemical verification in the SNpr (Brown, 
Stevens, & Haas, 2001), we identify this substrate as histamine. Threllfel et al. have 
previously shown that pharmacological activation of H-3 receptors inhibits 5-HT release 
(Threlfell et al., 2004). In accord with this, we find significant decreases in 5-HT release 
upon administration of SKF 91488, an agent that prolongs histamine lifetime in the synapse. 
With no drug present, we compare the 5-HT concentration release and uptake profiles 
between DRN and MFB stimulations and find that histamine release does not interfere with 
the quantification of the 5-HT signal. We thereby present a novel and robust method for 
studying 5-HT and histamine neurotransmission in the SNpr. 
Materials and Methods 
Animals 
Male Sprague–Dawley rats, 8–12 weeks old, weighing 250–350 g, were purchased 
from Charles River Labs (Raleigh, NC, USA). Rats were housed under 12h/12h light cycles 
with controlled temperature and humidity. Food and water were available ad libitum. All 
animal care was in accordance with the Guide for the Care and Use of Laboratory Animals 
and was approved by the Institutional Animal Care and Use Committees of the University of 
North Carolina.  
Surgery 
Rats were anesthetized with urethane (1.5 g kg
-1
 rat weight) and positioned into a 
stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA). Holes were drilled in the 
skull according to stereotaxic coordinates referenced from bregma and taken from Paxinos 
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and Watson’s Rat Brain Atlas (Paxinos & Watson, 2007). Nafion-modified carbon-fiber 
microelectrodes were implanted in the SNpr (stereotaxic coordinates AP -4.8 to -5.2; ML 
+2.0; DV -8.5). A bipolar stainless steel stimulating electrode, insulated to the tip (0.2 mm 
diameter, Plastics One, Roanoke, VA, USA) was implanted into the MFB (AP -2.5 to -2.8; 
ML 1.7; DV -8.0) or DRN as described previously (Hashemi et al., 2009). An Ag/Ag Cl wire 
serving as a reference electrode was implanted into the contralateral hemisphere. Computer-
generated biphasic pulse trains were applied through constant current stimulators (NL 800A, 
Neurolog, Medical Systems Corp., Great Neck, NY, USA), 2 ms in width and 350 µA each 
phase (unless otherwise noted), at 60 Hz for 2 s to evoke 5-HT release.  
Voltammetric Procedures 
Cylindrical carbon-fiber microelectrodes were constructed by aspiration of a single 
2.5-µm radius carbon fiber (T-650, Thornel, Amoco Co.) into a glass capillary of 0.6 mm 
external diameter and 0.4 mm internal diameter (A-M Systems, Inc., Sequim, WA). A 
micropipette puller (Narishige, Tokyo, Japan) was used to taper the glass and form a carbon-
glass seal. The exposed carbon fiber was cut to approximately 100 µm in length and was 
soaked for 30 minutes in isopropyl alcohol (IPA) to clean the surface. The procedure for 
electrodeposition of Nafion was described previously (Hashemi et al., 2009). Dopamine and 
5-HT specific electrochemical detection waveforms were used as described elsewhere (Heien 
et al., 2003; Jackson et al., 1995).  A customized version of TH-1 software (ESA, 
Chelmsford, MA) written in LABVIEW (National Instruments, Austin, TX) was used for 
waveform generation and data acquisition. A custom-built UEI potentiostat (University of 
North Carolina at Chapel Hill, Department of Chemistry Electronics Facility) was employed. 
All potentials are reported versus an Ag/Ag Cl reference electrode. Signal processing 
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(background subtraction, signal averaging, and digital filtering (4-pole Bessel Filter, 5 kHz)) 
was also done in TH-1 software. Voltammetric data are visualized as color plots that show 
multiple background-subtracted cyclic voltammograms that were consecutively collected. 
The abscissa is time and the current is encoded as false color (D. Michael, Travis, & 
Wightman, 1998). For most of the work in this paper, the ordinate is the voltage axis that 
peaks at 1.0 V, scans back to -0.1 V and returns to 0.2 V, the rest potential. The sensitivity 
with this waveform on Nafion modified microelectrodes to 5-HT is 49.5 nA µM 
-1
 and 0.4 
nA µM 
-1 
to histamine.  
Histology 
To verify the spatial placement of the electrodes in vivo, the carbon-fiber 
microelectrode that  acquired data was used to create a small, specific lesion in the recording 
site by a applying constant voltage (20 V for 10 s) (Park, Kile, & Wightman, 2009).  
Following the experiment, rats were sacrificed and perfused with 10% formalin solution. 
Brains were then removed from the skull and stored in 10% formalin. After at least 3 days, 
the brains were flash-frozen, sectioned into 40 µm slices in a cryostat, mounted on glass 
slides, and stained with 0.2% thionine. The brains were visualized and photographed with an 
optical microscope.  
Drugs and Reagents 
Serotonin hydrochloride, histamine dihydrochloride and thioperamide maleate were 
obtained from Sigma-Aldrich (St. Louis, MO, USA) at reagent quality and used without 
purification. SKF 91488 dihydrochloride was obtained from Tocris Biosience (Ellisville, 
MO, USA) and was delivered at a high dose to ensure permeation across blood brain barrier 
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and cause robust in vivo effects (50 mg kg
-1
). Drugs were dissolved in saline and were 
injected intraperitoneally at a volume of 0.6 ml kg
-1
. 
Data Analysis 
Kinetic characterization of 5-HT release and uptake was adapted from techniques 
previously used to describe kinetics of release and uptake of the dopamine system (P. A. 
Garris & Wightman, 1994) . Release was described as [5-HT]p*f, where [5-HT]p is the 
amount of 5-HT released per stimulation pulse, and f is the frequency of stimulation pulses. 
The rate of change during stimulation is: 
       
  
              
       
  
 
      
    (1) 
in which the duration of the release term is determined by the number of pulses in the 
stimulation. Only the uptake term dominates after the stimulation terminates. The uptake rate 
of 5-HT from the extra-cellular space (v) following electrically stimulated release was 
assumed to follow the Michaelis-Menten equation: 
   
       
  
 
      
 
    
  
      
  
      (2) 
Vmax is the maximal rate of uptake, and Km is the Michaelis-Menten constant that describes 
the affinity of the 5-HT transporter for the 5-HT molecule. It was taken to be 170 nM, a value 
found in rat brain synaptosomes (Mosko, Haubrich, & Jacobs, 1977; Shaskan & Snyder, 
1970).  
In all simulations, analyte diffusion through a thin layer (300 nm) of Nafion was 
accounted for (E.W. Kristensen, Kuhr, & Wightman, 1987). The amount of 5-HT released 
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per stimulation pulse ([5-HT]p) and Km and Vmax were determined by fitting the model to the 
experimental data. In experiments involving transport inhibition, Vmax was fixed to values 
determined in pre-drug models. 
Student’s t-tests were performed on paired data sets, p<0.05 was taken as significant. 
Flow Injection Analysis  
For experiments characterizing histamine and 5-HT in vitro, flow injection analysis 
was used (E. W. Kristensen, Wilson, & Wightman, 1986b). The carbon-fiber microelectrode 
was placed in the output of a six-port HPLC loop injector mounted on a two-position actuator 
(Rheodyne model 7010 valve and 5701 actuator), operated by a 12 V DC solenoid valve kit 
(Rheodyne, Rohnert Park, CA). The apparatus enabled the introduction of a rectangular pulse 
of analyte to the microelectrode surface using a syringe infusion pump (Harvard Apparatus 
model 940, Hollison, MA) at a flow rate of 2 ml min
−1
.  
For in vivo experiments, the recording electrode was used to make a lesion in the 
tissue at the end of all experiments to verify its placement histologically. The high voltage 
across the working electrode used to achieve this necessarily over-oxidizes the carbon 
surface altering its sensitivity. Therefore, post-calibrations would not be a reliable measure of 
the electrode response. Rather, pre-calibrations were used to obtain a calibration curve, as 
described previously (Hashemi et al., 2009).  
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Results 
Comparison of 5-HT following DRN or MFB stimulation 
Histology verified the location of the stimulating and carbon-fiber microelectrodes in 
coronal slices of brains used in in vivo experiments (Figure 3.1).  The stimulating electrode 
was in the MFB and the carbon-microelectrode was in the SNpr as indicated by the small 
lesions.  
We have previously shown that electrical stimulation of the DRN releases 5-HT in 
the SNpr (Hashemi et al., 2009). In Figure 3.2, we compare this type of electrically 
stimulated 5-HT release (Figure 3.2A) to 5-HT release elicited via MFB stimulation (Figure 
3.2B). The horizontal dashed lines in panel Figure 3.2A(iii) are at the peak potential for 5-HT 
oxidation (0.65 V) (1) and oxidation of an additional substrate (0.85 V) (2). The currents at 
these potentials were converted to concentrations and are plotted directly above this ((i) 5-
HT, (ii) additional substrate). In (i) the current begins to rise at stimulus initiation and peaks 
within 0.5 seconds of the stimulation termination. In Figure 3.2A(ii), there is a small increase 
in current in response to the stimulation. The vertical dashed line in the color plot (iii) at the 
end of the stimulation and the current at this time were used to construct the cyclic 
voltammogram (inset). This cyclic voltammogram is identical to those obtained in vitro for 
5-HT where the presence of the reverse wave is characteristic of 5-HT. Similar results were 
obtained with MFB stimulation (Figure 3.2B). In Figure 3.2B(i), the 5-HT current profile 
closely matches the 5-HT current profile in Figure 3.2A(i), however the current obtained 
upon stimulation in Figure 3.2B(ii) is 3-fold greater with MFB stimulation that with DRN  
69 
 
stimulation. The cyclic voltammogram (inset ) is taken at the vertical dashed line at the end 
of the stimulation. An additional vertical dashed line () is taken two seconds after the 
stimulus termination, the current at this time was used to construct the cyclic voltammogram 
in inset . Panel C shows the averaged maximal release amplitudes of (1) 5-HT and (2) the 
additional substrate as the stimulating electrode is lowered down the dorsal/ventral tract 
above the MFB (n=6 ± SEM).  For each line, the data are normalized to the maximal signal 
along the stimulation track.  When two points are statistically different, the p value is added. 
The concentration changes extracted from the current at 0.65 V exhibit a time-course 
in the SNpr very similar to the DRN stimulation. DRN and MFB averaged maximal 
concentrations in the SNpr are statistically identical:  12.7 ± 1.6 nM (n=6  SEM) 5-HT with 
DRN stimulation (Hashemi et al., 2009) and 12.8 ± 1.0 nM (n=6  SEM) with MFB 
(p=0.29). Similarly, the time for 5-HT to be cleared to one half of its maximal value (t1/2) is 
1.7 ± 0.3 s with DRN stimulation (n=6  SEM) and 1.8 ± 0.2 s with MFB stimulation (n=6  
SEM) (p=0.45).  
Examination of the color plot reveals additional features around the time of the 
stimulation. An oxidation process at 0.85 V on the reverse scan accompanied by a reduction 
process at 0.1 V are simultaneous with the 5-HT signal. Because these processes disappear 
rapidly after the stimulation, a cyclic voltammogram collected at 2 s after the stimulation 
(inset ) has the characteristic 5-HT cyclic voltammogram. However, when it is recorded at 
the end of the stimulation (inset ), it has additional features. Because 5-HT is oxidized at a 
potential that is reached before the additional species, the presence of the second species does 
not distort the time-course of 5-HT detection. 
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Characterization of Histamine Cyclic Voltammetry 
The additional oxidation and reduction occur on the backwards oxidation scan and 
forwards reduction scan. This indicates a kinetically limited reaction that is dependent on the 
initial sweep that regenerates the electrode’s carbon surface (Takmakov et al., 2010). The 
SNpr is populated with histaminergic terminals (Panula, Pirvola, Auvinen, & Airaksinen, 
1989) and histamine displays this type of kinetically limited electrochemistry as 
demonstrated by following the direction of the potential sweep with the arrows in Figure 3.3. 
This figure compares in vitro responses at a carbon-fiber microelectrode, using the 5-HT 
waveform (see above) of (A) 5-HT (500 nM), (B) histamine (20 µM), (C) 5-HT + histamine 
(500 nM + 20 µM, respectively) to (D) the in vivo response in the SNpr during MFB 
stimulation. Panel (i) shows the color plots and panel (ii) shows the cyclic voltammograms 
taken at the white dashed vertical lines. The microelectrode’s response to histamine (20 µM) 
injected alone is 7.9  0.9 nA (n=4  SEM) and to histamine (20 µM)  injected with 5-HT is 
7.5  0.7 nA (n=4  SEM)( p=0.6). The features of the in vivo response (D) are clearly 
electrochemically reproduced via a 5-HT + histamine mixture (C). 
Figure 3.4 shows how the histamine signal changes with the applied waveform. 
Figure 3.4A shows a log-log trace of the current response (n=5 ± SEM) in vitro to flow 
injections of histamine (20 µM) as a function of increasing the scan rate of the detection 
waveform.  It can be seen that the histamine response is proportional to the scan rate; the 
slope of the log-log plot is 0.56 indicating diffusion-driven electrochemistry.  In Figure 3.4B, 
the peak amplitude for histamine oxidation is shown as a function of increasing the positive 
limit of the applied voltage. Increasing the potential window of the detection waveform 
causes an increase in the histamine response from 6.6 ± 2.2 nA (n=5 ± SEM) at 1.2 V to 13.4 
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± 3.7 nA (n=5 ± SEM) at 1.3 V (p=0.01).  This behavior has been seen previously for 
dopamine (Hafizi, Kruk, & Stamford, 1990). At the same time, the peak on the reverse scan 
occurs at more positive potentials as the scan limit is increased, shown by the inset cyclic 
voltammograms.  
Responses to Inhibition of Histamine N-methyltransferase 
 Unlike most biogenic amine neurotransmitters, histamine is not thought to be 
inactivated by a specific transporter (Brown et al., 2001).  Instead, it is primarily inactivated 
by methylation, a process that is catalyzed by histamine N-methyltransferase.  To 
pharmacologically verify the species detected at more positive potentials as histamine, an 
inhibitor of histamine N-methyltransferase, SKF 91488 (50 mg kg
-1
) was administered. SKF 
91488 is a potent, non-competitive inhibitor of histamine N-methyl transferase that is 
inactive at histamine receptors (Beaven & Shaff, 1979).  Panel (i) of Figure 3.5 displays the 
effects of this agent in one rat. Figure 3.5A shows the average color plot of 5 control 
stimulations, taken 10 minutes apart. Figure 3.5B shows the average color plot of 5 
stimulations one hour after drug administration, taken 10 minutes apart. Horizontal white 
dashed lines  and  were used to construct concentration vs. time plots of histamine () and 
5-HT () which were then averaged for 5 animals and displayed in panel (ii) (n=5 ± SEM). 
The control responses are shown in blue and the drug responses are shown in black. 
Electrically stimulated histamine release was 2.8 ± 1.3 µM (n=5 ± SEM). After drug 
administration, the t1/2 for histamine was significantly increased from 4.1 ± 0.9 s to 10.4 ± 2.1 
s (p=0.03) with no change in amplitude. The maximal evoked concentration of 5-HT 
decreased from 9.3 ± 1.0 nM to 4.6 ± 0.4 nM (p=0.01) without a change in its t1/2 value.  
Figure 3.5iii shows the effects of SKF 91488 on 5-HT release amplitude in control rats (A) 
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(n=5 ± SEM) and in rats pre-treated with thioperamide (10 mg kg
-1
) (n=6 ± SEM), a selective 
H-3 receptor antagonist (B). In rats pre-treated with thioperamide, 5-HT release is not 
significantly affected after SKF 91488 administration; the control response was 10.2 ± 1.3 
nM and 10.4 ± 1.5 nM after SKF 91488 administration (p=0.76). 
Modeling 5-HT Release and Uptake 
Figure 3.6 compares experimental and modeled 5-HT data between the two 
stimulations. The experimental data (blue dots) are superimposed on the model (black line). 
The model is a composite of linear release and uptake governed by Michaelis-Menten 
kinetics (R.M. Wightman et al., 1988). The concentration of 5-HT released per stimulation 
pulse, [5-HT]p, and the maximal uptake velocity, Vmax, were adjusted for the best fit while 
the value of the Km for uptake was fixed at 170 nM.  During DRN stimulation, the model 
yields [5-HT]p of 1.5 nM  and a Vmax of 0.63 µM s
-1
, and during MFB stimulation, the model 
yields  [5-HT]p  of 1.1 nM, with a Vmax of 0.67 µM s
-1
.  
Discussion  
Electrical MFB stimulation evokes 5-HT Release in the SNpr  
The efferent circuitry of the DRN to the SNpr is well-documented (Corvaja, Doucet, 
& Bolam, 1993; Dray, Gonye, Oakley, & Tanner, 1976; Fibiger & Miller, 1977; Wirtshafter 
et al., 1987), as are its projections to the striatum (Miller, Richardson, Fibiger, & McLennan, 
1975; Steinbusch, Nieuwenhuys, Verhofstad, & Van der Kooy, 1981; Steinbusch, van der 
Kooy, Verhofstad, & Pellegrino, 1980).  Some studies, including a retrograde labeling study 
by Van der Kooy et al., show that the same 5-HT projection branches to both the SNpr and 
the striatum (Imai et al., 1986; van der Kooy & Hattori, 1980). Striatal bound 5-HT fibers 
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travel within the MFB (Miller et al., 1975). If axonal stimulation in the MFB could be used in 
place of DRN stimulation, certain experimental challenges associated with DRN stimulation 
can be avoided. These challenges arise primarily from the small size, inaccessible location 
and complicated topography of the DRN (Dib, 1994; Whishaw, Cioe, Previsich, & Kolb, 
1977). However, before this work, it had not been established whether electrical stimulation 
of the MFB at a location anterior to the terminal site (SNpr) would release 5-HT. We had 
previously reported a similar phenomenon: the release of an unidentified substance in the red 
nucleus terminals upon anterior stimulation of the MFB (Kita et al., 2009). We suspected this 
substance was 5-HT, but since we had not yet optimized our electrochemical detection 
method with Nafion, we were unable to electrochemically verify this. Due to our recent 
technological advances for in vivo 5-HT detection (Hashemi et al., 2009), we are able to 
study whether this phenomenon applies to 5-HT release in the SNpr with MFB stimulation. 
In Figure 3.2, we compare the terminal output in the SNpr upon DRN and MFB 
stimulation. Comparison of the inset cyclic voltammograms electrochemically confirms that 
5-HT is released upon MFB stimulation. However another substrate is present in the MFB 
cyclic voltammogram in Figure 2.2B. The main reductive process of 5-HT is delayed with 
both DRN and MFB stimulation and indeed in in vitro (inset ). However, the reduction 
associated with the other substrate occurs simultaneously with the oxidation (inset ) 
showing this substrate is electrochemically independent from 5-HT. While the second 
substrate overlaps with the voltammograms for 5-HT, it does not interfere with the 
concentration of 5-HT obtained at 0.65 V because its electrolysis peaks occur later in the 
cyclic voltammogram.  We have previously found somatodendritic dopamine release in the 
VTA upon MFB stimulation (Kita et al., 2009), however due to the low levels of dopamine 
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in the SNpr (Heeringa & Abercrombie, 1995) and the low sensitivity of the 5-HT specific 
waveform to dopamine (Hashemi et al., 2009), it is unlikely that there is a significant 
contribution from dopamine to this signal. Moreover, we had previously shown that the 
signal in the SNpr is unresponsive to pharmacological manipulations by GBR 12909 when 
we stimulate the DRN (Hashemi et al., 2009). We also confirmed this to be true for MFB 
stimulation (data not shown). 
Histamine is Simultaneously Released with 5-HT in the SNpr during MFB Stimulation  
The oxidation and reduction peaks of the additional substrate occur on the backward 
sweep of the oxidation scan and the forward sweep of the reduction scan.  Such features have 
been previously seen in fast-scan cyclic voltammetry (Pihel, Hsieh, Jorgenson, & Wightman, 
1995), and they are indicative of an electrochemical process that requires electrochemical 
cleaning of the electrode prior to its oxidation.  Possible candidates based on these 
electrochemical characteristics are histamine, adenosine, or hydrogen peroxide (Cechova & 
Venton, 2008; Pihel, Hsieh, Jorgenson, & Wightman, 1998; Sanford et al., 2010).  All three 
of these compounds are oxidized at very positive potentials and could be released by 
electrical stimulation of the medial forebrain bundle.  We have previously shown that 5-HT 
itself can have distorted peaks when the electrode surface is fouled, but Nafion 
electrodeposition employed in our technique minimized this effect (Hashemi et al., 2009). 
Additionally, some groups have found ‘switching’ artifacts that occur at the switching 
potential of the waveform (Bull et al., 1990). The small current obtained at 0.85V in Figure 
3.2A(ii) may have contributions by such a switching artifact at around 1 V, however, the 
equivalent MFB stimulation causes a much larger current at 0.85 V (Figure 3.2B(ii)). 
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Collectively, the evidence presented in this paper indicates that histamine is the 
substance detected along with 5-HT.  Histaminergic projections originate from the 
tuberomammillary nucleus (TM), located immediately ventral to the MFB, and traverse the 
MFB (Garbarg, Barbin, Bischoff, Pollard, & Schwartz, 1976; Garbarg, Barbin, Feger, & 
Schwartz, 1974; Kohler, Swanson, Haglund, & Wu, 1985; Panula et al., 1989).  One of the 
target regions is the SNpr where dense populations of histamine containing nerve terminals 
and histaminergic receptors are found (Panula et al., 1989; Schwartz, Arrang, Garbarg, 
Pollard, & Ruat, 1991).  High amounts of histamine and histidine decarboxylase, the enzyme 
responsible for histamine synthesis from histidine, have been chemically verified in the SNpr 
using microenzymatic methods (Pollard, Llorens-Cortes, Barbin, Garbarg, & Schwartz, 
1978). Furthermore, the H-3 receptors present in the SNpr (Anichtchik et al., 2000; 
Cumming, Shaw, & Vincent, 1991; Pollard, Moreau, Arrang, & Schwartz, 1993) have been 
shown to modulate GABA and 5-HT dynamics (Garcia, Floran, Arias-Montano, Young, & 
Aceves, 1997; Korotkova, Haas, & Brown, 2002; Threlfell et al., 2004). Thus, histamine 
release in the SNpr following MFB stimulation is an anticipated result. Given the close 
locality of these two locations (MFB and TM), it is not possible to selectively stimulate the 
TM without activating the MFB. Thus, to gain more insight into the nature of the stimulation, 
we recorded maximal 5-HT and histamine release in the SNpr while we lowered the 
stimulating electrode down the dorsal/ventral tract above our MFB coordinates in 0.5mm 
intervals from 5.5 – 10mm. Figure 3.2C shows that the maximal response for both 5-HT and 
histamine are at D/V 8.5 mm (n=6 ± SEM) which is not surprising since this is the 
dorsal/ventral location of the MFB. However, the histamine response significantly peaks 
earlier than the 5-HT response dorsal to this location. This implies that the histaminergic 
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fibers have a broader and independent fiber distribution through the MFB than the 5-HT 
fibers. In contrast to the MFB, the DRN has very little histaminergic innervation (Panula et 
al., 1989), explaining why stimulation of this region causes 5-HT release in the SNpr with 
little or no histamine release.  
Further evidence that the additional species is histamine comes from our 
electrochemical and pharmacological experiments.  First, as shown in Figure 3.3, the cyclic 
voltammetry of the unknown species closely resembles that for histamine in pH 7.4 solution.  
Second, administration of the highly selective ligand, SKF 91488, which potently inhibits 
histamine N-methyltransferase (Beaven & Shaff, 1979), significantly increased the clearance 
time of the signal in comparison to the control with no effect on the signal amplitude (Figure 
3.5ii()). This drug also caused a significant decrease in the release amplitude of 5-HT after 
drug administration ().  Prior work has shown that activation of H-3 receptors inhibits 5-HT 
release (Threlfell et al., 2004).  Since SKF 91488 prolongs histamine’s half-life in the 
extracellular space, this would result in increased activation of H-3 receptors and suppression 
of 5-HT release.   We confirm this by pre-treating rats with thioperamide (10 mg kg
-1
), a 
highly selective H-3 receptor antagonist (Arrang et al., 1987) prior to SKF 91488 
administration. Figure 3.5iii shows that thioperamide pre-treatment significantly arrests the 
SKF 91488 mediated inhibition of 5-HT release (n=6 ± SEM). 
Thus, on the basis of electrochemical, anatomical, physiological, and 
pharmacological evidence, we assign the second signal simultaneously released upon MFB 
stimulation to histamine.    
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The Dynamic Rate of Electrically Stimulated 5-HT Release is Independent of DRN or MFB 
Stimulation 
To confirm that MFB and DRN stimulations evoke release from a similar population 
of terminals in the SNpr, we compared 5-HT signals obtained with each stimulation and 
compared kinetic parameters based on a model previously used to characterize 5-HT release 
in brain slices containing the SNpr (Bunin & Wightman, 1998). Figure 3.6 illustrates that 
there are no significant differences in [5-HT]p or Vmax in the SNpr with stimulation of the 
DRN or MFB.  Furthermore, the calculated values of Vmax in the SNpr with both types of 
stimulation (0.63 and 0.67 µM s
-1
, respectively) agree with ones previously established in 
tissue slice preparations (0.57 µM s
-1
) (Bunin et al., 1998). Since Vmax is a function of the 
number of active transporters, this term is expected to be the same in slices and in vivo.  
Thus, our finding of similar maximal uptake rates for 5-HT is consistent with removal of 5-
HT by a transporter in each preparation.   
However, these quantitative modeling studies reveal that 5-HT release evoked in vivo 
is much smaller than evoked in tissue slice preparations ([5-HT]p = 55 nM in slices 
containing the SNpr  (Bunin et al., 1998) but 1.5 nM in vivo with MFB stimulation). This 
large difference in release amplitude may have contributed to the previous physical and 
analytical challenges of in vivo 5-HT voltammetric detection. It would appear that the local 
stimulations that were employed in the tissue slice preparation, bypassed the regulatory 
mechanisms that tightly control 5-HT release in vivo. This suggests that intact in vivo 
physiological mechanisms, combining both cell body and terminal feedback, may profoundly 
regulate 5-HT release. This regulation may be at the level of 5-HT autoreceptors (Blier, 
Pineyro, el Mansari, Bergeron, & de Montigny, 1998; Daws, Gould, Teicher, Gerhardt, & 
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Frazer, 2000), release of different vesicular pools (Pellegrino de Iraldi, 1992), or activation of 
other inhibitory mechanisms (R. W. Invernizzi et al., 2007). These regulatory mechanisms, in 
combination with the fact that there is no known transporter for histamine, may also explain 
why the magnitude of histamine release is far greater than 5-HT release. These mechanisms 
are the focus of our ongoing studies. 
In conclusion, this work shows that 5-HT release can be evoked by stimulating a 
collateral 5-HT projection in the MFB that branches to both the SNpr and the striatum. We 
verified electrochemically, anatomically, physiologically and chemically that the additional 
species present upon MFB is histamine.  We confirmed that MFB stimulation evokes 5-HT 
release that is quantitatively equivalent to that evoked by DRN stimulation; however, in both 
models, release is profoundly less than in tissue slice culture experiments. This highlights the 
importance of in vivo methods in exploring the mechanisms of 5-HT dynamics.  
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Figure 14Figure 3.1 Histology of Stimulating and Carbon-Fiber Electrode Placements in the MFB and SNpr 
 
Figure 3.1 Histology of Stimulating and Carbon-Fiber Electrode Placements in the MFB and 
SNpr.  Left hemisphere is a diagram showing intended placement of (i) stimulation electrode 
in the MFB or (ii) carbon fiber microelectrode in the SNpr at coordinates described in the 
methods section. Right hemisphere shows actual placement in a representative brain. 
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Figure 15Figure 3.2 5-HT Color Plot, CV and Time Profile of Response in SNpr with DRN and MFB Stimulation. 
 
 
 
Figure 3.2 5-HT Color Plot, CV and Time Profile of Response in SNpr with DRN and MFB 
Stimulation. (A) and (B) - Comparison of signals obtained in SNpr obtained following DRN 
and MFB electrical stimulation respectively. Concentrations vs. time taken at the horizontal 
white dashed lines are shown above the color plots in panels (i) and (ii), and representative 
cyclic voltammograms (vs. Ag/ Ag Cl) taken at the vertical white dashed lines are inset. 
Bipolar stimulation onset at 5 seconds is 350 µA, 60 Hz and 120 pulses, represented by blue 
bar. (C) shows averaged, normalized maximal release amplitude of 5-HT (1) and the 
additional substrate (2) at 0.5 mm dorsal/ventral intervals of the stimulating electrode (n=6 ± 
SEM). Where the two values are statistically different, the p value is added. 
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Figure 16Figure 3.3 Comparison of In vivo Signal to a Mixed In vitro 5-HT and Histamine Signal 
 
 
 
 
 
Figure 3.3 Comparison of In vivo Signal to a Mixed In vitro 5-HT and Histamine Signal. In 
vitro injections of (A) 5-HT (500 nM), (B) histamine (20 µM), or (C) 5-HT (500 nM) + 
Histamine (20 µM), and (D) in vivo response shown in (i) color plot format and (ii) cyclic 
voltammograms. Current is represented in false color and is a dual scale (left for in vitro and 
right for in vivo). Representative cyclic voltammograms were taken at the white dashed lines; 
in (D), the cyclic voltammogram was taken at 0.5 s after stimulation duration, indicated by 
the white dashed line. This position best captures both substrates. 
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Figure 17Figure 3.4 Effect of Varying Scan Rate and Upper Potential Limit on Histamine Response In vitro. 
 
 
 
 
Figure 3.4 Effect of Varying Scan Rate and Upper Potential Limit on Histamine Response In 
vitro. (A) Log-log current response to in vitro injections of histamine (20 µM) as the 
waveform scan rate is increased from 100 V s
-1
 to 2000 V s
-1
 with conventional 5-HT 
waveform (-0.2 – 1.0 V) (n=5 ± SEM), where the line of best fit is a linear regression. (B) 
Current response to in vitro injections of histamine (20 µM) as the upper potential window is 
increased from 0.9 V to 1.4 V (n=5 ± SEM) vs. Ag / Ag Cl.  Representative cyclic 
voltammograms are inset at 1.0, 1.3 and 1.4 V.   
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Figure 18Figure 3.5 Pharmacological Characterization of Histamine with SKF 91488 
 
Figure 3.5 Pharmacological Characterization of Histamine with SKF 91488. (i) Color plots 
showing electrically stimulated response in the SNpr in (A) control and (B) 1 hour after intra-
peritoneal SKF 91488 (50 mg kg
-1
) administration. (ii)() Averaged concentration vs. time 
responses taken at oxidation potential  in control (blue) and 1 hour after intra-peritoneal 
SKF 91488 (50 mg kg
-1
) administration (black) (n=5 ± SEM). (ii)() Averaged concentration 
vs. time responses taken at oxidation potential  in control (blue) and 1 hour after intra-
peritoneal SKF 91488 (50 mg kg
-1
) administration (black) (n=5 ± SEM). The blue bars 
represent the durations of the stimulus (350 µA, 60 Hz and 120 pulses) and error bars are 
SEM. (iii) Averaged maximal 5-HT release concentraion in control rats (A) and rats pre-
treated with thioperamide (10mg kg
-1
) (B). The bars are averages of the maximal 5-HT 
release in control stimulations (blue) and after SKF 91488 (50 mg kg
-1
) administration (n=6 ± 
SEM). 
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Figure 19Figure 3.6 A Comparison of 5-HT Experimental Data and Kinetic Analysis Between DRN and MFB 
Stimulation 
 
Figure 3.6 A Comparison of 5-HT Experimental Data and Kinetic Analysis Between DRN 
and MFB Stimulation. Averaged, normalized experimental data evoked by a 350 µA, 60 Hz 
and 120 pulse stimulation of the DRN (A) and the MFB (B) (blue dots, n=6 ± SEM). 
Kinetically modeled data (black line) is superimposed and kinetic parameters Vmax and [5-
HT]p are inset when Km is fixed at 170 nM. Blue box indicates duration of stimulation and 
error bars are SEM.  
  
85 
 
 
CHAPTER 4: DIFFERENTIAL MECHANISMS IN THE REGULATION OF IN 
VIVO DOPAMINE AND SEROTONIN RELEASE 
4
 
Introduction  
Dopamine and serotonin (5-hydroxytryptamine or 5-HT) are neurotransmitters with 
important, conserved roles in the vertebrate nervous system.  Dopamine is important in 
neuronal circuitry that controls reward and in brain regions that regulate movement (Haber & 
Knutson, 2010).  Assigning a specific functional role to 5-HT has proven more difficult 
because electrophysiological recordings of 5-HT neurons reveal unchanged firing in response 
to most stimuli (Jacobs & Fornal, 1999).  Competing roles have been suggested for dopamine 
and 5-HT in reward circuitry, with dopamine signals predicting positive stimuli and 5-HT 
signals predicting negative consequences (Boureau & Dayan, 2011; Daw, Kakade, & Dayan, 
2002).  Biochemically, their regulation is quite similar, with similar proteins regulating 
synthesis, storage, release, uptake, and metabolism.  To compare functional dopamine and 5-
HT regulation in the brain, methods have been developed to monitor dynamic changes in 
their concentrations in the extracellular space.  
Transient fluctuations of dopamine concentrations in the extracellular space of the 
nucleus accumbens core (Monachon, Burkard, Jalfre, & Haefely) can be evoked by electrical 
stimulation of the medial forebrain bundle (MFB) and have been characterized in the rat 
using in vivo voltammetric methods (Gonon & Buda, 1985; Millar et al., 1985).  Dopamine is 
                                                          
4
 This chapter previously appeared as an article in Proceedings of the National Academy of Sciences (U.S.A). 
The original citation is as follows: Hashemi P, Dankoski EC, Lama R, Wood KM, Takmakov P, and Wightman 
RM. “Brain dopamine and serotonin differ in regulation and its consequences.” Proc. Natl. Acad. Sci. U.S.A. 
109, 29 (Jul 2012): pp 11510-5. 
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easily oxidized, and electrochemical methods such as fast-scan cyclic voltammetry can be 
used for detection (Robinson, Hermans, Seipel, & Wightman, 2008).  A carbon-fiber 
microelectrode is placed in the brain region of interest. The shape of the cyclic 
voltammogram identifies dopamine and its amplitude can be used to calculate concentration.  
Each cyclic voltammogram can be collected in less than 10 ms, enabling fast, repetitive 
acquisition.  Successive recordings of fluctuations in dopamine concentration lead to 
visualization of dopaminergic transmission events with sub-second temporal resolution.  This 
method has shown that electrical stimulations of dopaminergic axons immediately evoke 
dopamine release that is rapidly uptaken by the dopamine transporter (DAT).  During 
behavior, receipt of unexpected rewards (J. J. Day, Roitman, Wightman, & Carelli, 2007) or 
cues that predict reward (Owesson-White, Cheer, Beyene, Carelli, & Wightman, 2008) result 
in transient changes in dopamine concentration.  These transients arise from the spontaneous 
firing of dopaminergic neurons in the ventral tegmental area and are regulated by the same 
mechanisms as electrically evoked release (Sombers, Beyene, Carelli, & Wightman, 2009).   
Similar sub-second characterizations of 5-HT transmission are possible because 5-HT 
is also easily oxidized.  However, voltammetric detection of 5-HT is complicated by 
oxidative products that foul the electrode surface, lowering sensitivity and temporal 
resolution (Jackson et al., 1995).  Furthermore, 5-hydroxyindole acetic acid (5-HIAA), the 
primary metabolite of 5-HT, can similarly degrade the electrode surface.  To minimize these 
issues, we have modified the detection waveform to prevent formation of oxidation products 
that foul the electrode surface. We also electrodeposit Nafion, a cation exchange polymer, on 
the carbon fiber to decrease sensitivity to 5-HIAA (G.A. Gerhardt, A.F. Oke, G. Nagy, B. 
Moghaddam, & R.N. Adams, 1984; Hashemi et al., 2009). Using these modifications, we 
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have demonstrated that stimulated 5-HT release can be measured in the substantia nigra pars 
reticulata (SNr) by stimulating the MFB (Hashemi et al., 2011) at a location that also evokes 
dopamine release (Millar et al., 1985).     
This work characterizes and compares factors that regulate extracellular 
concentrations of 5-HT and dopamine.  In-house hardware and software developments enable 
application of two different waveforms at separate electrodes in different brain regions 
(Zachek, Takmakov, Moody, Wightman, & McCarty, 2009).  Using simultaneous dopamine 
and 5-HT measurements evoked by a common stimulation, physiological and 
pharmacological manipulations of release amplitude and uptake properties were evaluated.  
We find that distinctly different processes govern dopamine and 5-HT dynamics.  Taken 
together, these results show that mechanisms controlling 5-HT in the extracellular space are 
more stringent than those of dopamine.   
Methods  
For full experimental procedures, see Supplemental Information. 
Surgical Procedures 
Stereotaxic surgeries for voltammetric measurements were performed as previously 
described (Hashemi et al., 2009). Briefly, Nafion-modified carbon-fiber microelectrodes 
were implanted in the SNr and in NAc. A bipolar stainless steel stimulating electrode was 
implanted into the MFB.  As noted, heart rate, breathing, and body temperature were 
monitored in some animals (see Supplemental Information). 
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Voltammetric Procedures 
Quad UEI potentiostats described previously (Zachek, Takmakov, Moody, et al., 
2009) were modified by enabling independent control of the potential on two pairs of 
operational amplifiers in the head stage.  A data acquisition system capable of generating two 
independent waveforms and collecting from two sets of channels was previously described 
(Zachek, Takmakov, Moody, et al., 2009). All potentials reported are against Ag/AgCl.   
Drugs and Reagents 
Pharmaceutical grade pargyline hydrochloride, NSD 1015 (3-
hydroxybenzylhydrazine dihydrochloride), GBR 12909 dihydrochloride, raclopride, 
methiothepin, citalopram and tetrabenazine were administered interperitoneally.  
Data Analysis 
Two-tailed Student’s T-tests were performed on paired data sets. p<0.05 was taken as 
significant. Error bars are given as ±SEM.  Two-way ANOVA was used for the analysis of 
body temperature and heart rate. 
Results  
Simultaneous Dopamine and 5-HT Release Evoked by a Common Stimulation 
A carbon-fiber microelectrode was placed in the NAc of each rat and the dopamine 
waveform was applied. A second microelectrode was placed in the ipsilateral SNr and 
utilized the 5-HT waveform.  Both waveforms are illustrated in Figure 4.1 (left panel).  
Release was evoked in both brain regions by electrically stimulating the ipsilateral MFB (60 
Hz, 2 s duration, biphasic pulses, 2 ms each phase, 350 µA), shown in the color plots in 
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Figure 4.1.  Each color plot encodes 300 cyclic voltammograms recorded over 30 s around 
the stimulation (initiated at 5 s, vertical black line).  The shape of the cyclic voltammograms 
(upper current-voltage curve, left panel) recorded in the NAc and SNr identify dopamine and 
5-HT, respectively.  Strikingly, the amplitude of stimulated dopamine is approximately 300 
times greater than 5-HT.  The uptake rates of the neurotransmitters are more comparable.  
Dopamine and 5-HT transporters follow Michaelis-Menten kinetics.  At low concentrations 
the rate constant for dopamine uptake in the NAc (k = Vmax/Km) is ~ 14 s
-1
 (P. A. Garris & 
Wightman, 1994),  and in the SNr, it is ~4 s
-1
 for 5-HT uptake (Hashemi et al., 2011).   
We first examined dopamine and 5-HT release as a function of the stimulating 
electrode’s dorsoventral position.  Figure 4.1 (right panel) shows the normalized amplitude of 
evoked 5-HT in the SNr and dopamine in the NAc obtained at varying stimulating electrode 
locations as it was lowered in 0.5 mm increments from -6 to -10.5 mm through the MFB. 
Stars indicate that significant release was evoked in that location (p<0.05).  Both 5-HT and 
dopamine release were maximal with the stimulating electrode at -8.5 mm.  The 5-HT 
response profile was broader, with measurable release at stimulation electrode depths 
between 7.0 – 10.0 mm below dura, whereas dopamine could only be recorded between 8.0 – 
9.0 mm below dura. 
Effect of stimulation parameters on release 
We varied stimulus parameters in the MFB to examine their effects on release relative 
to that obtained with our maximal conditions (depth, 8.5 mm from dura, 60 Hz, 2 s duration, 
biphasic pulses, 2 ms each phase, 350 µA).  Dopamine and 5-HT release are both sensitive to 
stimulus pulse width (Millar et al., 1985), reaching a maximum at 2 ms (Figure 4.2A).   
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Dopamine release increases with stimulus intensity up to 350 µA with 2 ms wide 
pulses (Wiedemann, Garris, Near, & Wightman, 1992), and 5-HT responds similarly (Figure 
4.2B).  Stimulated dopamine release diminishes when stimulations are repeated rapidly 
(Montague et al., 2004).  Using maximal stimulation trains repeated every minute, we found 
that dopamine release decreased with consecutive stimulations, dropping to 38 ± 7 % of the 
maximum normalized value (n=6, p<0.05) after the 20
th
 stimulation (Figure 4.2C).  In 
contrast, maximal 5-HT release did not show signs of depletion.  
Pharmacology of Synthesis, Packaging, Release, Uptake and Metabolism 
Various aspects of dopamine transmission, including synthesis (Millar et al., 1985), 
packaging (Owesson-White et al., 2012), autoreceptor regulation of release (Gonon & Buda, 
1985), uptake (P. A. Garris & Wightman, 1994; P.A. Garris & Wightman, 1995), and 
metabolism (J.A. Stamford, Z.L. Kruk, & J. Millar, 1988), were characterized with 
pharmacology and in vivo voltammetry.  In this study, we compared the dopaminergic and 
serotonergic responses to these manipulations.  The averaged predrug and drug responses of 
stimulated 5-HT release are shown in the top rows of Figures 4.3 and 4.4 and the responses 
for dopamine to equivalent treatments are shown immediately below. Histograms with 
amplitude and t1/2 (both expressed relative to predrug value) are displayed in the bottom two 
rows, respectively.  Where the response to pharmacological treatment is significantly 
different from pre-drug, statistical significance (p<0.05) is noted with a star. Stimulation 
duration is indicated by horizontal bars below each concentration vs. time plot 
We investigated the role of synthesis on dopamine and 5-HT release by administering 
NSD 1015 (100 mg kg
-1
), an aromatic amino acid decarboxylase inhibitor (Figure 4.3, left 
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column).  Inhibition of decarboxylase results in accumulation of L-DOPA and 5-
hydroxytryptophan (Carlsson, Davis, Kehr, Lindqvist, & Atack, 1972).  Sixty minutes 
following NSD 1015 administration, dopamine release was reduced to 18.0 ± 4.5 % of its 
original amplitude (n=6, p<0.05).  In contrast, 5-HT release was reduced to 48.1 ± 2.8 % of 
its pre-treatment amplitude at the same time point (n=6, p<0.01). There were no significant 
effects of NSD 1015 on the t1/2 of dopamine or 5-HT.  
Dopamine and 5-HT are both released via exocytosis from vesicular stores. We 
investigated the significance of rapid vesicular packaging in both systems by comparing the 
effects of a vesicular monoamine transporter 2 (VMAT2) inhibitor, tetrabenazine (10 mg kg
-
1
)
 
(Quinn, Shore, & Brodie, 1959; Zheng, Dwoskin, & Crooks, 2006).  Tetrabenazine 
significantly reduced dopamine release to 6.3 ± 3.0 % of its predrug value 60 minutes after 
its administration (n=5, p<0.05, Figure 4.3, center column).  Effects on 5-HT release were 
not significant (71.6% ± 8.8 % of predrug value, n=5).  However, the time delay between 
stimulation onset and maximum signal increased from 2.21 ± 0.15 seconds to 3.52 ± 0.34 
seconds (n=5, p<0.05) after tetrabenazine administration. Tetrabenazine reduced dopamine 
release close to the limit of detection, therefore, t1/2 analyses for statistical significance were 
not possible.  The t1/2 of 5-HT was significantly increased from 1.9 + 0.25 seconds to 2.59 ± 
0.43 seconds (135 ± 21% of original; n=5, p<0.05). 
To examine autoreceptor control of release at 5-HT terminals in the SNr, we 
administered methiothepin (20 mg kg
-1
), a non-selective 5-HT 1a and 1b receptor antagonist 
(Monachon et al., 1972). Stimulated 5-HT release increased to 161 ± 10 % of its original 
(Figure 4.3, right column) (n=6, p<0.05).  We administered raclopride, a D2 receptor 
antagonist, to examine the effects of autoreceptors in the dopaminergic system (Kohler, Hall, 
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Ogren, & Gawell, 1985). Raclopride (2 mg kg-
1
) increased stimulated dopamine release to 
184 ± 34 % (n=6, p<0.05) of the predrug value.  While raclopride had no significant effects 
on t1/2 for dopamine, methiothepin significantly increased t1/2 for 5-HT from 1.36 ± 0.17 
seconds to 1.99 ± 0.24 seconds (n=6, p<0.05). 
Figure 4.4 (left panel) shows the effects of inhibition of the 5-HT uptake transporter 
(SERT) and DAT.  SERT was inhibited with the selective serotonin reuptake inhibitor 
citalopram (10 mg kg
-1
) (Hyttel, 1982) (i), while GBR 12909 (15 mg kg
-1
), was used to 
inhibit DAT (ii) (Andersen, 1989).  Citalopram significantly increased stimulated 5-HT 
amplitude to 476 ± 134 % of its original value (n=6, p<0.05) and significantly increased t1/2 
from 2.27 ± 0.07 s to 7.35 ± 1.46 seconds (n=6, p<0.05).  GBR 12909 significantly increased 
stimulated dopamine amplitude to 279 ± 70 % of its predrug value (n=6, p<0.05) and 
significantly increased t1/2 from 0.86 ± 0.14 seconds to 2.12 ± 0.2 seconds (n=6, p<0.05).   
Figure 4.4 (right panel) compares the effects of monoamine oxidase (MAO) 
inhibition with pargyline (75 mg kg
-1
) on dopamine and 5-HT stimulated release (J.A. 
Stamford et al., 1988).  5-HT release amplitude increased to 349 ± 60 % of its original value 
(n=6, p<0.05) while dopamine release did not increase significantly (175.1 ± 27.3 %, n=6, 
p>0.05). There were no significant effects of pargyline on dopamine t1/2, however, the 5-HT 
t1/2 significantly increased from 1.58 ± 0.07 seconds to 2.97 ± 0.49 seconds (n=6, p<0.05). 
SSRI and MAOI administration 
Figure 4.5 shows spontaneous efflux of dopamine (A) and 5-HT (B) occurring after 
respiratory arrest caused by administration of citalopram (10 mg kg
-1
) followed by pargyline 
(150 mg kg
-1
). The concentration of dopamine efflux at its peak averaged 37.7 ± 3.4 µM 
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(n=4), while 5-HT efflux was significantly lower at 0.296 ± 0.080 µM (n=4, p<0.001) 
(Figure 4.5C). The time elapsed between onset and peak of efflux also differed significantly, 
averaging 77 ± 4 s for dopamine and 266 ± 50 s for 5-HT (n=4 for each, p<0.01) (Figure 
4.5F). Figures 4.5D and 4.5E compare responses of body temperature and heart rate between 
anaesthetized rats that received electrical stimulation (ES) and two injections of saline 35 
minutes apart (n=4, white) or ES followed by citalopram (T1) and pargyline (T2) (n=6, 
black).  Pargyline administration coincides with a significant decrease in body temperature 
(D) and heart rate (E) that persists throughout the remainder of the experiment (p<0.05). 
Discussion  
5-HT Release Regulation is More Stringent Than for Dopamine 
In this work electrical stimulation of the MFB simultaneously evoked dopamine 
release in the NAc and 5-HT release in the SNr.  Stimulation at a common site that releases 
different neurotransmitters provides a way to compare dynamic alterations in their regulatory 
mechanisms (Park, Takmakov, & Wightman, 2011).  A particularly noteworthy finding was 
that dopamine release was approximately 300 times greater than 5-HT release despite similar 
tissue content in the two regions examined (90 ng/mg protein for dopamine in the NAc (P. A. 
Garris & Wightman, 1994) and 21 ng mg
-1 
protein for 5-HT in the SNr (Palkovits et al., 
1974)).  Thus, in spite of comparable stores, the releasable pool of 5-HT in the SNr is 
miniscule compared to the releasable pool of dopamine in the NAc.  Distinct storage and 
releasable pools for both 5-HT and dopamine have been described (Shields & Eccleston, 
1973; Shore, 1976), but the large difference in their relative size had not previously been 
appreciated.  Moreover, we previously noted that evoked release of 5-HT in the SNr is much 
lower in vivo compared to its electrically evoked release from SNr slice preparations 
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(Hashemi et al., 2011).  This suggests that in vivo 5-HT release is subject to tighter control 
mechanisms than both 5-HT in slices and dopamine in vivo.  
To identify possible mechanisms for these differences, we explored the effects of the 
electrical stimulation on the dopamine and 5-HT axons that course through the MFB.  
Dopaminergic and serotonergic fiber bundles responded similarly to the stimulation 
parameters tested, giving greater release with wide electrical pulses and large current 
amplitudes (Figure 4.2).  These properties are consistent with our predictions, given that both 
fibers are unmyelinated (Beaudet & Descarries, 1981; Grace & Bunney, 1983).  Varying the 
dorsoventral location of the stimulating electrode revealed that 5-HT release can be evoked 
over greater region than dopamine, suggesting that serotonergic fibers have a broader 
topographic distribution. However, this is not sufficient to explain the 300-fold greater 
release of dopamine because even direct stimulation of serotonergic cell bodies in the dorsal 
raphe evokes comparably low 5-HT release (Hashemi et al., 2011).  
The disparity between 5-HT and dopamine release amplitudes is attributed to 
differences in the readily releasable pool.  Dopamine release was sensitive to repetitive 
application of stimulation trains, exhibiting a fatigue in release that did not occur for 5-HT in 
the SNr.  The diminished release of dopamine after repeated stimulations has been attributed 
to depletion of the releasable pool (Yavich & MacDonald, 2000).  In contrast, some 5-HT 
may be stored in dense core vesicles (Van Bockstaele & Pickel, 1993) or other compartments 
that do not exocytose.  This would produce effects consistent with a small quantity of 5-HT 
available for release.  
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Dopamine Release is Synthesis and Packaging Sensitive While 5-HT is an 
Uptake/Metabolism Controlled System 
Several of the pharmacological agents investigated in this work (Figures 4.3 and 4.4) 
inhibit the same processes in dopaminergic and serotonergic neurons.  For example, 
inhibition of aromatic amino acid decarboxylase with NSD 1015 inhibits synthesis of both 5-
HT and dopamine (Carlsson et al., 1972).  Because the preceding experiments suggest that 
the releasable pool of dopamine is more sensitive to depletion, we predicted that releasable 5-
HT would also be less sensitive to synthesis inhibition, and this was found to be the case.  5-
HT and dopamine are both packaged into vesicles via the action of VMAT2 (Henry, Sagne, 
Bedet, & Gasnier, 1998), and inhibition of this transporter with tetrabenazine resulted in a 
greater decrease in dopamine release than 5-HT. We propose that a smaller releasable pool 
contributes to lower release amplitudes, which in turn reduces the requirement for packaging 
in serotonergic terminals. This is supported by the comparatively moderate response of 5-HT 
to manipulations that affect synthesis and packaging.  There was, however, a significant 
increase in the t1/2 for 5-HT clearance.  An increase in cytoplasmic 5-HT caused by VMAT2 
inhibition could decrease uptake rates by altering the concentration-dependent driving force 
for SERT, a common feature of amine transporters (Torres & Amara, 2007).  There was a 
delay in the onset of 5-HT release that may be indication of tetrabenazine-insensitive 
vesicular pools, possibly dense core vesicles, compensating for the demand on release.   
Following release, one fate for monoamines is metabolic degradation by MAO (Jain, 
Sands, & Von Korff, 1973).  Prior work has shown that there is a small increase in dopamine 
release following MAO inhibition, presumably because repackaging into vesicles becomes 
more likely during a reduction in metabolic degradation (J.A. Stamford et al., 1988).  
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However, the increase in stimulated 5-HT release following MAO inhibition is greater than 
3-fold, indicating that serotonergic neurons have greater regulation by MAO.  Moreover, 
while MAO inhibition had no effect on the rate of dopamine clearance, a significant increase 
in the t1/2 of the 5-HT signal indicates that this treatment caused a reduction in 5-HT reuptake 
rate.  Similar to inhibition of VMAT2, MAO inhibition could alter the driving force of 
SERT, resulting in decreased rate of uptake.   
Another means for extracellular regulation is uptake via transporters.  However, 
because different receptors and transporters regulate dopamine and 5-HT release, it was 
necessary to administer different agents to evaluate these control points.  We found that both 
neurotransmitter systems were sensitive to selective inhibition of their transporters (Figure 
4.4D), results consistent with previous work (Budygin, Kilpatrick, Gainetdinov, & 
Wightman, 2000; Hyttel, 1982).  5-HT autoreceptors are known to suppress 5-HT release in a 
manner similar to the regulation of dopamine release by the dopamine autoreceptor in the 
NAc (Chaput, Blier, & de Montigny, 1986; Sesack, Aoki, & Pickel, 1994; Threlfell et al., 
2010).  We used methiothepin, a non-selective 5-HT autoreceptor antagonist to target the 
multiple 5-HT autoreceptors (Barnes & Sharp, 1999).  Following raclopride and 
methiothepin, release of dopamine and 5-HT, respectively, was moderately increased.  This 
suggests that regulation by 5-HT autoreceptors is not responsible for the differences between 
5-HT and dopamine release.  The increase in the t1/2 of the 5-HT signal after methiothepin 
administration is consistent with the suggestion by Daws and colleagues that 5-HT1B 
autoreceptors modulate 5-HT clearance (Daws, Gerhardt, & Frazer, 1999; Daws et al., 2000).   
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Disrupting 5-HT Control Mechanisms Results in Serotonin Syndrome 
Within 2.5 hours of SERT and MAO inhibition respiratory arrest was followed by 
spontaneous efflux of dopamine and 5-HT (Figure 4.5A and B).  Synchronized dopamine and 
5-HT efflux likely reflects reversal of their transporters, which use secondary active transport 
coupled to the respiration-sensitive Na
+
/K
+
 ATPase (Torres & Amara, 2007).  The 
spontaneous efflux preceding death resembles evoked release in that the maximum 5-HT 
amplitude is much lower than for dopamine (Figure 5C).  Furthermore, 5-HT efflux is 
prolonged (Figure 4.5D) adding support to the concept that 5-HT is constrained more tightly 
with neurons.  Following citalopram, pargyline administration led to decreases in heart rate 
and body temperature leading up to eventual death (Figure 4.5D and E). These findings 
concur with previous reports that combined administration of MAO and SERT, but not DAT, 
inhibitors cause fatalities in rats (Marley & Wozniak, 1984).  In humans, this 
pharmacological combination is known to induce serotonin syndrome, which arises from 
excess serotonergic activity in the central nervous system (Izumi et al., 2006; Lane & 
Baldwin, 1997; Mitchell, 1997).  Our findings reveal the consequences of serotonin 
syndrome in anesthetized animals.   
Conclusions 
In prior work we used a similar comparative approach to compare release of 
norepinephrine and dopamine evoked by a single stimulation, and found that their release and 
uptake characteristics were quite similar (Park et al., 2011).  In this work, high time 
resolution recordings revealed much greater differences in regulation of dopamine and 5-HT.  
We found that 5-HT release is highly regulated and is dominated primarily by re-
uptake/inactivation systems that could not be unraveled with slower monitoring techniques 
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such as microdialysis.  Moreover, use electrochemical monitoring has revealed 
neurochemical processes that occur as a result of serotonin syndrome fatality.  
Supplemental Methods 
Animals 
 Sprague Dawley rats (male, 8-12 weeks, 250-350g) were purchased from Charles 
River Labs (Raleigh, NC, USA).  All animal care was in accordance with the Guide for the 
Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use 
Committees of the University of North Carolina.  Rats were housed in a 12:12 hour light 
cycles with controlled temperature and humidity. Rats were given ad libitum access to food 
and water.  
 Rats were anesthetized with urethane (15 g kg
-1
 rat weight) and positioned in a 
stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA).  Surgeries were performed 
as previously described (Hashemi et al., 2009) using stereotaxic coordinates referenced from 
bregma and taken from Paxinos and Watson’s Rat Brain Atlas (Paxinos & Watson, 2007).  
Nafion-modified carbon-fiber microelectrodes were implanted in the SNR (stereotaxic 
coordinates AP -4.8 to -5.2; ML+2.0; DV -7.3) and in NAc (stereotaxic coordinates AP +2.0 
to +2.3; ML +2.0; DV -7.3).  A bipolar stainless steel stimulating electrode, insulated to the 
tip (0.2mm diameter, Plastics One, Roanoke, VA, USA) was implanted into the MFB (AP -
2.5to -2.8; ML 1.7; DV -8.0).   
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Voltammetric Procedures 
 Carbon-fiber microelectrodes were fabricated by aspiration of a single 2.5-µm carbon 
fiber (T-650, Thornel, Amoco Co.) into a glass capillary with a 0.6mm external diameter 
and 0.4 mm internal diameter (A-M Systems, Inc., Sequim, WA).  A micropipette puller 
(Narishige, Tokyo, Japan) was used to form a carbon-glass seal.  The exposed carbon fiber 
was cut to approximately 100 µm in length and soaked in isopropyl alcohol (IPA) for 30 
minutes to clean the surface (Cahill et al., 1996). The procedure for electrodeposition of 
Nafion was previously described (Hashemi et al., 2009).  The reference electrodes were 
chloridized silver wire (0.5mm diameter, Sigma-Aldrich) in 0.1 M HCl. All potentials 
reported are against Ag/AgCl.   
 Quad UEI potentiostats (University of North Carolina Department of Chemistry 
Electronics Shop), described previously (Zachek, Takmakov, Park, Wightman, & McCarty, 
2009), were modified by enabling independent control of the potential on two pairs of 
operational amplifiers in the head stage chip. A data acquisition system capable of 
generating two independent waveforms and collecting from two sets of channels was 
previously described (Zachek, Takmakov, Moody, et al., 2009). One NI 6251M card was 
used for generation of “5-HT waveform” (-0.1 to 1.0 V with a resting potential of 0.2 V at 
1000 Vs
-1
 at 10 Hz) as described elsewhere (Jackson et al., 1995) and for data collection 
from the microelectrode placed in the SNR. The other NI-6251M card was used for 
generation of “dopamine waveform” (-0.4 to 1.3 V with a resting potential of -0.4 V at 400 
Vs
-1
 at 10 Hz) and data collection from the microelectrode placed in the nucleus accumbens 
core (NAc).  
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Drugs and Reagents 
 Chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) at 
pharmaceutical quality.  Doses were selected from literature sources.  Pargyline 
hydrochloride (75 mg/kg or 150 mg/kg) (Millar et al., 1985), NSD 1015 (100 mg/kg) 
(Muck-Seler & Diksic, 1995), GBR 12909 dihydrochloride (15 mg/kg) (Reid, Hsu, & 
Berger, 1997), raclopride (2 mg kg
-1
) (Park et al., 2009), methiothepin (10 mg kg
-1
) 
(Monachon et al., 1972), and citalopram (10 mg kg
-1
) (Hashemi et al., 2009) were dissolved 
in saline and injected intraperitoneally at a volume of 0.6 ml kg 
-1
.  Tetrabenazine (10 
mg/kg) (Larsson & Komisaruk, 1972) was first dissolved in 0.2 ml 20% ethanol and diluted 
in saline and injected intraperitoneally at a volume of 0.6 ml kg 
-1
.  Prior to drug 
administration, the voltammetric responses were evaluated following an i.p injection of the 
vehicle.  There were no significant changes. For all drugs except pargyline, readings were 
taken 60 minutes after i.p administration. Readings were taken 90 minutes after pargyline 
administration to ensure enough time for the full effects to occur (Millar et al., 1985; J. A. 
Stamford, Z. L. Kruk, & J. Millar, 1988). 
Monitoring of Physiological Conditions 
 A SurgiVet V3395 TPR (Temperature, Pulse Rate, and Respiration) monitor was 
used to record the rat’s body temperature and heart rate every 5 minutes throughout 
experiments. Heart rate was measured using a SpO2 digital oximetry probe (range 20-350 
beats per minute, accuracy ±2%). For consistent results, the oximeter probe was positioned 
under a shaved region of the rat’s body. Body temperature was measured using a 
temperature probe (range 32-140ºF, accuracy ± 1ºF) positioned under the length of the 
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animal. Heart rate and temperature are reported as a percentage of baseline, a minimum of 
30 minutes in between completion of stereotactic surgery and onset of electrical 
stimulations. Breathing was monitored by observation throughout the experiment as use of 
the respiration sensor was not possible with the animal positioned in a stereotaxic frame. 
Data Analysis 
 In this work we used t1/2 to describe neurotransmitter clearance rates. It is defined as 
the time to go from the maximum evoked concentration to half of the maximal value.   
Two-tailed Student’s T-tests were performed on paired data sets, p<0.05 was taken as 
significant. 
 Two-way ANOVAs were performed on heart rate and temperature data sets using 
Bonferroni post-hoc tests to determine significance at each time point. p<0.05 was taken as 
significant. 
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Figure 20Figure 4.1 Comparison of dopamine and serotonin release evoked by electrical stimulation of MFB 
 
Figure 4.1 Comparison of dopamine and serotonin release evoked by electrical stimulation 
of MFB. Left panel: Representative color plots with potential on the y-axis, time on the x–
axis, and the current in false color. Horizontal white dashed line was used to construct the 
current vs. time traces plotted above the color plots.  Stimulation onset (dashed black vertical 
line) and duration is represented by the blue bar under the current vs. time traces.  Cyclic 
voltammograms taken at the vertical white dashed lines are inset. Right panel: averaged, 
normalized responses recorded in the NAc (dopamine) and SNr (5-HT) as the stimulating 
electrode was lowered down a vertical tract to the MFB (n=6).  Stars indicate normalized 5-
HT maximal release values that are significantly different from the corresponding dopamine 
normalized release values (p<0.05). 
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Figure 21Figure 4.2 Comparison of dopamine and serotonin release evoked by varying stimulation parameters. 
 
Figure 4.2 Comparison of dopamine and serotonin release evoked by varying stimulation 
parameters. Averaged, normalized dopamine and 5-HT maximal release with (A) variation of 
stimulation pulse width and (B) stimulation current amplitude (n=6 for each transmitter). (C) 
Averaged, normalized dopamine and 5-HT responses to repeated stimulation trains (n=6).  
Stimulations were 120 biphasic pulses at 60Hz, 350 µA and 2ms delivered once every 60 
seconds for 20 minutes.   
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Figure 22Figure 4.3 Effects of manipulating dopamine and serotonin synthesis, packaging and release. 
 
Figure 4.3 Effects of manipulating dopamine and serotonin synthesis, packaging and release. 
Comparison of averaged responses of 5-HT in the SNr (top; n=5) and dopamine in the NAc 
(below, n=6 ) to pharmacological inhibition of synthesis, packaging and release (left to right). 
Synthesis was inhibited with NSD 1015 and vesicular packaging was inhibited with 
tetrabenazine.  Release was increased by autoreceptor antagonists (methiothepin for 5-HT 
and raclopride for dopamine).  The two bottom rows show histograms of the percent change 
in amplitude and t1/2 induced by the drug 60 min after its administration.  Stars on the 
histogram indicate a significant change from pre-drug values (p<0.05). 
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Figure 23Figure 4.4 Effects of uptake and MAO inhibitors on dopamine and serotonin release. 
 
Figure 4.4 Effects of uptake and MAO inhibitors on dopamine and serotonin release. 
Comparison of averaged responses of 5-HT in the SNr (top; n=5) and dopamine in the NAc 
(below; n=6) to pharmacological inhibition of uptake and metabolism by MAO.  Uptake was 
inhibited by GBR 12909 for dopamine and citalopram for 5-HT.  Pargyline inhibited MAO 
and is effective for both neurotransmitters.  The two bottom rows show histograms 
displaying the percent change in amplitude and t1/2. Stars on the histogram indicate a 
significant change from predrug values (p<0.05). 
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Figure 24Figure 4.5 Dual uptake and MAO inhibition disregulates serotonin signaling. 
 
 
 
 
 
 
Figure 4.5 Dual uptake and MAO inhibition disregulates serotonin signaling. (A, B) 
Representative results from individual animals for dopamine (Monachon et al.) and 5-HT 
(SNr) efflux that both occur spontaneously immediately following respiratory arrest. (C) 
Maximal dopamine and 5-HT concentrations (n=4 for each). (D) Response of body 
temperature relative to baseline (0-25 min) during electrical stimulations (six 2-s 
stimulations, 5 min apart, ES), following citalopram (T1), and following pargyline (T2). 
Drug-treated animals shown in black circles (n=6) and saline controls shown in white circles 
(n=4). (E) Response of heart rate to electrical stimulations (ES), citalopram (T1), and 
pargyline (T2). Drug-treated animals shown in black bars (n=4), saline controls shown in 
white circles (n=4). (F) Mean time between onset of efflux and peak of efflux for dopamine 
and 5-HT (n=4). Stars on graphs indicate significant differences between groups (*, p<0.05; 
**, p<0.01; ***, p<0.001). 
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CHAPTER 5:  THE DORSAL RAPHE NUCLEUS MEDIATES SSRI-INDUCED 
FACILITATION OF SEROTONIN SIGNALING 
Introduction 
 Nearly 1 in 8 adults in the United States will suffer from depression in their lifetimes, 
and over half will seek medical treatment for their symptoms (Kessler et al., 2003).  
Enhancing serotonin signaling is a common goal of these treatments because hypofunction of 
the serotonergic system is widely believed to underlie depressive symptoms (Jacobsen, 
Medvedev, & Caron, 2012).  The most commonly-prescribed pharmacotherapies for 
depression are selective serotonin reuptake inhibitors (SSRIs), which increase serotonin 
levels by reducing serotonin transporter (SERT) function.  However, given that 3-6 weeks 
lapse before clinical improvements are observed, it is believed that SSRIs exert their effects 
via plasticity in serotonergic function and its downstream targets (Blier & de Montigny, 
1998). This plasticity arises from two key effects of acute SSRI exposure: increases in 
extracellular serotonin levels, and reduced spontaneous firing of serotonergic neurons 
(Pineyro & Blier, 1999). The former is a consequence of a functional shift in the release and 
uptake equilibrium due to reductions in SERT function. The latter arises due to increased 
activation of 5-HT1a autoreceptors, which inhibit excitation of serotonergic neurons (Blier et 
al., 1998). Sustained increases in serotonin levels during chronic SSRI treatment leads to 
functional desensitization of these autoreceptors, and this desensitization is a critical 
component in the therapeutic effects of SSRI treatment (Bortolozzi et al., 2012; Ferres-Coy 
et al., 2013). 
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 In this work, we use fast-scan cyclic voltammetry (FSCV) to examine how serotonin 
release is affected by acute SERT inhibition. Previously, we reported that serotonin evoked 
in vivo is remarkably lower in concentration than that evoked in brain slices (Bunin et al., 
1998; Hashemi et al., 2011), and we demonstrated that SERT function is critical to 
maintaining physiological release and uptake equilibria in vivo (Hashemi et al., 2012). To 
better understand how SERT function may contribute to limited release in vivo, we examined 
how citalopram (CIT), a commonly-prescribed SSRI, alters serotonin release evoked by 
stimulations ranging in frequency. Varying stimulation frequency is one way to differentiate 
between effects on release vs. uptake in measurements of neurotransmission (Wightman & 
Zimmerman, 1990). Although seroto’nin release is consistently frequency-dependent in brain 
slices, we were surprised to find that it was not frequency-dependent in vivo. Moreover, acute 
SSRI treatment with CIT produced frequency-dependent release. We show evidence that 
CIT-induced enhancement of serotonin release is anatomically dissociable from changes in 
uptake, and implicate the dorsal raphe nucleus (DRN) in mediating these effects. This work 
demonstrates that SSRIs can rapidly alter serotonin signaling in distal brain regions by 
inhibiting SERT activity in the DRN. This novel property of SSRIs may provide important 
clues into how the acute effects of SSRIs translate into therapeutic efficacy during chronic 
treatment.  
Materials and Methods 
Animals 
All experiments were conducted in accordance with protocols approved by University 
of North Carolina at Chapel Hill (UNC-CH) Institution Animal Care and Use Committee. 
Male C57Bl6/J WT and Slc6a4 homozygous knock-out mice were received from Jackson 
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Laboratories (Bar Harbor, ME) at 5-6 weeks of age and housed in groups of 4 for a minimum 
of 2 weeks after arrival. Mice were provided with food and water ad libitum and kept on a 
12-hour-day/light cycle.  
Electrochemistry 
Carbon-fiber microelectrodes were fabricated as previously described (Cahill et al., 
1996). Carbon fibers were aspirated into a glass capillary (external diameter: 0.6, internal 
diameter: 0.4) and pulled on a vertical capillary puller (Narashige, Japan) so that glass 
formed a tapered seal with carbon fiber. The exposed length of carbon fiber was then 
trimmed to 150 µM. To enhance sensitivity to serotonin, Nafion (5% in methanol, Sigma-
Aldrich, St. Louis, MO) was applied to microelectrodes in a dip-coating process. Briefly, the 
tip of each electrode was dipped into Nafion solution then baked at 70 ºC for 10 minutes to 
evaporate solvent. This was repeated 7 times to obtain the the desired Nafion thickness. 
Electrodes were post-calibrated in a flow-injection system to obtain in vitro calibration 
factors as previously described (Hashemi et al., 2009).  
Application of waveform, data collection, and stimulation application were controlled 
by Tarheel CV software via an in-house manufactured potentiostat (UEI, UNC-CH 
Electronics Facility). Voltammetric measurement of in vivo serotonin release has been 
previously described (Hashemi et al., 2009). For serotonin detection, a voltage waveform 
scanning from -0.1 to 1 V at 1000 V/s was applied at a rate of 10 Hz and held at 0.2 V 
between scans (Jackson et al., 1995).   
 
In vivo experiments 
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Mice were anaesthetized with urethane (2 mg/g, i.p.) prior to stereotaxic surgery. A 
stainless-steel bipolar stimulating electrode (PlasticsOne, Roanoke, VA) was implanted into 
the DRN (AP: -4.1, ML: 0.0, DV: -2.5 to -2.7 mm) and a carbon-fiber microelectrode was 
lowered into the SNpr (AP -3.2, ML: +1.5, DV -4.0 to -4.2 mm). An Ag/AgCl reference 
electrode was secured in the contralateral hemisphere. 
Detection of electrically evoked serotonin was optimized by moving stimulating 
electrode and carbon-fiber microelectrode in 0.1 mm increments within the given coordinate 
ranges. At the end of every experiment, CIT (10 mg/kg, i.p.) was administered to 
pharmacologically validate the signal recorded. In a few experiments, clearance was 
unaffected by CIT. This was attributed to unsuccessful targeting of the SNpr or DRN, and 
these experiments were excluded from statistical analyses. 
For microinfusion experiments, prior to stimulation electrode implantation, a 
microinjection needle was lowered into the DRN, and approximately 25 µL of saline or CIT 
(800 mM, in saline) was ejected into the targeted region. After 15 minutes, the microinjector 
needle was removed and stimulating electrode was implanted as described above. Because of 
its close proximity to the cerebral aqueduct, misplacement of microinjector needle resulted in 
brainwide CIT exposure. A large increase in clearance half-life clearly demonstrated the 
failure of the microinfusion procedure, and these experiments were excluded from analyses. 
Drugs and reagents 
Citalopram hydrobromide and urethane were purchased from Sigma-Aldrich (St. 
Louis, MO) and used as received.  Nafion (10% in mixed alcohols) was purchased from 
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Sigma-Aldrich and concentrated in a rotovap to replace solvent with methanol. 
Intraperitoneal-injected drugs were administered at a volume of 0.01 mL/g body weight.   
Data analysis 
Results are average values ± SEM except when representative data is presented.  
Trends in maximum evoked amplitude ([5-HT]max), release rate, clearance half-life (t1/2), and 
net overflow were analyzed using a repeated measures ANOVA with Tukey’s multiple 
comparisons post-hoc analysis.  
Release rate, t1/2, and net overflow were calculated using concentration traces evoked 
by 20-60 Hz stimulations in each subject. Release rate was calculated by fitting lines to the 
rising phase of serotonin release, approximately the first 2 s. Adjustments of the fitting frame 
of up to 0.1 s were made to avoid stimulation artifacts and to ensure linear behavior 
(R
2
>0.70). Clearance half rate (t1/2) was calculated in Clampfit (Molecular Devices, LLC, 
USA) as the decay time between 100% and 50% evoked concentration.  Net overflow was 
calculated in Clampfit using the integral under the curve for the first 15 seconds following 
the stimulation event.  t1/2 and net overflow analyses have been shown to correlate well with 
kinetic models of neurotransmitter release (Yorgason, Espana, & Jones, 2011). 
Results 
Serotonin release evoked in vivo varies with stimulation pulse number, but not frequency 
 Serotonin release was measured in the SNpr during stimulation of the DRN. A 
representative color plot identifies serotonin evoked after a 325 μA, 60 Hz, 1 s stimulation 
(Figure 5.1A). The concentration trace obtained at the oxidation potential for serotonin 
(Figure 5.1B) shows its release during the stimulation followed by its subsequent clearance. 
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 In brain slices, prior work showed that serotonin release evoked in the SNpr by an 
adjacent stimulating electrode is pulse- and frequency-dependent. This was confirmed in the 
present work, where we found that [5-HT]max doubled when comparing release evoked by 20 
Hz and 60 Hz stimulations in the SNpr (n=5). To characterize the responsiveness of serotonin 
release to different stimulation parameters in vivo, we compared [5-HT]max evoked by 
stimulations of the DRN that varied in pulse number and frequency. In dramatic contrast to 
the slice results, varying stimulation frequency in vivo did not affect [5-HT]max (Figure 5.1C). 
However, [5-HT]max was significantly affected by varying stimulation pulse number (Figure 
5.1D; repeated measures ANOVA, F(4,16)=9.374, P<0.001). To rule out an effect of 
stimulus duration on pulse-dependence, we covaried pulse number with frequency to fix the 
total stimulus presentation time at 1 s. Again, increasing pulse number correlated with 
increasing [5-HT]max (Figure 5.1E; F(4,24)=18.49, P<0.0001). This confirms that evoked 
release can be manipulated by varying stimulation pulse number, but not frequency. 
 To determine what aspects of signaling contributed to lack of frequency-dependence, 
we examined how stimulation frequency affected release rate, t1/2, (a measure of uptake; 
Yorgason, Espana, & Jones, 2011 ) and net overflow in serotonin concentration traces. We 
found no effect of frequency on t1/2 (Figure 5.1G). This was expected, as clearance rate 
should be unaffected by physiological stimulation. However, although stimulation frequency 
should directly correlate to the rate of neurotransmitter release (R.M. Wightman et al., 1988), 
no differences were observed in evoked release rate (Figure 5.1F). The consequence of this 
frequency insensitivity is that net overflow evoked by 20-60 Hz stimulations is identical 
(Figure 5.1H), such that in this range of frequencies, transient increases in extracellular 
serotonin do not differ.  
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SERT inhibition enhances serotonin release in a frequency-dependent manner 
  We then looked at the effects of CIT (10 mg/kg, i.p.) on serotonin dynamics. 
Unexpectedly, after CIT treatment, [5-HT]max was significantly affected by stimulation 
frequency in vivo (Figure 5.2A; repeated measures ANOVA, F(4,20)=16.56, P<0.0001). To 
confirm that this effect of CIT was not due to a non-selective effect of the drug, we 
administered CIT in mice whose copies of SERT (Slc6a4) had been genetically deleted 
(SERT-/- mice). Baseline serotonin release in SERT-/- mice was also frequency-independent, 
and CIT had no effect on [5-HT]max or t1/2 in SERT-/- mice at any frequency. Moreover, 
serotonin release evoked by 20 Hz stimulations looked nearly identical to CIT-treated wild-
type mice (Figure 5.2B). This suggests that the dosage of citalopram in these experiments is 
sufficient to saturate SERT. Tellingly, [5-HT]max is significantly enhanced in CIT-treated 
wild-type mice compared to SERT-/- mice (Figure 5.2C). This suggests that acute SERT 
inhibition has an excitatory, frequency-dependent effect on serotonin signaling.  
 After we confirmed that CIT effects on [5-HT]max were selective for SERT, we 
examined concentration traces in wild-type mice to determine what aspects of 
neurotransmission contributed to frequency-dependent differences. Across all stimulation 
frequencies, t1/2 was consistent. However, rate of evoked release varied significantly with 
stimulation frequency (Figure 5.2C; repeated measures ANOVA, F(5,20)=24.18, P<0.0001), 
suggesting that acute CIT treatment unexpectedly modified regulation of serotonin release. 
As a result of this enhancement in release rate, net evoked release is also frequency 
dependent (Figure 5.2E, repeated measures ANOVA, F(5,20)=18.16, P<0.0001). The finding 
that CIT enhances serotonin signaling in a frequency-dependent manner has not been 
previously reported and may be a major component of its therapeutic efficacy. 
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Inhibiting SERT in DRN enhances serotonin release in a frequency-dependent manner 
 Data presented above shows effects of CIT and other uptake inhibitors on [5-HT]max 
and t1/2 after the effects of the drug have stabilized. For example, after 30 minutes, CIT 
effects are stable and remain consistent for up to 2 hours. However, the onset of CIT effects 
follows an interesting pattern that provides additional insights concerning its release-
enhancing mechanisms. To characterize CIT onset, 60 Hz, 1 s stimulations were applied at 2 
minute intervals and changes in [5-HT]max and t1/2 relative to pre-drug release were 
determined. Figure 4A compares the response of these measurements for the first 16 minutes 
following CIT exposure. While t1/2 does not increase for up to 12 minutes after SSRI 
exposure, [5-HT]max doubles within the first 6 minutes. Representative traces illustrating the 
separate effects on [5-HT]max and t1/2 can be seen in Figure 5.3B. The apparent disassociation 
of changes in [5-HT]max from t1/2 suggests that the acute effects of CIT on serotonin release 
may occur in a different anatomical location from where we measured uptake. Since we do 
not observe effects on [5-HT]max in brain slices, where serotonergic terminals are severed 
from cell bodies, we hypothesized that high-affinity SERT inhibition in the DRN contributed 
to these excitatory effects. 
To test whether the DRN mediated CIT effects on [5-HT]max in the SNpr, we 
microinfused saline (μ-SAL) or CIT (μ-CIT) directly into the DRN and compared the effect 
of stimulation frequency on evoked release (Figure 5.3C). To confirm that CIT 
microinfusions did not access the cerebral aqueduct, which would enable drug to spread 
rapidly throughout the brain, we compared t1/2 of serotonin release evoked by 60 Hz 
stimulations between µ-SAL and µ-CIT. No difference between μ-SAL and μ-CIT were 
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observed at baseline or in their response to i.p. CIT (10 mg/kg). Thus, microinfusions were 
limited to a localized area and did not alter SERT activity in the SNpr.  
 Next, we compared [5-HT]max evoked by varying stimulation frequencies. There was 
no effect of stimulation frequency in μ-SAL mice. However, there was a significant effect of 
stimulation frequency in μ-CIT mice (Figure 5.3D; repeated measures ANOVA, 
F(2,8)=11.62, P<0.01). When we compared μ-CIT with μ-SAL, there was a significant effect 
of treatment (repeated measures ANOVA, F(1,16)=12.58, P<0.05) and frequency x treatment 
interaction (F(4,16)=10.10, P<0.001). Post-hoc analyses revealed significant differences 
between [5-HT]max at 40 Hz (P<0.05), 50 Hz (P<0.01), and 60 Hz (P<0.001).  
Discussion 
Under normal conditions, serotonin signaling is under robust regulation from multiple 
inhibitory elements. The extent of this regulation is illustrated by a nearly 50-fold difference 
between serotonin concentrations evoked in brain slices vs. in vivo in the SNpr (Bunin et al., 
1998; Hashemi et al., 2011; John & Jones, 2007a). This difference implies that some 
elements controlling serotonin release require intact circuitry. In spite of limited release, 
uptake by SERT remains relatively similar between in vivo and brain slice preparations 
(Daws & Toney, 2007). Since uptake that occurs during and between stimulus pulses shapes 
dynamic release as well as maximal evoked concentrations (R.M. Wightman et al., 1988), 
similarities in SERT function predict similarities in frequency-dependent release. As 
predicted by this model, in brain slices, [5-HT]max is frequency-dependent (Bunin & 
Wightman, 1998; Iravani & Kruk, 1997; O'Connor & Kruk, 1991b). Surprisingly, stimulation 
frequency did not affect serotonin release in vivo (Figure 5.1), even though other measures of 
stimulation intensity correlate well to findings in slices (Figure 5.1C-D). However, this result 
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is not totally unfounded in our understanding of serotonergic function. Serotonergic neurons 
in the DRN predominantly fire at a rate of 1-5 Hz (Pineyro & Blier, 1999). Burst-firing can 
occur at frequencies up to 100 Hz (Hajos et al., 1995), but its prevalence is correlated with 
behavioral arousal (Jacobs, 1991; Jacobs & Fornal, 1999). GABAergic inputs to the DRN are 
also behavioral state-dependent and may contribute to limitations in firing rate (Levine & 
Jacobs, 1992). Lack of frequency-dependence may reflect serotonergic function during low-
arousal states, a theory consistent with our anaesthetized preparation.    
 Models of neurotransmission predict that slower stimulation frequencies will be most 
affected by changes in transporter function, because uptake occurs for a longer proportion of 
their release period (Wightman & Zimmerman, 1990). In our experiments, [5-HT]max and 
release rate were unaffected by stimulation frequency, so we anticipated that SERT inhibition 
would have similar effects on [5-HT]max across all stimulation frequencies. Instead, CIT 
enhanced serotonin release in a frequency-dependent manner, with the highest [5-HT]max and 
release rate occurring at 50 Hz or 60 Hz in all subjects (Figure 5.2A). Interestingly, at high 
frequencies, CIT treatment enhanced serotonin release in wild-type mice compared to 
SERT-/-. This suggests that frequency-dependent effects on release may not be a direct effect 
of reduced clearance in the SNpr, but due to SERT-mediated changes elsewhere. Differences 
in frequency sensitivity between CIT-treated wild-type vs. SERT-/- mice likely reflect 
developmental compensations for SERT deletion, potentially in autoreceptor populations and 
secondary transport systems  (Gobbi, Murphy, Lesch, & Blier, 2001; Thompson et al., 2011). 
We have previously shown that loss of DAT expression significantly alters autoreceptor 
function (Jones et al., 1999). 
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In all wild-type mice, CIT effects on [5-HT]max preceded effects on t1/2 (Figure 5.3A). 
This effect of CIT has not previously been shown because it can only be measured using a 
technique with temporal and spatial resolution commensurate with neurotransmission, such 
as FSCV. It suggests that SSRI-induced changes in release are dissociable from changes in 
uptake. Since CIT exposure does not affect [5-HT]max in brain slices, where terminal release 
sites are severed from their neurons, we hypothesized that CIT effects on [5-HT]max in vivo 
were mediated in the DRN. Using microinjections targeted to the DRN, we found CIT effects 
on [5-HT]max were indeed mediated by the DRN, while its effects on uptake were not (Figure 
5.3). One possible mechanism for SERT-selective effects of CIT on release is desensitization 
of autoreceptors. Although desensitization is classically thought to occur after 3-6 week 
exposure to SSRIs, 5-HT1a receptors can rapidly internalize after acute exposure to SSRIs or 
5-HT1a agonists (Riad, Watkins, Doucet, Hamon, & Descarries, 2001; Riad et al., 2004). In 
the case of acute SERT inhibition, 5-HT1a receptors may desensitize as a response to 
extremely high local serotonin levels, enabling faster firing rates. Alternatively, acute SERT 
inhibition may maximally activate autoreceptors and other 5-HT-mediated inhibitory 
circuitry, creating a “ceiling effect” for inhibitory control. Under normal conditions, 
inhibitory control probably upregulates in response to excitatory inputs to the DRN. 
However, SSRIs have substantial effects on serotonin signaling in the DRN (Bunin et al., 
1998). CIT acutely increases serotonin levels 400% in the DRN, compared to approximately 
200% in other forebrain regions (R. Invernizzi et al., 1992). If rising ambient serotonin levels 
maximize inhibitory feedback, unchecked responses to excitatory input would result in 
dramatic enhancements to transient serotonergic activity. This could explain paradoxical 
findings that acute SSRI treatment induces activity-dependent increases brainwide serotonin 
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levels and simultaneously prohibit serotonergic firing (Gartside et al., 1995; Hajos et al., 
1995; Perry & Fuller, 1992).   
In this work, we demonstrate novel properties of serotonin signaling and its response 
to SERT inhibition that have implications for the clinical efficacy of SSRIs. First, we show 
that serotonin release is not frequency-dependent in vivo. Although this finding was not 
expected based on prior voltammetric studies in brain slices, it may reflect behavioral state-
dependent regulation of serotonin signaling. Our experimental method may model serotonin 
signaling during low-arousal states, where regulation of serotonergic signaling may be most 
robust. Next, we showed that SSRIs induce frequency-dependent release by selectively 
inhibiting SERT function, suggesting that serotonergic burst-firing is enabled after acute 
SSRI use. The ability to burst-fire in states of low arousal may underlie certain side effects of 
SSRI treatment, such as irregular sleep patterns (Bridoux, Laloux, Derambure, Bordet, & 
Monaca Charley, 2013; Katai et al., 2013). Finally, we found that the effects of SSRIs on 
forebrain release, but not uptake, were mediated by their effects in the DRN. SSRI-induced 
changes in ambient serotonin levels and enhancement of serotonin signaling related to burst-
firing may coordinate during treatment to produce antidepressant outcomes.  Acute increases 
in burst-firing may be masked by increases in ambient serotonin levels. However, as these 
levels normalize over the chronic treatment period, enhancements in serotonin release may 
register as larger, clearer signals throughout the brain. Therefore, a better understanding of 
how SSRIs can rapidly modify regulation of serotonergic activity may lead to more effective 
therapies for depression and related disorders. 
 
119 
 
Support 
Douglas Kirkpatrick and Dr. Susan Carroll contributed data to this chapter. The 
authors would like to acknowledge technical support from the UNC Electronics Facility and 
Meg Fox, Nina Owesson-White, and Anna Belle for helpful methodological discussions.  
 
  
120 
 
Figure 25Figure 5.1 Serotonin release is not frequency-dependent in vivo 
 
Figure 5.1 Serotonin release is not frequency-dependent in vivo. (A) Representative color 
plot showing serotonin release evoked in SNpr by a 60 Hz, 1 s stimulation of DRN. Color 
plot shows time (x-axis) vs. voltage waveform potential (y-axis), with change in current 
plotted in pseudocolor. Stimulus duration indicated by red bar. Peak oxidation potential for 
serotonin indicated by white dashed line. (B) Concentration trace obtained at the oxidation 
potential for serotonin and calculated using an in vitro post-calibration factor. Stimulus 
duration indicated by red bar. (C) Average [5-HT]max for 60 pulse stimulation trains applied 
at 20- 60 Hz (n=6). (D) Average [5-HT]max for stimulation pulse trains 30, 60, 90, 120, and 
180 pulses in length (n=5). (E) Average [5-HT]max to stimulations of 1 s duration (n=7). (F) 
Average rate of change in serotonin concentration evoked by 60 pulse stimulation trains 
applied at 20- 60 Hz (n=6). (G) Average clearance half-life for these stimulations (n=6). (H) 
Average net overflow (area under concentration trace) of evoked serotonin release (n=6).   
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Figure 26Figure 5.2 Inhibiting SERT induces frequency-dependent serotonin release 
 
Figure 5.2 Inhibiting SERT induces frequency-dependent serotonin release. (A) Average [5-
HT]max of CIT-treated WT (white squares) and SERT-/- mice (green circles) evoked by 60 
pulse stimulations ranging from 20-60 Hz. (B) Average concentration trace showing 
serotonin release evoked by 20 Hz stimulations in CIT-treated WT or SERT-/- mice. (C) 
Average concentration trace showing serotonin release evoked by 60 Hz stimulations in CIT-
treated WT (black) or SERT-/- mice (green). Inset shows change in clearance half-life 
compared to pre-drug values. (D) Rate of serotonin release evoked in WT mice by 
stimulations varying in frequency from 20-60 Hz. (E) Clearance half-life of serotonin release 
evoked by stimulations of varying frequency. (F) Net overflow of serotonin release evoked 
by stimulations of varying frequency. (WT, n=6; SERT-/-, n=5)  
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Figure 27Figure 5.4 DRN mediates enhancement of serotonin signaling by SSRIs  
 
Figure 5.3 DRN mediates enhancement of serotonin signaling by SSRIs. (A) Average 
response of [5-HT]max (blue squares) and t1/2 (red circles) to acute CIT treatment. Values 
shown are percent increase from pre-drug release. (B) Representative concentration traces 
showing serotonin release 6 minutes, 14 minutes, and 22 minutes after acute CIT treatment. 
Red bar indicates stimulus duration. (C) Illustration showing targeting of the DRN for 
microinfusions of CIT. (D) Representative color plot (top) and concentration trace (bottom) 
showing serotonin release evoked by 60 Hz, 1 s stimulation after microinfusion of CIT into 
DRN. (E) Comparison of average t1/2 in saline microinfused (gray) and CIT microinfused 
subjects (blue) before and after acute CIT challenge (10 mg/kg, i.p.). (F) Average response of 
[5-HT]max in saline microinfused (gray circles) and CIT microinfused (blue squares) subjects.   
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CHAPTER 6: FACILITATION OF SEROTONIN SIGNALING BY SSRIs IS 
ATTENUATED BY SOCIAL ISOLATION 
Introduction 
Disorders involving depression and anxiety, including major depression and 
obsessive compulsive disorder (OCD), have high rates of comorbidity and are frequently 
attributed to hypofunction of the serotonergic system (Bespalov, van Gaalen, & Gross, 2010; 
Jacobsen et al., 2012).  The most commonly prescribed medications in the treatment of 
depression and OCD are selective serotonin reuptake inhibitors (SSRIs), which inhibit 
serotonin’s transporter (SERT).  Acute SERT inhibition increases brain-wide serotonin levels 
and depresses firing of serotonergic neurons (Blier & de Montigny, 1998).  Clinically, 3-6 
weeks of continuous SSRI treatment are required before symptoms of depression and OCD 
begin to improve (de Montigny, Pineyro, Chaput, & Blier, 1992).  This gap between 
treatment onset and therapeutic response suggests that the mechanism by which SSRIs exert 
anti-depressive and anxiolytic effects is not only due to an increase in ambient serotonin, but 
to an adaptive response in neural systems to sustained increases in serotonin levels.  Indeed, a 
multitude of changes in gene expression, receptor sensitivity, neurochemical signaling, and 
functional activity coincide with the therapeutic window of SSRI therapy (Bespalov et al., 
2010; Blier & de Montigny, 1998; de Montigny et al., 1992). 
Although it is common to treat depression and OCD with SSRIs, the effectiveness of 
the treatment is also notoriously variable between individuals.  Reports estimate that over 
60% of depressed individuals and 40-60% of individuals with OCD are resistant to 
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improvement while on SSRI therapy (Brandl, Muller, & Richter, 2012; Gaynes et al., 2008).  
Depressed individuals with comorbid anxiety disorders have poorer outcomes on all types of 
antidepressant medication when compared with non-anxious depressed individuals (Fava et 
al., 2008).  The serotonergic system is highly sensitive to stress, and genetic variability in its 
function contributes to stress resilience and responsiveness to SSRI therapy (Chaouloff, 
Berton, & Mormede, 1999; Oreland, Nordquist, Hallman, Harro, & Nilsson, 2010; Uher, 
2011).  Clinical research suggests that ongoing stress, including the absence of social support 
networks, can contribute to treatment-resistant depression and anxiety (Karelina & DeVries, 
2011).Thus, improving pharmacotherapies for depression and OCD will likely require an 
understanding of how stress and anxiety interact with SSRI treatments.   Social isolation is a 
form of chronic mild stress that replicates naturalistic environmental stressors for rodents and 
has been suggested as an animal model for depressive disorders (Nestler & Hyman, 2010; 
Wiborg, 2013).  In mice, social isolation significantly upregulates the function of the 
hypothalamic-pituitary-adrenal (HPA) axis, altering levels of glucocorticoid (Ferres-Coy et 
al.) and corticotropin releasing factor (CRF) in various brain regions (Backstrom & Winberg, 
2013; Blanchard, McKittrick, & Blanchard, 2001; Valzelli, 1973). The HPA axis also 
regulates serotonin signaling and the effects of antidepressants (Barden, 1996, 2004; Pariante 
& Miller, 2001).  Understanding how social isolation alters serotonin signaling in mice, 
particularly in response to SSRIs, may provide clues about how stress influences treatment-
resistant depression and OCD. 
SSRI treatment changes serotonin metabolism, receptors, and transporters in a way 
that that could facilitate serotonergic activity.  However, prior to this work, the effects of 
chronic SSRIs on endogenous in vivo serotonin release and uptake have not been reported.   
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We used fast-scan cyclic voltammetry (FSCV) to monitor serotonin signaling and alterations 
in its dynamics induced by chronic citalopram (CIT).  FSCV is an electrochemical method 
with sufficient chemical resolution necessary to detect serotonin (Hashemi et al., 2009) and 
sufficient temporal resolution to resolve the processes of release from neuronal uptake 
(Hashemi et al., 2012).  We have established that FSCV can monitor serotonin release in 
vivo, specifically in the substantia nigra pars reticulata (SNpr), which receives a dense 
serotonergic projection from the dorsal raphe nucleus (DRN).  Here, we use FSCV to 
evaluate the effects of 20-day CIT exposure on serotonin signaling in pair-housed and single-
housed mice.  We found robust behavioral and neurochemical differences in the effects of 
SSRI treatment between these groups.   
Materials and Methods 
Animals 
All experiments were performed in compliance with the University of North Carolina 
at Chapel Hill (UNC) Institutional Animal Care and Use Committee.  Subjects were 
C57BL/6J male mice (4-5 weeks in age and 20-27 g at arrival from Jackson Laboratory, Bar 
Harbor, ME), initially housed in groups of 4.  After one week of acclimation, 40 mice were 
housed individually, and 36 mice were housed in pairs.  All subjects were kept on a 12-hour-
day/light cycle and given ad libitum access to food and water. 
Chronic CIT Treatment 
To eliminate stress contribution from daily injections, citalopram hydrobromide (CIT; 
Roxane Laboratories) or vehicle (VEH) was administered via water bottles for 20 days.  
Briefly, water consumption was monitored for 7 days to establish a baseline for each subject 
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or pair of subjects.  The concentration of CIT added to water during the treatment period was 
adjusted to 15 mg/kg/day (per oral) based on subject weights and previous-day consumption 
volumes throughout treatment.  CIT was obtained in a sweetened oral solution formulation; 
therefore, VEH-treated animals received water containing D-Sorbitol (1.68 g/5 mL; Sigma 
Aldrich) to match the concentration of CIT solution.  Comparisons of overall consumption 
can be found in Supplemental Figure 1A-B.  On day 21, treatment was discontinued, and 
mice were given bottles containing only water. 
Marble-Burying Assay 
On day 21, 20 marbles were arranged in a 4 x 5 grid in a (34 x 20.5 x 13.5 cm) cage 
containing 5 cm of bedding.  Mice were placed inside the cage for 30 minutes, after which 
the number of buried marbles (<2/3 visible above bedding) were counted.  
Open field test 
4-5 hours following the marble-burying assay on day 21, mice were evaluated for 
activity in an open field chamber (41 x 41 x 30 cm) crossed by a grid of photobeams 
(VersaMax system, AccuScan Instruments).  Counts were taken of the number of 
photobeams broken during the trial in 5-minute intervals across one hour, with separate 
measures for total distance traveled, fine movements (repeated breaking of the same set of 
photobeams), and rearing movements (vertical activity).  Time spent in the center region of 
the open field was also recorded. 
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Detection of Evoked 5-HT Release 
24 hours after withdrawal of CIT or VEH solutions, mice were evaluated for CIT-
induced changes in electrically-evoked serotonin release, using previously described methods 
(Hashemi et al., 2009).  See Supplemental Information for more details. 
Drugs and Reagents 
Citalopram hydrobromide (obtained as oral solution, 10 mg/5 mL; Roxane 
Laboratories) was diluted in sterile saline (0.9%) for acute administration, or diluted with 
water for chronic treatment.  Nomifensine maleate salt and urethane (Sigma-Aldrich, St. 
Louis, MO) were dissolved in sterile saline (0.9%).  Intraperitoneal-injected drugs (for acute 
treatments) were administered at a volume of 0.01 mL/g body weight.  All reagents were 
purchased from Sigma-Aldrich and used as received.   
Data analysis 
Results are average values ± SEM.  Behavioral data were analyzed using a 2-way or 
repeated measures ANOVA with Bonferroni post-hoc analyses.  Trends in maximum evoked 
amplitude ([5-HT]max) were analyzed using a repeated measures ANOVA with Sidak 
multiple comparisons post-hoc analysis.  
Release rate was calculated by fitting lines to the rising phase of serotonin release for 
each stimulation frequency (for each subject).  Clearance half rate (t1/2) was calculated in 
Clampfit (Molecular Devices, LLC, USA) as the decay time between 100% and 50% evoked 
concentration for each subject and averaged.  Net overflow was calculated in Clampfit using 
the integral under the curve for the first 15 seconds following the stimulation event for each 
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stimulation frequency (for each subject).  t1/2 and net overflow analyses have been shown to 
correlate well with kinetic models of neurotransmitter release (Yorgason et al., 2011). 
Groups were compared using a 2-way ANOVA with Bonferroni post-hoc analysis. 
To verify whether evoked serotonin release was frequency-dependent, [5-HT]max 
evoked at each stimulation frequency was normalized within-subjects to [5-HT]max evoked by 
20 Hz stimulations.  A line was fit to each group of normalized values and a hypothesis test 
determined whether the regression coefficient (slope) was significantly different from zero.  
Treatment groups described as having frequency-dependent release meet criteria by having a 
slope that is significantly different from zero. 
Results  
Electrical stimulation of the dorsal raphe nucleus evokes serotonin release in the substantia 
nigra pars reticulata 
To verify the chemical origin of signals measured using our recording electrode 
coordinate, we tested the acute effects of a norepinephrine/dopamine uptake inhibitor 
(nomifensine, 5 mg/kg, i.p.) and an SSRI (CIT, 10 mg/kg, i.p.) on evoked release.  In 
previous studies, a similar nomifensine dosage had robust effects on dopamine signals but 
was low enough to avoid non-selective effects (Robinson & Wightman, 2004).  Likewise, the 
selected CIT dosage has been used with robust results on serotonin signaling in prior studies 
(Hashemi et al., 2012; Hashemi et al., 2009).  Color plots and traces show serotonin release 
at baseline (Figure 6.1A), unaltered 30 minutes after nomifensine (Figure 6.1B), and 
increased in amplitude and t1/2 30 minutes after CIT (Figure 6.1C).  This response 
pharmacologically confirms that signals measured at this location are serotonergic, without 
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contribution from catecholamines. Representative histology shows the location of the 
stereotaxic coordinate used for carbon-fiber electrode placement (Figure 6.1D).  Because 
electrolytic lesions from Nafion-coated carbon-fiber microelectrodes are difficult to locate, 
we did histology following electrolytic lesions with tungsten wires at the same stereotaxic 
coordinate.  Inset shows the contralateral SNpr, illustrating its dense serotonergic terminal 
field. 
Anxiety-like behavior is reduced by chronic CIT treatment 
We selected the treatment period and dosage for chronic citalopram (cCIT) based on 
prior studies that used oral SSRI administration and found robust neurochemical effects 
(Davidson & Stamford, 1997a, 2000).  We used the marble-burying assay, a standard index 
of anxiety-like behavior, since previous studies had found that chronic SSRI treatment in 
mice leads to reductions in buried marbles (Arora et al. 2013; Ichimaru et al. 1995).  We also 
performed an open field test for CIT effects on overall activity, as well as additional 
measures of anxiety-like behavior (Jiao, Nitzke, Doukas, Seiglie, & Dulawa, 2011; 
Strekalova et al., 2013). 
In line with previous reports (Arora, Bhowmik, Khanam, & Vohora, 2013; Ichimaru, 
Egawa, & Sawa, 1995), we found that cCIT decreased the number of marbles buried (Figure 
6.2A).  These effects of SSRI treatment were only significant in paired-housed, and not 
single-housed, mice (post-hoc analyses following 2-way ANOVA, main effect of treatment, 
F(1,72)=9.7, P<0.01).  In the OF test, cCIT did not significantly affect general locomotion in 
either housing group (Figure 6.2B-C), confirming previous findings on CIT effects in 
C57BL/6 mice (Jiao et al., 2011; Strekalova et al., 2013).  However, cCIT led to highly 
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significant decreases in time spent in the center region of the open field, in comparison to 
VEH (Figure 6.2D; main effect of treatment, F(1,72)=19.0, P<0.0001).  cCIT also led to mild 
reductions in fine movements, an index of repetitive and stereotyped behavior (Figure 6.2E; 
main effect of treatment, F(1,72)=10.0, P<0.01).  Rearing movements, another measure of 
active exploration in the open field, were decreased by cCIT, although this effect was only 
significant in the pair-housed mice (Figure 6.2E; post-hoc analyses following main effect of 
treatment, F(1,68)=9.5, P<0.01).  Overall, cCIT had anxiolytic effects in the marble-burying 
assay, but not in the OF test, with more significant effects in the pair-housed mice. 
cCIT increases serotonin release in pair-housed mice  
Serotonin release exhibits robust dependence on stimulation frequency when 
examined in brain slices (Dankoski & Wightman, 2013) .  This is the result of uptake 
occurring throughout stimulation pulse trains and has been described using Michaelis-
Menten models of neurotransmission (Bunin et al., 1998; Dreyer, Herrik, Berg, & 
Hounsgaard, 2010).  Table 6.1 compares maximal release ([5-HT]max) evoked by a range of 
stimulation frequencies (20-60 Hz, 60 pulses each).  In marked contrast to the slice results, 
we found that in vivo serotonin signaling was not frequency-dependent under baseline 
conditions.  No significant effect of cCIT or frequency was found when comparing [5-HT]max 
in single-housed mice.  However, cCIT increased [5-HT]max in pair-housed mice (repeated 
measures ANOVA, main effect of treatment, F(1,12)=5.4, P<0.05), with main effects of 
stimulation frequency (F(4,48)=3.9, P<0.01), as well as a treatment x frequency interaction 
(F(4,48)=5.9, P<0.001).  Post-hoc analysis revealed significant differences at 50 Hz and 60 
Hz (P<0.05).  
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After an acute CIT challenge (Table 6.1, bottom), the effects of cCIT in pair-housed 
mice were maintained and intensified (repeated measures ANOVA; main effect of treatment, 
F(1,12)=9.8, P<0.01; frequency, F(4,48)=68.9, P<0.0001, and treatment x frequency 
interaction, F(4,48)=7.6, P<0.0001).  Post-hoc analyses revealed differences between VEH 
and cCIT pair-housed mice at stimulus frequencies of 30 Hz, 40 Hz (both at P<0.05), 50 Hz, 
and 60 Hz (both at P<0.01).  Changes in [5-HT]max are not correlated with a change in local 
serotonin content (Figure 6.S1C).  Therefore, functional changes in neurotransmission must 
underlie the effects of cCIT treatment. 
Increased [5-HT]max in cCIT pair-housed mice is due to facilitation of release 
To determine what underlies changes in [5-HT]max, we analyzed the rate of release, 
clearance half-life (t1/2), and net overflow in serotonin concentration traces evoked by 60 Hz, 
1s stimulations (Figure 6.3).  Figure 6.3A-B shows average concentration traces of serotonin 
release at 60 Hz (concentration traces for all stimulation frequencies are in Figure 6.S2).  
cCIT treatment increased release rate (2-way ANOVA, main effect of treatment F(1,25)=6.1, 
P<0.05), and there was an interaction between treatment and housing (F(1,25)=4.6, P<0.05) 
(Figure 3C).  Post-hoc analysis revealed differences in 60 Hz release rate between pair-
housed VEH and cCIT mice (7.4 ± 1.1 nM s
-1
 vs 19.2 ± 3.1 nM s
-1
, n=6 and n=8, 
respectively, p<0.01), but not between single-housed VEH and cCIT mice.  
Surprisingly, clearance (t1/2) of evoked serotonin was unaltered by housing or cCIT 
treatment (Figure 6.3D).  This demonstrates that increases in [5-HT]max (Table 6.1) were due 
to facilitation of release following cCIT treatment.  Similar results have been obtained in 
previous voltammetric studies (Davidson & Stamford, 1997a, 2000); however, our result 
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conflicts with the work of Benmansour et al. (1999), who found that baseline SERT function 
was impaired by chronic SSRI treatment.  Their study was conducted in the hippocampus 
and measured SERT function using high concentrations of exogenously applied serotonin, 
critical differences which may explain this discrepancy.  
 In the present study, cCIT increased net overflow (Figure 6.3E, 2-way ANOVA, 
F(1,25)=6.6, P<0.05) and post-hoc analysis showed differences between VEH and CIT 
treatment in pair-housed (0.11 ± 0.02 µM s vs 0.22 ± 0.04 µM s, n=6 and n=8, respectively, 
P<0.05) but not single-housed mice.  Additional post-hoc analysis comparing effect of 
housing found differences between cCIT single- vs pair-housed mice (0.14 ± 0.01 µM s vs 
0.22 ± 0.04 µM s, n=9 and n=8, respectively, P<0.05).  Taken together, these data show that 
facilitation of serotonin release is a major contributor to the enhanced serotonergic 
neurotransmission in pair-housed cCIT mice, whereas uptake is unaffected. 
Because differences in release rate and t1/2 were only apparent in release evoked by 
higher-frequency stimulations, we developed an assay to quantitatively establish frequency-
dependence, described in Methods.  Only serotonin release in pair-housed cCIT mice met 
the criteria for frequency-dependence (Figure 6.3F; hypothesis test for regression slope, 
F(1,38)=14.4, p<0.001).  Frequency-dependent facilitation in pair-housed cCIT mice is a 
major shift in the dynamic regulation of serotonin release. 
Acute uptake inhibition enhances facilitation of serotonin release in cCIT pair-housed mice 
Next, we examined how cCIT treatment altered responses to CIT itself (Figure 6.4).  
Mice were withdrawn from CIT or VEH for 24 hours, sufficient to metabolize all remaining 
drug (Fredricson Overo, 1982).  An acute challenge dose of CIT (10 mg/kg, i.p.) was 
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administered at the end of each experiment.  Differences in uptake are evident when 
comparing average concentration traces evoked by 60 Hz, 60 pulse stimulations (Figure 
6.4A-B).  In all groups, t1/2 increased, but to a lesser extent in cCIT mice (2-way ANOVA, 
F(1,25)=7.4, P<0.05) (Figure 6.4D).  This finding concurs with Benmansour et al. (1999), 
who found that SERT function was less responsive to uptake inhibitors after chronic SSRI 
treatment. 
Post-hoc analysis revealed differences in release rate between pair-housed VEH and 
cCIT mice (14.3 ± 2.5 nM s
-1
 vs 26.9 ± 3.8 nM s
-1
, n=6 and n=8, respectively, p<0.05) 
(Figure 4C).  Acute CIT also increased net overflow in cCIT mice (main effect of treatment, 
F(1,25)=6.0, P<0.05), with significant main effect of housing (F(1,25)=4.50, P<0.05) and a 
treatment x housing interaction (F(1,25)=8.5, P<0.01) (Figure 6.4E).  Post-hoc analysis of net 
overflow revealed differences between VEH and cCIT in pair-housed mice (0.53 ± 0.06 µM 
s vs 1.13 ± 0.15 µM s, n=6 and n=8, respectively, P<0.01) and also between single- and pair-
housed cCIT mice (0.57 ± 0.09 µM s
 
vs 1.13 ± 0.15 µM s, n=9 and n=8, respectively, P< 
0.01).  The overall increase in release rate and net overflow after acute CIT was expected, 
due to SSRI-induced reductions in uptake (Wightman & Zimmerman, 1990).  Consistent 
with this, release rates measured in the various groups of mice varied in proportion to the 
pre-CIT release rates, and differences were still only observed in pair-housed mice. 
We used a hypothesis test to quantitatively confirm frequency-dependence following 
acute CIT.  Frequency-dependence was determined for all groups (Figure 6.4F, hypothesis 
test for regression slope; VEH-single, F(1,28)=182.4, p<0.0001; CIT-single, F(1,38)=25.9, 
p<0.0001; VEH-pair, F(1,28)=96.2, p<0.0001; CIT-pair, F(1,43)=84.5, p<0.0001).  Although 
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all groups showed frequency-dependence following acute CIT, the magnitude of release at all 
frequencies was much greater in cCIT-treated paired animals (Table 6.1, bottom).  
Discussion 
Though SSRIs are commonly prescribed to treat disorders involving depression and 
anxiety, the mechanisms by which these agents exert therapeutic effects are not clear.  Prior 
studies have examined how chronic SSRI treatment affects the serotonin system, but this is 
the first to compare effects of SSRI treatment on endogenous, in vivo release dynamics. 
Furthermore, this study directly addresses the interaction of social environment with 
serotonergic function in this context.  Here, we found distinct differences in the effects of 
chronic SSRI treatment on serotonin signaling in single- vs pair-housed mice.  We describe a 
novel effect of this treatment—the facilitation of serotonin signaling in a frequency-
dependent fashion—and the ability to attenuate this outcome with concurrent social isolation.  
Levels of neurotransmitter in the extracellular space are determined by a dynamic 
equilibrium between release and uptake (Dreyer et al., 2010).  Previously, we reported that 
disruptions of serotonergic equilibria can be fatal, and release and uptake are both tightly 
controlled to maintain this balance (Hashemi et al., 2012).  Further evidence of this control 
can be seen in Table 6.1 and Figure 6.3F:  in vivo release is insensitive to the rate of 
stimulation.  Spontaneous serotonergic burst-firing does occur during distinct behavioral 
states (Gartside et al., 2000; Jacobs, 1991);.  Furthermore, serotonin neurons have the 
capacity for frequency-dependent release as measured in brain slices (Dankoski & 
Wightman, 2013), likely because inhibitory feedback from intact serotonergic neurons and 
other neuromodulatory systems are severed during slice preparation.  Multiple inhibitory 
systems preserve the pacemaker-like firing (1-5 Hz) of serotonergic neurons.  For instance, 
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somatodendritic 5-HT1a autoreceptors profoundly limit the firing rate of serotonergic 
neurons (Blier et al., 1998), and the DRN also receives complex feedback from prefrontal 
cortex (Celada, Puig, Casanovas, Guillazo, & Artigas, 2001).   
Following chronic CIT treatment, [5-HT]max was frequency-dependent in pair-housed 
mice (Table 6.1).  Our analysis showed this was due to increases in release rate, not t1/2 
(Figure 6.3C-D).  Thus, cCIT increases the responsiveness of serotonergic neurons to higher 
stimulation frequencies.  This could arise from 5-HT1a autoreceptor desensitization, a 
process that is well-documented following chronic SSRI exposure and is a critical component 
of their antidepressant effects (Celada, Bortolozzi, & Artigas, 2013; Ferres-Coy et al., 2013).  
Frequency-dependent signaling in cCIT-treated, pair-housed mice could arise from the 
suppression of autoreceptor feedback and would be a functional consequence of their 
desensitization. Even at low frequencies, cCIT substantively enhanced release in pair-housed 
mice after the acute CIT challenge. This indicates that during chronic treatment, baseline 
increases in release are intensified by ongoing uptake inhibition and may occur at low (1-5 
Hz) firing rates.  Increased release allows greater interaction of extracellular serotonin with 
its post-synaptic targets.   
It could be hypothesized that chronic mild stress experienced by single-housed 
C57BL/6J mice would produce a depressive phenotype and intensify the effects of cCIT 
treatment when compared with VEH-treated counterparts. Surprisingly, social isolation 
blocked cCIT-induced facilitation of serotonin release, but did not induce changes in VEH-
treated mice.  Many behavioral and neurochemical effects of social isolation are correlated 
with an upregulation of HPA axis activity, including brain-wide increases in CRF and CORT 
levels (Backstrom & Winberg; Blanchard et al., 2001).  C57BL/6J mice are a resilient strain, 
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and under ordinary conditions, these increases may not be behaviorally or neurochemically 
significant (Voikar, Polus, Vasar, & Rauvala, 2005).  However, chronic SSRI treatment 
increases negative feedback to the HPA axis, reducing its function (Barden, 1996, 2004; 
Pariante & Miller, 2001).  SSRI-induced changes in HPA axis activity directly affect 
serotonergic activity (Celada, Puig, Amargos-Bosch, Adell, & Artigas, 2004; Celada et al., 
2001; Johnson, Grant, Ingram, & Gartside, 2007; Kirby et al., 2008).  Isolation-induced 
increases in HPA axis function could negate the opposing effects of chronic SSRI exposure.  
Thus, social isolation and cCIT treatment may work against each other so that serotonin 
signaling is not altered in single-housed mice.  Our finding that cCIT led to significant 
reductions in marble-burying in the paired-housed, but not the single-housed, mice provides 
additional evidence for lower sensitivity to SSRI effects with chronic social isolation. 
Plasticity in serotonergic function and its downstream targets underlies the efficacy of 
SSRI therapies for depression and OCD (Blier & de Montigny, 1998).  However, prior 
studies have not characterized the changes in endogenous serotonin dynamics that occur 
during the therapeutic period of SSRI treatment.  In this study, we used in vivo measurements 
to show that 20-day CIT treatment facilitates serotonin release in a frequency-dependent 
manner without altering SERT function.  Prior studies have shown that autoreceptor 
desensitization occurs with the onset of therapeutic effects.  Here, we demonstrate a 
consequence of this desensitization, revealing profound increases in evoked terminal 
serotonin release at all frequencies, a major mechanistic change that may contribute to the 
therapeutic actions of SSRIs.  The observation that individually housing animals can entirely 
block this effect in both baseline and challenge conditions indicates that ongoing stress 
during SSRI treatment is an important variable in individual outcomes.  This work shows that 
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plasticity in the serotonergic system is sensitive to environmental stress, and this can 
influence the effects of SSRI therapies. 
Supplemental Methods 
Carbon-fiber microelectrode construction and calibration 
Carbon-fiber microelectrodes were assembled as previously described (Cahill et al., 
1996). To enhance sensitivity to serotonin, Nafion (5% in methanol, Sigma-Aldrich) was 
applied to the electrodes using a dip-coating procedure. Briefly, microelectrodes were dipped 
into Nafion solution individually then baked at 70ºC for 10 minutes, for seven repetitions. An 
electrode calibration standard was determined by post-calibrating electrodes in vitro in 
phosphate buffered saline. 
Detection of Evoked 5-HT release 
On day 22, after 24 hours of withdrawal from CIT or VEH treatment, mice were 
anaesthetized with urethane (2 mg/g body weight in saline, i.p.) for stereotaxic surgery. A 
bipolar, stainless steel stimulating electrode (PlasticsOne, Roanoke, VA, USA) was 
implanted in the DRN (AP: -4.4, ML: 0.0, DV: -2.5 mm) and a carbon-fiber microelectrode 
was positioned into the SNpr (AP: -3.2, ML: +1.5). Serotonin release evoked by electrical 
stimulation of the DRN (325 μA biphasic pulses, 2 ms each phase, 20-60 Hz, 20-60 pulses) 
and optimized in the SNpr for maximal release between -4.0 and -4.2 mm dorsoventral from 
skull.  Electrical stimulations were fixed-number of pulses (60 pulses, 20-60 Hz). To ensure 
stability of signal across experimental time course, 135 seconds elapsed between each 
stimulus presentation.  
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After baseline measurements were collected, an acute challenge dose of CIT (10 
mg/kg i.p., Sigma-Aldrich) was administered to verify the identity of the measured signal as 
serotonin. Serotonin was identified by its unique cyclic voltammogram as well as its 
pronounced increase in evoked response following CIT challenge.   
Because of technical difficulties lesioning with Nafion-coated carbon-fiber 
microelectrodes, representative histology was performed by lesioning with a tungsten 
electrode using a typical SNpr recording coordinate (AP: -3.2, ML: +1.5, DV: -4.1 mm). 
Immunohistochemistry was then performed as described below. 
Immunohistochemistry 
Mice were anesthetized with urethane and then perfused with 4% paraformaldehyde 
in PBS. Samples were incubated in 10, 20, and then 30% sucrose in PBS before being cut at 
40 µm using a freezing-sliding microtome (Leica). Sections were collected, rinsed and 
blocked with 5% normal donkey serum and 0.2% Triton X-100 in PBS. Sections were then 
incubated in this blocking solution with primary antibody for 48 hours at 4°C. The primary 
antibodies used in this study were mouse anti-NeuN (1:500, MAB377, Millipore), rabbit 
anti-GFAP (1:1500, A2052, Sigma-Aldrich), and rabbit anti-5-HT (1:500, sc-13024, Santa 
Cruz Biotechnology). Secondary detection was performed with Alexa Fluor 488, 546, or 647 
conjugated donkey anti-rabbit or anti-mouse antibodies (Invitrogen). Mounted sections were 
imaged on a Zeiss LSM 710 confocal microscope using 20×/0.8 NA objective. 
Tissue content analysis 
Mice were anesthetized with ethyl ether, decapitated, and the brain was rapidly removed and 
placed on ice.  Coronal sections (300 µm thick) containing  the SNpr were collected with a 
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Lancer Vibratome (World Precision Instruments, Sarasota, FL) in ice cold artificial cerebral 
spinal fluid (aCSF).  The aCSF contained (in mM) 126 NaCl, 25 NaHCO3, 2.45 KCl, 12 
NaH2PO4, 1.2 MgCl2, 2.4 CaCl2, 20 HEPES, and 11 glucose.  The pH of the buffer was 
adjusted to 7.4 and saturated with 95% O2 /5% CO2.  The SNpr was excised with a 1 mm 
punch, and tissue was pooled such that each sample contained 5-8 mg total tissue from 3 
mice. The samples were mixed with 200 µL of 0.1 N HClO4 containing 1 µM hydroquinone, 
the internal standard, and subsequently homogenized using a sonic dismembrator (Fisher 
Scientific, Model 60, Pittsburgh, PA).  The homogenate was then spun down at 6000 rpm for 
10 minutes, and the supernatant was removed and filtered using a 0.2 µm syringe filter 
(Millex-LG).  High performance liquid chromatography was performed using the methods of 
Mefford and Lähdesmäki et al (Lahdesmaki et al., 2002; Mefford, 1981).  Briefly, 20 µL 
injections were made onto a revered-phase column (5 µm, 4.6 x 5 mm, Waters Atlantis).  The 
mobile phase consisted of 0.1 M citric acid, 1 mM sodium hexylsulfate, 0.1 mM EDTA (pH 
= 3), and 10% methanol organic modifier at a flow rate of  1.0 mL/min.  Neurotransmitters 
were detected with a thin layer radial electrochemical cell (BASi, West Lafayette, IN) at a 
potential of +800 mV vs Ag/AgCl.  Data was collected at 60 Hz using a LabVIEW stripchart 
recorder program (Jorgenson Lab, UNC-CH) and homebuilt electronics.  The peak area of 
the analyte was ratioed to the peak area of the internal standard, and the analyte concentration 
in the tissue was calculated.   
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Figure 28Figure 6.1 Voltammetric determination of serotonin release in the substantia nigra pars reticulata of the 
mouse brain. 
 
Figure 6.1 Voltammetric determination of serotonin release in the substantia nigra pars 
reticulata of the mouse brain.  (A-C) Representative color plots (top) and concentration vs. 
time traces (bottom) showing electrically-evoked serotonin release (A) prior to drug 
treatment, (B) 30 minutes after administration of nomifensine (5 mg/kg, i.p.), and (C) 30 
minutes after administration of citalopram (CIT, 10 mg/kg, i.p.).  Traces were obtained from 
the oxidation current of serotonin, indicated by the dotted white line on the color plots, at 
approximately 0.8 V.  (D) Representative histology from lesion showing targeted 
dorsoventral location of recording electrodes in SNpr. Green, NeuN; Magenta, GFAP; Blue, 
5-HT.  Inset shows contralateral SNpr containing dense serotonergic terminals.  (E) 
Representative current-voltage trace taken at time point indicated by the dashed line in color 
plot C.  (F) Timeline of experiments outlined in this paper:  Mice were transferred to single-
or pair-housing one week prior to chronic CIT (cCIT) treatment.  CIT (15 mg/kg/day) or 
vehicle (VEH) was administered via water bottles for 20 days.  On day 21, marble burying 
and open field assays were performed and animals were withdrawn from CIT or VEH for 24 
hours.  On day 22, anaesthetized voltammetry experiments were performed.  Data shown are 
means ± SEM.  
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Figure 29Figure 6.2 Effects of cCIT or VEH treatment on marble-burying and OF assays in pair- and single-housed 
mice 
 
Figure 6.2 Effects of cCIT or VEH treatment on marble-burying and OF assays in pair- and 
single-housed mice.  (A) Number of marbles (out of 20) buried during a 30 minute marble-
burying assay.  (B-C) Distance traveled across a 60 minute OF test.  (D) Time spent in center 
of the OF chamber.  (E) Fine movements during OF testing.  (F) Incidences of rearing during 
OF testing.  Data shown are means ± SEM.  Bonferroni post-hoc analysis:  **p<0.01, 
*p<0.05.  
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Figu 
 
 
re 30Table 6.1 Maximal serotonin release  measured in SNpr 
  
Table 6.1 Maximal serotonin release ([5-HT]max) measured in SNpr as evoked by electrical 
stimulation of DRN. Stimulation trains for each frequency were 60 pulses in length.  
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Figure 31Figure 6.3. Comparison of serotonin release and uptake evoked by electrical stimulation of the DRN 
 
Figure 6.3. Comparison of serotonin release and uptake evoked by electrical stimulation of 
the DRN. (A-B) Averaged concentration vs. time traces of serotonin release evoked by a 60 
Hz, 60 pulse stimulation of the DRN.  Shaded bar below trace indicates the duration of 
stimulation. (C) Mean rate of change in [5-HT] during the rising phase of release evoked by 
60 Hz, 60 pulse stimulation.  (D) t1/2 of evoked serotonin following 60 Hz, 60 pulse 
stimulation.  (E) Mean net overflow (area under curve) following 60 Hz, 60 pulse 
stimulations.  (F) Averages of normalized maximal release amplitudes evoked by 20 – 60 Hz 
stimulations.  Dotted lines show best-fit linear regressions for each treatment group.  Data 
shown are means ± SEM. Bonferroni post-hoc analysis: **p<0.01, *p<0.05.   
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Figure 32Figure 6.4 Comparison of electrically-evoked serotonin release following acute CIT challenge 
 
Figure 6.4 Comparison of electrically-evoked serotonin release following acute CIT 
challenge. (A-B) Averaged concentration vs. time traces of serotonin release evoked by a 60 
Hz, 60 pulse stimulation of the DRN 30 minutes after acute CIT. Shaded bar below trace 
indicates the duration of stimulation.  (C) Mean rate of change in [5-HT] during the rising 
phase of release evoked by 60 Hz, 60 pulse stimulation after acute CIT challenge.  (D) Mean 
t1/2 of evoked serotonin following 60 Hz, 60 pulse stimulations.  (E) Mean area under curve 
(AUC) following 60 Hz, 60 pulse stimulations.  (F) Averages of normalized maximal release 
amplitudes evoked by 20 – 60 Hz stimulations.  Dotted lines show best-fit linear regressions 
for each treatment group.  Data shown are means ± SEM. Bonferroni post-hoc analysis:  
**p<0.01, *p<0.05. 
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Figure 33Figure 6.S1. Comparison of liquid consumption before and during CIT/VEH treatment and tissue content 
analysis. 
 
 
 
 
 
 
Figure 6.S1. Comparison of liquid consumption before and during CIT/VEH treatment and 
tissue content analysis. (A) Mean individual water volume consumed per day for the 7 days 
prior to treatment. (B) Mean individual liquid volume consumed per day during 20 days of 
CIT of VEH treatment. (C) Serotonin content analyzed using HPLC from tissue punches of 
SNpr. 
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Figure 34Figure 6.S2. 5-HT concentration traces evoked by each stimulation frequency 
 
 
 
Figure 6.S2. 5-HT concentration traces evoked by each stimulation frequency. Duration of 
each 60 pulse stimulation train is denoted by the yellow bar over each trace: 20 Hz = 3 s, 30 
Hz = 2 s, 40 Hz = 1.5 s, 50 Hz = 1.2 s, and 60 Hz = 1 s. Each trace shows 5 s prior to 
stimulation onset and 25 seconds after, for a total of 30 s. A dotted line indicates 
[5-HT]=0 nM (baseline) and the dashed line indicates [5-HT]=17 nM, the average [5-HT]max 
for 20 Hz release in VEH-treated single- and pair-housed mice. Serotonin release in VEH-
treated mice looks kinetically similar across all frequencies. In single-housed cCIT mice, 
release is modestly increased, and the effect is similar across all frequencies. In contrast, 
enhancement of serotonin release in pair-housed cCIT mice intensifies with increasing 
stimulation frequency. Single-VEH (N=6), Single-cCIT (N=9), Pair-VEH (n=6), Pair-cCIT 
(n=8). 
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CHAPTER 7: CONCLUSION 
Summary of findings 
Fast-scan cyclic voltammetry of 5-HT 
 This work began with the goal of measuring serotonin release in vivo. Prior work had 
characterized a waveform that addressed a major obstacle in the electrochemical detection of 
serotonin: the electrode-fouling side-products formed by serotonin’s oxidation and reduction 
(Jackson et al.). Unlike dopamine, which oxidizes and reduces predictably and with a clean 
cyclic voltammogram, there are over 30 products formed from serotonin’s oxidation, and 
some of these polymerize and foul the surface of the carbon-fiber microelectrode. The result 
of this fouling is a deterioration of electrode sensitivity and temporal response. Jackson et al. 
(1995) condensed the voltage waveform used to measure dopamine so it did not scan as high 
or as low (-0.1 V to +1.0 V). Furthermore, the waveform was shifted so that between scans, 
the waveform was held at +0.2 V. Avoiding high and low potentials in this manner reduces 
the formation of fouling side-products. Additional fouling was avoided by kinetically out-
running side-product formation: this is why the waveform scans at a faster speed than for 
dopamine (1000 V/s). The Jackson 5-HT waveform had been used successfully in brain 
slices to describe the release and uptake kinetics of serotonin (Bunin et al.), the extrasynaptic 
nature of its release (Bunin & Wightman), and had also been used to study serotonin release 
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in fly ventral nerve cord (Borue, Condron, & Venton, 2010; Borue, Cooper, Hirsh, Condron, 
& Venton, 2009) 
 In spite of these improvements, electrochemical detection of serotonin in vivo was 
still not possible. This was in part due to interference by metabolites of serotonin, specifically 
5-hydroxyindoleacedic acid (5-HIAA). 5-HIAA is present at high levels in brain tissue and 
interferes with detection of serotonin due to its similar electrochemistry (Ross & Stenfors, 
1997). Constant perfusion of buffer through brain slices reduces 5-HIAA to negligible levels, 
but methodological modifications were needed to avoid its detection in vivo. During the 
development of voltammetric methods to measure dopamine, anionic species such as 
ascorbic acid posed similar threats to the sensitivity and selectivity of dopamine detection. To 
exclude these anionic species, a cation-exchange polymer, Nafion, was applied to the carbon-
fiber electrode in a dip-coating process (G. A. Gerhardt et al., 1984; Wiedemann et al., 1990). 
Nafion decreased sensitivity to anions like ascorbic acid, which in turn enhanced dopamine 
detection. Since 5-HIAA is an anion, and the serotonin molecule has a net positive charge, 
Nafion was also a good candidate for enhancing serotonin detection. We hypothesized that in 
vivo serotonin measurements would be possible using a combination of the modified Jackson 
5-HT waveform and Nafion-coated microelectrodes. 
Anatomical Choices for Serotonin Measurements 
 Although in vitro experiments confirmed that the Jackson 5-HT waveform and 
Nafion-coated electrodes heightened sensitivity and selectivity for serotonin, anatomical 
locations for stimulating and carbon-fiber microelectrodes still required optimization. In 
Chapter 2, we selected the dorsal raphe nucleus (DRN) as the site for electrical stimulation 
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because the majority of serotonergic neurons that send projections into forebrain are located 
there (Azmitia & Segal, 1978; Moore et al., 1978b). We selected the substantia nigra pars 
reticulata (SNpr) as the location for our recording electrode because its terminal serotonin 
field is second in density only to the DRN itself (Fibiger & Miller, 1977; Wirtshafter et al., 
1987). Optimizing placement of the two electrodes in the target brain regions enabled the 
first measurements of in vivo, endogenous serotonin release (Hashemi et al.). 
 Although measuring serotonin release was now possible, a few problems still 
remained. Serotonin release evoked in brain slices of the SNpr was 50 times larger than 
serotonin release evoked in vivo. Additionally, electrical stimulation of the DRN had a low 
success rate, probably owing to its small size and location deep in the brainstem. In Chapter 
3, we investigated whether stimulation of the medial forebrain bundle (MFB) could produce 
serotonin release that resembled release evoked by DRN stimulation. Ascending serotonergic 
projections run through the MFB and can be electrically stimulated to excite serotonergic 
neurons in the DRN (Hajos & Sharp). We demonstrated that electrical stimulation of the 
MFB could evoke serotonin release in the SNpr that closely resembled DRN-evoked release 
(Hashemi et al.). However, the MFB comprises a large number of projections, including 
those containing other electroactive neurotransmitters such as dopamine and norepinephrine. 
Although dopamine and norephinephrine did not contribute to release evoked in the SNpr by 
MFB stimulation, an oxidation peak on at the waveform’s ‘switching’ potential (+1.0 V) 
suggested the presence of another electroactive molecule, histamine. In spite of less 
selectivity in evoked release, experimentation using the MFB stimulation site had a much 
higher success rate, and is utilized in Chapter 4. 
In vivo modulation of serotonin release 
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 In Chapter 4, we compared in vivo dopamine and serotonin signaling, evoked by a 
common stimulation of the MFB, to ascertain which biochemical mechanisms were most 
influential on their release. The same dorso-ventral location of the stimulating electrode 
evoked maximal release for both neurotransmitters; however, evoked dopamine 
concentrations were 300-fold greater than evoked serotonin concentrations. We observed that 
dopamine release declined rapidly after repeated stimulus presentation. Inhibition of 
synthesis and packaging also quickly depleted dopamine stores, suggesting that release is 
mostly limited by neurotransmitter availability. Serotonin release was not affected to the 
same extent as dopamine, possibly because its release was low enough to maintain a 
sufficient vesicular pool (Aghajanian et al.). Inhibition of serotonin’s transporter (SERT) or 
monoamine oxidase (MAO), which metabolizes serotonin, enhanced serotonin release as 
well as decreased clearance rate. We hypothesized that clearance mechanisms, rather than 
synthesis and packaging mechanisms, play a large role in regulation of serotonin release in 
vivo. In support of this, we found that simultaneous inhibition of SERT and MAO caused 
rapid dysregulation of serotonin levels, resulting in death. We concluded that serotonin 
signaling is robustly regulated by clearance mechanisms to maintain viable extracellular 
levels (Hashemi et al.). 
Role of SERT in dynamic modulation of serotonin signaling 
 Previously, our investigations of in vivo serotonin release showed that evoked 
concentrations were much lower in vivo than in brain slices. Chapter 5 demonstrates another 
major difference: serotonin release is positively correlated with stimulation frequency in 
brain slices, but not in vivo. Frequency-dependence has been described for in vivo dopamine 
release, and the effect is well-understood: longer inter-pulse intervals during low frequency 
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stimulations allow for more neurotransmitter uptake during the stimulus duration, so net 
release is lower (R.M. Wightman et al.). Accordingly, uptake inhibition affects dopamine 
release evoked by low frequency stimulations to a greater extent than high frequency 
stimulations. Because frequency dependence is a function of  transporter activity, dopamine 
evoked by varying stimulation frequencies can be modeled using Michaelis-Menten kinetics 
for quantitative comparison of its dynamics (Wightman & Zimmerman). Lack of frequency-
dependence in in vivo serotonin release was therefore a very surprising finding. More 
surprising was our observation that SERT inhibition by selective serotonin reuptake 
inhibitors (SSRIs) induced frequency-dependent release. 
  Chapter 5 investigates these unexpected effects of acute exposure to SSRIs. 
Although their effects on uptake are well-characterized, the observation that SSRIs enhance 
serotonin signaling in a frequency-dependent manner is unique. We hypothesized that the 
effects of SSRIs on serotonin release, but not uptake, were localized in the DRN. The DRN 
contains the highest SERT expression of any brain area, and serotonin levels there modulate 
feedback circuitry that inhibits serotonergic firing (Blier et al., 1998; Pineyro & Blier, 1999). 
Microinfusing an SSRI into the DRN replicated its systemic effects on release without 
affecting uptake. This suggests that SSRI-induced increases in DRN serotonin levels 
dysregulate local modulatory circuitry to favor responsiveness to high-frequency excitatory 
inputs. One way this could happen is via rapid desensitization of 5-HT1a autoreceptors, 
which has been shown after acute exposure to 5-HT1a agonists and SSRIs (Riad, Watkins, 
Doucet, Hamon, & Descarries, 2001; Riad et al., 2004). High extracellular concentrations of 
serotonin may similarly desensitize these autoreceptors, which would eliminate their 
restrictions of serotonergic firing rate. Alternatively, local increases in 5-HT may maximally 
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activate inhibitory feedback within the DRN that would normally escalate to relegate 
responsiveness to excitatory inputs. If inhibitory feedback cannot upregulate, stimulation 
frequency would have a more direct effect on serotonin release, as we observed. Additional 
experiments are needed to fully elucidate the mechanisms of SSRI effects in the DRN, and 
these future directions are discussed in a later section. 
Effects of chronic SSRI treatment on serotonin signaling 
 Although SSRIs have robust acute effects, 3-6 weeks of chronic treatment are 
required before they exert clinical improvements in depression and anxiety-related disorders. 
Antidepressant effects of SSRIs likely depend on plasticity in serotonergic function and its 
targets during this time period (Branchi, 2011). We hypothesized that changes in serotonin 
signaling related to the acute effects of SSRIs may accompany the onset of antidepressant 
effects during chronic treatment. Chapter 6 describes how 20-day SSRI treatment improved 
behavioral indices of anxiety and enhanced serotonin release in pair-housed mice. As in 
Chapter 5, the effects on serotonin signaling were frequency-dependent, indicating that 
similar SERT-mediated mechanisms may underlie long-term effects of SSRI treatment. 
Interestingly, no enhancement of serotonin release was observed in singly-housed mice, 
suggesting that chronic mild stress during SSRI treatment can attenuate its effects. These 
findings underscore how SERT function modulates serotonin release in a way that is 
distinguishable from its effects on uptake. They also suggest that neurobiological systems 
involved in the transduction of stress may endogenously modulate SERT, and thus, the 
effects of stress may interact with both the pathophysiology and treatment of depressive 
disorders.  
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Discussion and Future Directions 
 Stimulation of the MFB and DRN evoke serotonin release with similar properties, 
and each stimulation location has advantages and disadvantages. The DRN in the rat brain 
extends barely over 1 mm in any dimension. As rats grow, their skulls increase in length and 
their brain does not, making bregma an unreliable predictor of DRN location in larger, older 
subjects. In contrast, the MFB is a large and developmentally stable target. In chapters 3 and 
4 of this dissertation, MFB stimulation was used because of its much higher experimental 
success rate. However, electrical stimulations in this region evoke many kinds of 
neurotransmitter in many brain regions. When we began using this technique in mice 
(chapters 5 and 6), we found that the DRN and MFB were equally facile targets as long as 
age and weight ranges for mice were well-controlled (8-14 weeks, 25-30 g). The DRN is 
considered a superior electrical stimulation site because it offers some level of specificity.  
 Future work would benefit from an even more selective stimulation method. The 
dorsal raphe contains 30% GABAergic neurons, many of which contribute to local 
modulatory circuitry. In our experiments, it is unclear whether GABAergic circuitry is partly 
responsible for the effects of SSRIs on evoked serotonin signaling. Optogenetic stimulation 
of serotonin release has been successful in fly ventral nerve cord (Borue, Condron, & 
Venton, 2010; Borue, Cooper, Hirsh, Condron, & Venton, 2009), and has been employed in 
several mammalian studies, but not in combination with FSCV. Use of this cell-type 
selective technique could clarify whether SERT inhibition selectively modifies serotonergic 
activity. One proposed experiment would be to compare serotonergic neuronal firing as well 
as release evoked by electrical vs. optogenetic stimulations. Additionally, our work has 
concentrated on serotonin signaling in the SNpr to avoid interference from other electroactive 
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neurotransmitters, such as dopamine and norepinephrine. However, light-activation of 
serotonin neurons would enable chemically-selective measurements in other brain regions, 
including the nucleus accumbens and hippocampus, where serotonergic signaling is known to 
be important.  
 One further aspect of this work that remains unclear is the role of various serotonin 
receptors in mediating the effects of SSRIs in the DRN. Although presynaptic 5-HT1a 
receptors are abundantly implicated in the effects of SSRIs, postsynaptic 5-HT2a, 2c, and 7 
receptors on DRN interneurons may also contribute to the local feedback circuitry that is 
modified by dramatic alterations in ambient serotonin levels. Though we have attempted to 
study the roles of these receptors with available agonists and antagonists, these agents have 
weak effects. This could be due to poor passage through the blood brain barrier, rapid 
metabolism, cycling of receptor pools, homeostatic feedback, or constitutive receptor 
activity. Use of designer receptors exclusively activated by designer drugs (DREADDs, or 
RASSLs) could better elucidate the effects of these receptors on serotonin signaling. 
Recently, the Roth lab at University of North Carolina – Chapel Hill has shown that chronic 
activation of a 5-HT1a-like designer receptor has antidepressant behavioral effects in mice 
(Dan Urban, personal communication). It would be interesting to compare the effects of this 
treatment to the enhancements in serotonergic signaling observed in chapter 6.  
 In this work, serotonin release was measured in both rat and mouse models. The 
mouse model was developed because it offers several distinct advantages. First, serotonin 
release can be evoked by stimulations of much lower intensity in mice compared to rats (325 
μA, 60 pulses vs. 350 μA, 120 pulses). The serotonergic system is of comparable size in mice 
and rats, so increased density of neurons and fibers in the smaller mouse brain may be more 
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optimal for stimulating and measuring serotonin release. The effect of brain size in 
combination with inbreeding-driven consistency in the C57Bl/6J strain probably also 
contribute to increased success rate with DRN stimulation. Second, mouse models offer more 
options for genetic manipulation. We used this to our advantage to some extent with the 
SERT-/- mouse to show selectivity of SSRIs for SERT, but future work could make even 
better use of the mouse lines by employing optogenetic models and conditional knockouts. In 
particular, the hypothesis that desensitization of 5-HTa autoreceptors underlies enhancement 
of serotonin signaling after chronic SSRIs, discussed in chapter 6, could be addressed using 
CRE-lox recombination to delete presynaptic 5-HT1a receptors in adult mice.  
Concluding Remarks 
 Serotonin is a molecule found in nearly all organisms: plants, single-celled animals, 
invertebrates, and vertebrates. In every organism, it is possible to identify serotonin’s role in 
maintaining systemic homeostasis, whether it is to regulate the division of cells, capture free 
oxygen, stabilize microtubule structures, or influence neuronal excitability in the spinal cord 
and central nervous system (Azmitia, 2007). In the mammalian brain, less than 250,000 
serotonin-synthesizing neurons cluster in tiny nuclei in the brainstem, and yet these neurons 
send projections to innervate nearly every region of the forebrain and basal ganglia. They 
constitute 1/1,000,000 of total brain cells, but they may account for 1/500 of all synaptic 
terminals (Molliver, 1987). Though in complex organisms, serotonin participates in a wide 
array of nervous system functions, ranging in complexity from regulation of breathing and 
body temperature to high-level cortical processing, its evolutionary history as a homeostatic 
force remains a constant predictor for its role in these processes (Abrams, Johnson, Hollis, & 
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Lowry, 2004). The work in this dissertation fits within the interpretive framework that 
emphasizes this role of equilibrium in serotonin signaling. 
 Many studies have shown that the serotonin system is resistant to changes in function, 
a property that is maintained by feedback from forebrain structures as well as local inhibitory 
circuitry (Blier et al., 1998; Pineyro & Blier, 1999). Our findings agree that serotonin 
signaling is subject to tremendous limitations by these feedback systems. Under normal 
conditions, released concentrations in vivo are low and seemingly relegated by the slow firing 
rate of serotonergic neurons. We have shown enhancement of release induced by acute and 
chronic SERT inhibition that could be interpreted as a loss of homeostatic function. In “The 
Wisdom of the Body” (1932), Sir Walter Cannon disabuses this notion, asserting that “slight 
instability is the necessary condition for the true stability of the organism.” Flexibility, not 
rigidity, is the true hallmark of homeostasis, and it is an outstanding and fascinating property 
of all neural systems. Because many endogenous and naturally-occurring exogenous 
substances are able to modify serotonin transporter function, plasticity in serotonin signaling 
may be an adaptive response that transduces physiological states and environmental signals 
back to the nervous system. In the case of acute SSRIs, facilitation of serotonin signaling that 
coincides with increases in ambient serotonin levels is a temporary but dramatic 
dysregulation of the serotonin system. After 3-6 weeks of SSRI treatment, both ambient 
serotonin levels and serotonergic firing rates have normalized, but facilitation in signaling is 
sustained. Thus, by introducing instability to the serotonergic system, SSRIs may promote 
the plasticity in regulatory functions that result in their antidepressive effects.  
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